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I 
Abstract 
 
Adherence to Secondary Prevention Medicines by Coronary Heart Disease Patients 
Rani Khatib, Doctor of Pharmacy 
 
Keywords: Patient compliance, concordance, heart disease, angina, self-reported 
medicines adherence, medicines adherence assessment, shared decision making. 
 
Background 
Non-adherence to evidence based secondary prevention medicines (SPM) by coronary 
heart disease (CHD) patients limits their expected benefits and may result in a lack of 
improvement or significant deterioration in health. This study explored self-reported 
non-adherence to SPM, barriers to adherence, and the perception that patients in 
West Yorkshire have about their medicines in order to inform practice and improve 
adherence. 
 
Methods 
In this cross-sectional study a specially designed postal survey (The Heart Medicines 
Survey) assessed medicines-taking behaviour using the Morisky Medicines Adherence 
8 items Scale (MMAS-8),  a modified version of the Single Question Scale (SQ), the 
Adherence Estimator (AE), Beliefs about Medicines Questionnaire(BMQ) and additional 
questions to explore practical barriers to adherence. Patients were also asked to make 
any additional comments about their medicines-taking experience. A purposive sample 
of 696 patients with long established CHD and who were on SPM for at least 3 months 
was surveyed. Ethical approval was granted by the local ethics committee.  
 
Results 
503 (72%) patients participated in the survey. 52%, 34% and 11% of patients were 
prescribed at least four, three and two SPMs respectively. The level of non-adherence 
to collective SPM was 44%. The AE predicted that 39% of those had an element of 
intentional non-adherence. The contribution of aspirin, statins, clopidogrel, beta 
blockers, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor 
blockers (ARBs) to overall non-adherence as identified by the SQ scale was 62%, 67%, 
7%, 30%, 22% and 5%, respectively. A logistic regression model for overall non-
adherence revealed that older age and female gender were associated with less non-
adherence (OR = 0.96, 95% CI: 0.94, 0.98; OR = 0.56, 95% CI: 0.34, 0.93; respectively). 
Specific concern about SPM, having issues with repeat prescriptions and aspirin were 
associated with more non-adherence (OR = 1.12, 95% CI: 1.07, 1.18; OR = 2.48, 95% CI: 
1.26, 4.90, OR = 2.22, 95% CI: 1.18, 4.17). Other variables were associated with 
intentional and non-intentional non-adherence.  221 (44%) patients elaborated on 
their medicines-taking behaviour by providing additional comments about the need for 
patient tailored information and better structured medicines reviews.  
 
Conclusions 
The Medicines Heart Survey was successful in revealing the prevalence of self-reported 
non-adherence and barriers to adherence in our population. Healthcare professionals 
should examine specific modifiable barriers to adherence in their population before 
developing interventions to improve adherence. Conducting frequent structured 
medicines-reviews, which explore and address patients' concerns about their 
medicines and healthcare services, and enable them to make suggestions, will better 
inform practice and may improve adherence.  
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1 Introduction 
 
This chapter will set the scene for this research and elaborate on the rationale behind 
choosing medicines adherence to secondary prevention medicines in coronary heart 
disease.  
 
1.1 Setting the scene for this research 
 
One of the most common interventions in healthcare is the prescribing of medicines. 
The total cost of dispensed prescriptions for the National Health Service (NHS) in 
England in 2010 was £12.9 billion and around 32% of this use was in hospitals (The 
Health and Social Care Information Centre, 2010). Nearly 927 million prescription 
items were dispensed in the community in England in 2010 (The Health and Social Care 
Information Centre, 2011). Optimal use of this intervention requires the appropriate 
prescribing of evidence-based medicines with the aim of maximising patient benefit 
and minimizing harm. However, for medicines to deliver benefit they need to be taken 
in accordance with agreed directions according to best available evidence. The term 
used to describe patients’ medicines-taking behaviour is called medicines adherence 
and is defined as: the extent to which a person’s behaviour – of taking medicines – 
corresponds with agreed recommendations from a healthcare provider (WHO: World 
Health Organisation, 2003; Horne et al., 2005; NICE: National Institute for Health and 
Clinical Excellence, 2009). In the last decade there has been a transition from the use 
of the term ‘compliance’ to ‘adherence’ to reflect the patient involvement and 
agreement with the recommendations made by the prescriber (NICE, 2009). While 
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some literature distinguishes between taking medicines as agreed and prescribed e.g. 
40mg twice a day (adherence), and continuing to take it as prescribed (persistence) 
others consider adherence to mean both (Ho et al., 2009). In the UK, the term 
adherence is the currently recommended term (NICE, 2009).   
 
In recent years, many reports and publications have targeted the topic of medicines 
adherence. This interest is due to the association of medicines non-adherence with: 
increased health care spending, high readmission and hospitalisation rates, higher 
morbidity and mortality (Sherbourne et al., 1992; Osterberg & Blaschke, 2005). In 
2009, the National Institute for Health and Clinical Excellence (NICE) issued its 
guidance on medicines adherence in which it estimated that between a third and a half 
of all medicines prescribed for patients with long-term conditions are not used as 
recommended (NICE, 2009). Non-adherence to evidence-based medicines limits the 
potential benefits and so may result in a lack of improvement or significant 
deterioration in health. Deterioration of patients’ health necessarily increases the 
demands for healthcare, which together with wasted medicines, also has significant 
economic consequences. The current cost of unused or unwanted medicines is 
estimated to exceed £300 million per year in England alone (Traueman et al., 2010). 
Non-adherence is cited as one of the reasons for this avoidable cost (Traueman et al., 
2010). Non-adherence is therefore an important issue that needs to be considered and 
addressed during the provision of healthcare services.  
 
Healthcare professionals have the responsibility of ensuring that patients continue to 
derive the best from their medicines after they are prescribed and therefore the 
review of medicines adherence and factors that can influence it should be integrated 
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into healthcare practice and specifically medicines reviews or pharmaceutical care 
(Clyne et al., 2008; NICE, 2009). This is particularly important to patients with chronic 
conditions who are expected to take their medicines long term, and in most cases for 
the rest of their lives.   
 
Of all the long-term conditions, cardiovascular disease (CVD) is the main cause of 
death in the UK and almost half of CVD deaths are from coronary artery disease (CAD)
*
 
(BHF: British Heart Foundation, 2010). In England, around 266 million prescriptions 
were issued for the treatment of CVD in 2008 (BHF, 2010). The increase of mortality 
and morbidity due to medicines non-adherence in patients with CVD has been 
demonstrated in several studies (Horwitz et al., 1990; Blackburn et al., 2005; 
Rasmussen et al., 2007). 
 
The Leeds Teaching Hospitals NHS Trust (LTHT) cardiology service is one of the largest 
in the country providing secondary and tertiary care to the West Yorkshire region 
(LTHT, 2011). Large numbers of patients with CAD visit the LTHT on a daily basis. This 
provides healthcare professionals, including clinical pharmacists, with an excellent 
opportunity to optimise patients’ medicines. One aspect of medicines optimisation not 
formally addressed at LTHT is the issue of medicines non-adherence. The most 
frequently prescribed cardiovascular medicines are CAD secondary prevention 
medicines (see Section 1.3). These medicines tend to be prescribed for life and their 
benefit in reducing mortality and morbidity are well established (NICE, 2007; Gibbons 
et al., 2007).  
                                                 
*
 The terms Coronary Artery Disease (CAD) and Coronary Heart Disease (CHD) are used interchangeably 
in this thesis and are assumed to mean the same, although CHD can be due causes other than 
atherosclerosis (CAD) such as coronary vasospasm.      
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As experts on medicines, clinical pharmacists have a central role to play in medicines 
optimisation. A research project was developed to explore adherence to CAD 
secondary prevention medicines, to design interventions to address non-adherence 
and to test their effectiveness in a randomised controlled trial. This project was later 
called the ADHERE study (Adherence to Drugs Having Evidence of Real Effectiveness - 
A randomised controlled trial of structured pharmacist-led review of heart medicines 
as compared to usual-care for patients with established coronary artery disease). See 
Figure 1.1 for a summary which describes the stages of the ADHERE study. 
 
 
 
Figure  1.1 – Description of the stages of the ADHERE study (Adherence to Drugs Having 
Evidence of Real Effectiveness) and how the research idea came about. CAD = Coronary Artery 
Disease, RANI-1 = First Reported Adherence vs. Non-adherence Investigation. 
 
  
NICE and World Health Organisation (WHO) reviews of medicines adherence highlight 
the complexity and multidimensionality of the causes of non-adherence (WHO, 2003; 
NICE, 2009). They emphasise that addressing the issue of non-adherence requires an 
understanding of patients’ perspectives of medicines and the reasons behind why they 
may not want or are unable to use them effectively (NICE, 2009). Therefore, stage one 
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of the ADHERE study was designed to explore non-adherence behaviour among the 
LTHT’s CAD population and to quantify the level of non-adherence to inform any future 
interventions. In order to be able to measure the impact of any intervention, it was 
necessary to identify suitable tools to assess adherence.     
 
After conducting a full literature review and following discussions with various health 
professionals in the cardiology team, it was identified that non-adherence to 
secondary prevention medicines among our CAD population in West Yorkshire had not 
been explored previously. With regards to adherence assessment tools, none were in 
use in the Trust. The researcher also surveyed current practice around adherence 
assessment in Yorkshire and Humber in primary and secondary care in order to identify 
any assessment tools in use. Fourteen out of sixteen hospital NHS Trusts in Yorkshire 
and Humber completed the questionnaire and 28 out of approximately 150 
community pharmacies (Khatib et al., 2011).  Despite good awareness of the NICE 
guidelines on adherence among respondents, none of them reported the formal use of 
validated tools to measure adherence in routine practice (Khatib et al., 2011).      
 
Based on the above findings the First Reported Adherence vs. Non-adherence 
Investigation (RANI-1) was conducted (ADHERE Stage 1). The investigation of 
medicines non-adherence to secondary prevention medicines by CAD patients in West 
Yorkshire and nearby areas will be reported in this research study in order to inform 
practice and enable the design of suitable interventions that can be tested in later 
stages of the ADHERE study.  
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1.2 Why coronary artery disease?  
CAD or coronary heart disease (CHD) is an obstruction or narrowing in the arteries 
supplying blood to the heart muscle due to, mainly, atherosclerosis (deposits of plaque 
inside the arteries) (Kumar & Clark, 2009; Nabel & Braunwald, 2012). Patients with 
CAD may be diagnosed with, for example, angina pectoris, myocardial infarction (MI), 
unstable angina or silent myocardial ischaemia. In addition to medical treatment, some 
patients may have additional interventions for their CAD such as percutaneous 
coronary intervention (PCI) and coronary artery bypass grafting (CABG).  
 
CAD is a major cause of death and disability in the developed world and despite the 
decrease in the death rate from CAD over the last 4 decades, the UK death rate from 
CAD remains high compared to other Western European Countries, with nearly 88,000 
deaths per year (NICE, 2007; BHF 2010). In England around 2 million people have or 
have had angina and around 62,000 men and 39,000 women suffer a heart attack 
every year (BHF, 2010; NICE, 2011). Every six minutes someone dies of a heart attack in 
the UK (BHF, 2010). Based on the Framingham Heart Study, at the age of 40 years, it is 
estimated that the life-time risk for developing CAD is 1 in 2 for men and 1 in 3 for 
women (Lloyd-Jones et al. 1999). Apart from the high risk of death, CAD negatively 
impacts on patients’ quality of life, employment and personal relationships (DoH: 
Department of Health, 2000).  
 
It is estimated that CAD costs the UK economy approximately £9billion a year (BHF, 
2010). This total cost can be divided as follows: 36% due to direct healthcare costs, 
43% due to productivity losses and 21% due to the informal care of patients with CAD 
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(BHF, 2010). The magnitude of health and cost burden of CAD makes it an appropriate 
target condition for this research. In 2000 the National Service Framework on Coronary 
Heart Disease stated the following about CAD:  
 
“It is a condition that makes a significant impact on every aspect of an 
individual’s life including their quality of life, future employment and personal 
relationships, as well as increasing the risk of their dying early. Much can be done 
to reduce the suffering caused by CHD and to stop it developing in the first place. 
The Government sees this as a major priority” (DoH, 2000). 
 
1.3 Why CAD secondary prevention medicines? 
While the primary prevention of CAD is very important, the main focus of the study 
will be on secondary prevention of CAD using medicines. This is because of the 
secondary care nature of the setting of the study and the healthcare professionals 
involved. In addition, the evidence of the mortality and morbidity benefits of 
secondary prevention medicines for CAD is much more established and robust than 
primary prevention. 
 
As mentioned in Section 1.2, deaths from CAD have declined from 174,000 deaths per 
year in 1970s to 88,000 in 2008 (NICE, 2007; BHF, 2010). This decline in death rate is 
consistent across the developed world and largely attributable to better healthcare; 
particularly, the development and use of medicines such as lipid lowering and 
antihypertensive medicines, and certain life style changes such as smoking cessation 
(Ker, 2010; Unal et al., 2004). The prescribing of secondary prevention medicines after 
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MI had the largest contribution and it is estimated that each death avoided by treating 
a patient with CAD can yield an additional 7.5 years of life (Ker, 2010).  
Medicines for the secondary prevention of CVD that have a proven benefit in reducing 
mortality and morbidity include: antiplatelets (aspirin or/and clopidogrel), statins; and 
(in patients with MI or heart failure) beta blockers and angiotensin converting enzyme 
inhibitors (ACEI) (NICE, 2007; NICE, 2011). NICE (2007) makes it clear that all patients 
who have suffered an MI should be prescribed all these 4 classes of medicines unless 
they are contraindicated. Similar recommendations are made by NICE (2011) about 
antiplatelets and statins for patients with stable angina. In addition, there is some 
evidence to support the use of ACEI in stable CAD patients without MI or heart failure 
(Fox, 2003; Teo et al., 2004). The American and European guidelines on the 
management of stable angina recommend the use of beta blockers as first line in 
patients without MI or heart failure (Fox et al., 2006; Gibbons et al., 2007). Patients 
who cannot tolerate ACEI can be offered angiotensin receptor blockers (ARBs) instead, 
though the evidence for their use is not as robust as for ACEI (NICE, 2007).  
Optimal medical treatment post MI with all these 4 classes of medicines (5 medicines 
including aspirin and clopidogrel) was associated with a 74% reduction in total 
mortality compared to patients receiving only one or none of these medicines 
(Bramlage et al., 2010). Recent trials have also shown that PCI does not improve 
cardiovascular outcomes in patients receiving optimal medical treatment (with these 4 
classes of medicines) (Boden et al., 2007). This has led to renewed emphasis on the 
need to utilise these classes of medicines optimally. Table 1.1 summarises the 
evidence and benefits for the use of these 4 classes of medicines in CAD. Economic 
analysis has also shown that secondary prevention medicines are relatively cheap and 
cost effective (Fidan et al., 2007).  
Introduction                                                                                                        The Heart Medicines Survey 
 
 
9 
Consequently, these classes of medicines were specifically targeted by this research 
and every effort should be made to ensure that they are utilised optimally.  
 
Table  1.1 – Summary of the evidence and benefits for the use of the 4 classes of CVD 
secondary prevention medicines in CAD patients. 
 
Antiplatelets 
A meta-analysis of 12 randomized controlled trials of antiplatelet treatment in patients with 
established CAD found that long term treatment with aspirin reduced vascular death (14 fewer 
per 1000 treated, standard error (SE) 4, p < 0.0006) and non-fatal MI (18 fewer per 1000 treated, 
SE 3, p < 0.001) (Antithrombotic Trialists' Collaboration, 2002). Clopidogrel was slightly better 
than aspirin in reducing mortality and cardiovascular events in patients with CAD (CAPRIE 
Steering Committee, 1996). 
Statins 
A meta-analysis of 14 placebo-controlled trials in which all participants at study entry had CAD 
found that long term treatment with statins was associated with a reduction in all-cause 
mortality (RR 0.79, 95% CI 0.70 to 0.90),  CVD mortality (RR 0.75, 95% CI 0.68 to 0.83), non-fatal 
MI (RR 0.69, 95% CI 0.59 to 0.79), hospitalization for unstable angina (RR 0.90, 95% CI 0.84 to 
0.97), and need for coronary revascularization (RR 0.77, 95% CI 0.69 to 0.85)  (NICE, 2006).  
ACEI 
Long-term treatment of patients with CAD (with preserved left ventricular dysfunction (LVD)) 
post MI with ACEIs was associated with a reduction in total mortality (RR 0.87, 95% CI 0.81 to 
0.94), non-fatal MI (RR 0.84, 95% CI 0.75 to 0.94), and coronary revascularization (RR 0.93, 95% 
CI 0.85 to 1.00) (Al-Mallah et al., 2006). In CAD patients with LVD, long term treatment with ACEI 
was associated with substantial reductions in all-cause mortality (OR 0.74, 95% CI 0.66 to 0.83), 
recurrent MI (OR 0.80, 95% CI 0.69 to 0.94) and re-admission for heart failure (OR 0.73, 95% CI 
0.63 to 0.85) (Flather et al., 2000). ACEI were also found to reduce the risk of the composite of 
sudden death or non-fatal cardiac arrest in high-risk individuals who did not have an MI in two 
major studies (Fox, 2003; Teo et al., 2004). 
Beta Blockers           
Long-term treatment of CAD patients post MI with a beta-blocker was associated with reduction 
in all-cause mortality (OR 0.77, 95% CI 0.69 to 0.85) (Freemantle et al., 1999). In patients who 
had LVD, long term treatment with ACEI and BB was associated with reduction of all-cause 
mortality (HR 0.77, 95% CI 0.60 to 0.98) and non-fatal MI (HR 0.59, 95% CI 0.39 to 0.90) (Dargie, 
2001). Some weak evidence suggests that in people with severe CAD without MI or LVD, beta 
blockers may reduce the risk of all-cause death, but not the risk of future non-fatal MI (Bunch et 
al., 2005). 
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1.4 Medicines adherence in CAD 
For evidence based medicines to work they need to be taken by patients in accordance 
with the evidence and as C. Everett Koop said “Drugs don’t work in patients who don’t 
take them” (Osterberg & Blaschke, 2005). Non-adherence limits the maximum benefit 
that patients can derive from medical treatment which can in turn lead to poor health 
outcomes, lower quality of life and increased demands for healthcare, which together 
with wasted medicines, also has significant economic consequences (NICE, 2009). NICE 
(2009) estimates the level of non-adherence to medicines in patients with long-term 
conditions to be between 33 to 50%. Various levels of non-adherence, ranging from 
25% to 50% were reported by patients with chronic obstructive pulmonary disease 
(COPD), asthma, psychiatric disorders, arthritis, CVD, HIV and cancer (DiMatteo, 2005; 
Cramer & Rosenheck, 1998). Therefore, non-adherence is a growing concern to 
clinicians and healthcare systems.    
 
As mentioned in Section 1.3, a large number of clinical trials have demonstrated the 
efficacy of antiplatelets, beta blockers, ACEI and statins for secondary prevention of 
CAD. National and international guidelines and quality improvement initiatives have 
incorporated prescription of these medications as important quality of care measures 
in secondary and primary care (NICE, 2007; NICE, 2011; DoH, 2000; Gibbons et al., 
2007; Fox et al., 2006; BMA, 2011). This has improved the level of prescribing of these 
secondary prevention medicines in both primary and secondary care, though there is 
still room for further improvement (DeWilde et al., 2008).  However, even with these 
improvements in the prescription rates of secondary prevention medicines, a gap still 
exists between the efficacy shown in clinical trials and the effectiveness of these 
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medicines in clinical practice (Ho et al., 2008). One possible explanation for this is the 
level of adherence to these secondary prevention medicines.  
 
Many studies support this explanation and show that there is a significant level of non-
adherence to secondary prevention medicines by CHD patients.  Jackevicius et al. 
(2008) reported that almost a quarter of post-acute MI patients did not fill their 
prescription 7 days after discharge. Several authors suggest that as many as 50% of 
patients with recurrent MI were not taking their prescribed aspirin, beta blockers, or 
lipid-lowering medications - at the time of readmission (Majumdar et al., 1999; 
Krumholz et al., 1995; Rathore et al., 2003; Burwen et al., 2003). Sung et al. (1998) 
reported that only about one-third of patients took at least 90% of their lipid-lowering 
treatment. Others have estimated the discontinuation rates in this context to be 50% 
after one year and 85% after two years (Insull, 1997).  A study which assessed self-
reported adherence to evidence-based medicines used in secondary prevention of CAD 
found that adherence was highest for aspirin (83%); followed by lipid-lowering agents 
(63%), beta blockers (61%), both aspirin and a beta blocker (54%); the lowest 
measured adherence rate was for joint use of all 3 medications (39%) (Newby et al., 
2006). In another study, the rates of non-adherence among patients with established 
CAD were 28.8% for beta blockers, 21.6% for ACEI, and 26.0% for statins (Ho et al., 
2008). 
 
Despite reports of some improvement, adherence rates remain suboptimal for 
secondary prevention medicines. In 2003 levels of adherence by post MI Medicare 
patients in the USA, compared to 1995, increased from 38.6% to 56.2% for statins and 
29.1%  to 46.4% for all three secondary prevention medicines (statin, beta-blocker, and 
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ACEI/ARB) (Choudhry et al., 2008). Though there was an increase in adherence rates 
for statins and beta-blockers, there was no change in the rate of adherence to 
ACEIs/ARBs which remained around 50% (Choudhry et al., 2008). On the other hand, 
some longitudinal studies show that non-adherence to secondary prevention 
medicines decreases among the same population over time. For example, Chodick et 
al. (2008) reported that the mean levels of adherence to statin therapy among Israeli 
patients with CAD (initiated between 1998 and 2006) was 59% and more than 75% of 
patients stopped their statins within 2 years of the initial prescription. 
 
The above studies clearly demonstrate that non-adherence to secondary prevention 
medicines by patients with established CHD is a real problem which needs addressing. 
A Cochrane review on “interventions for enhancing medication adherence” concluded 
that improving adherence may have a far greater impact on clinical outcomes than an 
improvement in treatments (Haynes et al., 2008).  This statement can be better 
understood when one considers the impact and consequences of non-adherence to 
these secondary prevention medicines. CAD patients who had primary non-adherence 
(not filling prescriptions) by 120 days after MI in comparison with those who filled their 
prescriptions had an 80% increased risk of mortality (Jackevicius et al., 2008). Post MI 
patients in the Beta Blocker Heart Attack Trial who took 75% or less of their prescribed 
medicines were 2.5 times more likely to die than were those who were more adherent 
to treatment (Horwitz et al., 1990). Ho et al. (2008) reported that non-adherence to 
secondary prevention medicines (beta blockers, statins, ACEI) by patients with 
established CAD was associated with a 10–40% relative increase in risk of cardiac 
hospitalisations and a 50–80% relative increase in mortality. These findings further 
emphasise that non-adherence should be investigated to develop quality improvement 
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interventions which can maximise the outcomes of patients with CAD. This is why 
medicines adherence has been described as the “next frontier in quality improvement” 
(Heidenreich, 2004). 
 
1.4.1 Level of adherence required to gain benefit 
In order for patients to derive the benefits seen in clinical trials, they need to have a 
high adherence to the treatment plan. Though there is no agreement as to what 
constitutes an adequately high level of adherence, several trials consider rates of 
greater than 75% to be acceptable (Osterberg & Blaschke, 2005; Silcock & Standage 
2007). Pharmacy refill data and dosage counts are the most commonly used methods 
in the literature to quantify the level of adherence and patients with medications 
available greater than 75% of the time are considered adherent (Ho et al., 2009).  The 
percentage is worked out by calculating the number of doses absent in a given time 
period divided by the number of doses prescribed by the doctor in that same time 
period (Brown & Bussell, 2011). Though this cut off point is somewhat arbitrary, it has 
been used for a majority of the observational and randomized, controlled clinical trials 
on medicines adherence and has been associated with both intermediate and hard 
outcomes (Ho et al., 2009).  
 
Recent literature suggests that patients might be missing on additional benefits by 
using this cut off point. For example, adherence levels beyond 80% were associated 
with better reduction in Low Density Lipoprotein (LDL) cholesterol and blood pressure, 
which can lead to better outcomes (Bryson et al., 2007). The use of 75% as a cut-off 
point is considered very low for other medicines such as HIV medicines. In order to 
Introduction                                                                                                        The Heart Medicines Survey 
 
 
14 
establish better understanding of adherence benefits beyond 75%, future studies 
should report outcomes for different dichotomous cut-offs (Ho et al., 2009). 
 
1.4.2 Causes of medicines non-adherence 
In order to address the problem of non-adherence, it is necessary to understand the 
underlying causes of this behaviour. Non-adherence should not be perceived as a 
patient’s problem but as a limitation in the delivery of healthcare (NICE, 2009). The 
causes of medicines non-adherence are complex, multifactorial and cannot be 
explained by single fixed factors such as the type or severity of the disease and 
sociodemographics of patients (Horne et al., 2005). A large proportion of the research 
into causes of non-adherence attempts to identify factors distinguishing adherent from 
non-adherent patients such as sociodemographic and clinical factors (Horne, 2005; 
Brown & Bussell, 2011). Many of these factors, however, are fixed (e.g. gender, age, 
race) and others, although they can be modified, they cannot be addressed in a clinical 
practice setting (e.g. financial status). The WHO summarised the different factors that 
can contribute to non-adherence in 5 categories as can be seen in Table 1.2 with 
examples (WHO, 2003). It is important to emphasise that not all of these factors have 
been consistently associated with patient non-adherence (Brown & Bussell, 2011). The 
level of contribution of each one of these factors towards non-adherence is not 
consistent and depends on interactions with other factors. For example, patients with 
good knowledge and strong belief that they need their medicines may still be non-
adherent because they cannot afford the prescription charges, if applied, or are unable 
to swallow them. So it cannot be said that clear information about medicines, although 
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essential, can guarantee adherence to medicines because of the presence and absence 
of other factors which contribute to non-adherence (Horne, 2005). 
 
Adherence is a behaviour and various research studies investigating causes of non-
adherence have used psychosocial approaches to conceptualise adherence (Horne & 
Weinman, 1999). This type of research identifies that adherence and non-adherence 
behaviours are best understood in terms of patient’s motivation and capacity to follow 
therapeutic recommendations (Horne et al., 2005). Therefore, the patient’s medicines-
taking behaviour is determined by their beliefs, perceptions about illness and 
treatment, preferences and resources (Horne et al., 2005). With a better 
understanding of the patient’s perceptions and role in their non-adherence to 
medicines, the health professional can have a better understanding of the causes of 
non-adherence and possibly a positive impact on patients’ medicine-taking behaviour.   
 
Horne (2003) identifies two types of adherence: intentional and unintentional. 
Intentional non-adherence is when the patient decides to stop or change their agreed 
treatment regimen and their decision is often made through active reasoning, where 
the perceived benefits of the medicine are balanced against the perceived risks. 
Addressing this type of non-adherence requires interventions to address motivational 
and perceptual barriers (Horne et al., 2005). Unintentional non-adherence is when the 
patient wants to follow the treatment, but barriers beyond their control stop them 
from doing so (e.g. forgetfulness, lack of understanding, difficulty swallowing) (Horne, 
2003; Lowry et al., 2005; NICE, 2009). This type of non-adherence would require 
interventions targeting practical barriers and capacity and resources (Horne et al., 
2005). Patients may display both types of non-adherence behaviour simultaneously. 
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Furthermore, a patient may be intentionally non-adherent to one medicine and 
unintentionally non-adherent to another.    
 
Horne et al. (2005) mapped the determinants of adherence behaviour in an attempt to 
improve understanding of how patients approach the taking of medicines. As can be 
seen in Figure 1.2, the decision to take medicines and continue taking them is a 
complex behaviour. There are internal and external factors and influences on 
medicines-taking behaviour. These factors interact, which further shows the complex 
nature of causes behind non-adherence behaviour (NICE, 2009). The internal factors 
reflect the beliefs that the patient holds about their illness and medicines in general 
and specifically about their own condition and medicines. These beliefs about the 
necessity (or personal need/benefit), concern and the harm (or risk) that can be 
caused by medicines, heavily influence patients’ motivation and intention to take or 
not take their medicines (Horne et al., 2005). External factors such as communication 
with healthcare professionals, family and friends, feed into the patient’s own internal 
appraisal process and influence the decision making process of taking medicines (NICE, 
2009). 
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Figure  1.2 – Map of determinants of adherence which conceptualises non-adherence as 
unintentional and intentional behaviours with internal and external determinants.  The 
internal factors influence motivation, and capacities may be moderated by external variables, 
(Adapted from Horne et al. 2005). 
 
 
It is clear that reasons behind non-adherence are complex and require considering 
multiple factors. However, in this research the main focus will be on actual and 
perceived causes which can be modified in clinical practice. The main interest will be in 
factors in any of the 5 domains identified by the WHO (see Table 1.2) which are related 
to medicines or medicines related processes (e.g. repeat prescriptions). 
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• Medicines cost 
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Appraisal - assessment & interpretation of outcomes 
relative to expectations. Did it work? Is it worth continuing? 
Perception of illness 
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It is noteworthy that non-adherence is usually a hidden problem which is under -
recognised by prescribers and not necessarily disclosed by patients (Horne et al., 
2005). Patients do not often disclose their reluctance or disagreement with the 
prescriber’s recommendations and it is therefore expected that healthcare 
professionals would assess, elicit and explore patients’ beliefs and experiences with 
their medicines to help them make an informed choice on whether to take or not to 
take a medicine (NICE, 2009).   
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 Table  1.2 – The WHO five categories of factors that can contribute to medicines non-
adherence with examples for each factor.  
 
1) Socioeconomic Factors 
• Financial burden (cost of medicines) 
• Lack of transportation 
• Low levels of patient education and/or literacy 
• Language barriers  
• Lack of effective social support networks (e.g. family helping with medicines) 
• Unstable living conditions (problems at home, patients who travel frequently, homeless) 
• Attitudes associated with poverty (lower levels of self-efficacy, learned helplessness, low 
levels self-determination) 
2) Healthcare team and system factors 
• Health professionals’ lack of time (to identify & address patient medicine taking 
behaviour) 
• Healthcare professionals lack of involvement of patients & addressing their specific 
needs 
• Fragmented healthcare systems leading to lack of continuity of care & access to care 
• Inter-professional collaboration (important for better treatment plans and a better 
overview of patient adherence) 
• On-going communication after initiation of medicine (monitor progress & overall health) 
• Poor medicine distribution and costs (rural areas, repeat prescriptions) 
• Failing to recognise the non-adherence problem 
3) Disease – related factors 
• Permanent or chronic disease (e.g. CAD, HF)   
• Co-morbidities (e.g. depression)  
• No symptoms/no severe symptoms (e.g. hypertension)  
• Rate of progression and severity of the condition (e.g. HF progressive +  potential 
gradual aggravation) 
4) Therapy – related factors 
• Regimen complexity and how it fits into the patient’s routine  
• Side-effects and pharmaceutical properties of the medicine (e.g. taste, size of tablet etc.) 
• Frequent changes in treatment (example titrating ACEI) 
• Poor instructions, complex process of ordering refills  
• Lack of immediacy of beneficial effects (effect not immediate, or impact not apparent)  
• Reduced access to medicines and/or medical support (rural and remote areas, cost, 
access) 
5) Patient-related factors 
• Lack of understanding of the disease. 
• Lack of involvement in treatment decision-making process.  
• Language or literacy barriers  
• Actual or perceived side-effects 
• Own health beliefs and attitude towards medicines 
• Rejection of the diagnosis (lack of symptoms) 
• Limited understanding of the importance of medicines (asymptomatic conditions) 
• Previous experience and loss of faith in medicines  
• Poor sight, poor memory, inability to swallow  
• Lack of self-efficacy (lack of confidence to make recommended behavioural changes) 
• Poor mental health (e.g. depression and anxiety in CAD patients) 
(WHO, 2003; Horne et al., 2005; Brown & Bussell, 2011) 
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1.4.3 Interventions to Improve Adherence 
After discussing the complex nature of the reasons behind non-adherence the 
interventions that have been tested to improve adherence will be considered to 
inform the direction of this research. 
 
Several systematic reviews and meta-analyses evaluated the effectiveness of 
interventions to enhance medicines adherence (Roter et al., 1998; Horne et al., 2005; 
Kripalani et al., 2007). Some focused only on randomised controlled trials (e.g. 
Kripalani et al., 2007), while others included trials with controlled designs which were 
not necessarily randomised (e.g. Roter et al., 1998).  
 
The interventions can be summarised as follows (Roter et al., 1998; Horne et al., 2005; 
Kripalani et al., 2007; Dulmen et al., 2007):  
 
Informational or educational interventions – which provide the patients with 
intensive educational materials using different methods (written information, face to 
face educational sessions etc.). The methods used were very diverse and it was difficult 
to compare findings due to different methods.  
 
Behavioural interventions (skills) – help patients to deal with practicalities of taking 
medicines e.g. most common was dosage simplification, memory aids (reminders 
including using telephone etc.), monitoring, enhancing self-efficacy, self-training, 
providing repeated assessment of medicines use with feedback and reward.  These 
interventions were generally effective and stemmed from behavioural theories e.g. 
incentives and reminders. Though there was evidence that “technical interventions” 
Introduction                                                                                                        The Heart Medicines Survey 
 
 
21 
such as simplifying medication dosage schedules led to improved adherence, the 
effects of this simplification seem to become less the longer the treatment lasts and no 
theoretical explanation was always provided of the operating mechanisms for these 
interventions.  Others included specialised packaging, directly observed therapy and 
cognitive behaviour therapy, but these did not significantly improve adherence.  
 
Combined interventions – most studies included both informational and behavioural 
components and others had joined social support strategies with either informational 
or behavioural components. There were variable outcomes with these interventions. 
 
Though there was evidence to support some of these interventions, not all trials within 
the same category were effective and it was not possible to establish why the same 
intervention worked in one trial and did not in the other (Roter et al., 1998; Kripalani 
et al., 2007). There was also a lack of consistency in reporting the type of interventions 
used and the type of outcomes and adherence measurements (Kripalani et al., 2007).  
 
The interventions can also be categorized into two approaches based on their purpose 
(Horne et al., 2005): Perceptual (motivational) interventions which are aimed at 
changing motivation by influencing knowledge, beliefs, or attitudes and practical 
(capacity and resources) interventions which are aimed at changing specific patient 
behaviours (e.g. reminder or skill building) and removing barriers to performance.   
Interventions with a combined purpose can also be used. The augmented review by 
Horne et al. (2005) concluded that interventions to promote adherence were broadly 
efficacious and increased adherence by 4 – 11%. However, the interventions 
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consumed considerable resources and effort with small impact and considerable room 
for improvement.   
 
A Cochrane systematic review of “Interventions for enhancing medication adherence” 
included interventions with randomised controlled design and had a clinical outcome 
measure (Haynes et al., 2008).  It identified that only 36 of 83 interventions reported in 
70 trials were associated with improvements in adherence in long-term treatments 
and only 25 interventions led to improvement in at least one treatment outcome 
(Haynes et al., 2008). However, the improvements were not large and even the most 
effective interventions did not lead to large improvements in adherence and treatment 
outcomes.  Those interventions that were effective were complex and included various 
combinations of more convenient care, information, reminders, self-monitoring, 
reinforcement, counselling, family therapy, psychological therapy, crisis intervention, 
manual telephone follow-up, and supportive care (Haynes et al., 2008). 
 
In their critique of the interventions, Horne et al. (2005) listed the following limitations 
in the interventional studies to improve adherence: 
(1) Narrow focus of the intervention and lack of comprehensiveness. Very few 
interventions address both the practical and the perceptual barriers to adherence. 
(2) One size fit all approach. Very few of the interventions could be classed as patient-
centred in their approach. They broadly seem to fail to identify the reasons behind 
non-adherence in the population before designing the intervention. 
(3) Little information was provided about the content of the intervention which made 
it difficult to evaluate what worked and what did not work.   
(4) Lack of theoretical framework and specific targeting of determinants of adherence. 
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(5) Studies which used complex interventions did not evaluate the impact of each 
element on adherence.  
(6) Lack of evaluation of the changes in the antecedents of adherence and the extent 
to which the interventions were correctly implemented.  
 
The reviews seem to show that interventions to improve medicines non-adherence 
produced only modest success and uni-modal interventions were less successful than 
multi-modal interventions (Ho et al., 2009). Due to the often multifactorial nature of 
the reasons behind non-adherence, multimodal interventions are generally considered 
to be more likely to be successful than uni-modal approaches (Baroletti & Dell’Orfano, 
2010).  It is most important that the development of any intervention need to target 
patient or population specific barriers rather than the “one size fit all” approach.   
 
1.5 The direction of this research 
To optimise the medical treatment of CHD patients and maximise their opportunity to 
benefit from secondary prevention medicines, their medicines-taking behaviour needs 
to be understood by healthcare professionals and patient specific interventions need 
to be deployed to address barriers to adherence. The review of evidence about 
interventions to improve adherence emphasises the need to study the target 
population before implementing any intervention in order to tailor the intervention(s) 
to the needs of the population. This helps in building individualised or patient-centred 
interventions. This study will explore the medicines-taking behaviour of CHD patients 
to inform practice and enable us to address non-adherence which in turn should 
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contribute to an increase in the benefits patient derive from secondary prevention 
medicines.  
 
As explained earlier, non-adherence is usually a hidden and under–recognised 
problem. Therefore, there is a need to have appropriate practical assessment tools 
which enable identifying non-adherence in practice. Indeed NICE (2009) and the WHO 
(2003) recommend that patients’ level of adherence should be assessed routinely as 
whenever one prescribes, dispenses and reviews medicines. It would be very useful if 
these assessment tools could also identify the specific barriers that prevent patients 
from adhering to their secondary prevention medicines. 
 
Despite its importance and its significant negative impact on patients and healthcare 
systems the assessment of patients’ non- adherence and use of interventions to 
improve adherence remain rare in routine clinical practice (Ho et. al., 2009). This 
research attempts to help inform and change practice in the LTHT and possibly wider 
context.   
 
In the next chapter, the literature will be comprehensively reviewed to identify the 
best ways of assessing and investigating medicines-taking behaviour among CHD 
patients. Any tools identified need to serve the following requirements: 
 
(1) The tool(s) needs to enable quantifying the level of non-adherence in order to be 
able to measure the impact of any interventions in the future. 
(2) The tool(s) needs to be practical and can be easily used in clinical practice to enable 
the assessment of adherence in routine practice  
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(3) The tool(s) needs to provide information about barriers to adherence to inform the 
design of interventions which are tailored to patients’ needs and specific barriers. 
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2 Literature Review 
Hippocrates observed over 2500 years ago that “(Physicians should) keep watch also 
on the faults of patients which often make them lie about the taking of things 
prescribed” (Horne, 2001) 
 
As identified in Chapter 1 the assessment of adherence behaviour is essential for 
optimising medical therapy. The purpose of the assessment is to measure non-
adherence levels and more importantly to reveal barriers to adherence. These findings 
are needed for effective and efficient treatment planning, ensuring that changes in 
health outcomes can be attributed to the recommended regimen and informing the 
development of patient-tailored adherence improvement interventions, which are 
more likely to be effective (WHO, 2003; NICE, 2009). The assessment of adherence is 
not about monitoring patients per se. Its fundamental purpose is to find out if patients 
need help and support in taking their medicines to optimise their therapy (NICE, 2009).  
 
Most health professionals overestimate their patients’ adherence and patients 
generally do not volunteer information about their non-adherence to medicines 
(Hansen et al., 2009). Therefore, health professionals need to make specific efforts to 
assess adherence. Healthcare professionals need to screen individual patients for 
perceptual and practical barriers to adherence. This should be not only at the time of 
prescribing but also during medicines reviews, because adherence may change over 
time (NICE, 2009). Therefore, there is a need for near patient adherence assessment 
tools that are practical, simple, accurate, valid and reliable. Tools should identify and 
measure non-adherence including its types and causes so that interventions to 
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improve adherence can be formulated and assessed (Horne et al., 2005; Hansen et al., 
2009). Such tools need to be non-judgmental and easy to use when prescribing, 
dispensing, reviewing medicines or discussing a patient’s health (Horne et al., 2005; 
NICE, 2009).  
 
This chapter will summarise an extensive literature review which attempted to identify 
the different tools that can be used to measure and assess adherence as described 
above. The main focus will be on practical tools that can be used in clinical practice 
specifically while providing care to CHD patients in secondary care setting.  
 
2.1 Direct and indirect methods to assess adherence 
Various adherence assessment strategies have been reported in the literature but 
there is no “gold standard” tool for measuring adherence behaviour and no single tool 
to detect all types of non-adherence (WHO, 2003; Osterberg & Blaschke, 2005; Simoni 
et al., 2006). The assessment of adherence can be carried out using direct and indirect 
methods (Osterberg & Blaschke, 2005). Direct methods include observing patients 
taking their medicines and the measurement of drug or metabolite levels in the blood 
or urine. Indirect methods of assessment include self-reporting (using questionnaires, 
interviews, surveys or patient diaries), rates of repeat prescription ordering, refill rates, 
dose counting, assessment of a patient’s clinical response or therapeutic outcomes 
(e.g. lipid levels, blood pressure), electronic monitoring devices, and measuring serum 
or urine markers  (Horne, 2001; Osterberg & Blaschke, 2005; Ho et al., 2009).  
Direct methods are considered to be more robust than indirect methods because they 
directly assess medicines-taking rather than relying on proxy indicators (Ho et al., 
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2009). However, their major limitation is that they are expensive and not practical for 
routine clinical use in daily practice (Osterberg & Blaschke, 2005; Ho et al., 2009). They 
can also be prone to error and manipulation. For example, there may be inter-
individual variations in metabolism that can affect serum levels, or patients can hide 
doses in their mouth and discard them later. The therapeutic outcome approach 
assumes a close relationship between adherence to treatment and clinical benefit. 
While this might be true for certain effective treatments, adherence does not 
guarantee benefit and its relationship with health outcome is rarely linear (Horne, 
2001). The identification and measurement of non-adherence behaviour are far from 
easy and each available method has its own advantages and disadvantages (Horne, 
2001; Hansen et al., 2009). Table 2.1 summarises some examples of direct and indirect 
methods of assessing adherence including the advantages and disadvantages of these 
methods. 
 
Adherence is assessed by each of these methods at different stages of the prescribing 
and medicines-use time line. Therefore, they have the potential to identify different 
adherence behaviours e.g. adhering to ordering the prescription but not filling the 
prescription. They also differ in terms of the gap between adherence assessment and 
the actual medicines-taking behaviour (Hansen et al., 2009). Some methods may be 
good for acute or recent medicine-taking e.g. serum levels. Others may reflect a 
pattern of behaviour over a certain period e.g. prescription refill data over 6 or 12 
months. Self-report methods may ask questions about medicines-taking behaviour at a 
time and place which are distant from the actual event and the answer, therefore, can 
be affected by the ability of recall (Horne, 2001). People can experience the “golden 
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halo” effect of recalling the “good” rather than the “bad” in relation to an event 
(Horne, 2001).   
 
 
Table  2.1 – Examples of direct and indirect adherence assessment methods including their 
advantages and disadvantages. 
 
Tool Description Advantages Disadvantages 
Direct    
Measurement of 
the level of 
medicine or 
metabolite in the 
blood or Urine 
Depending on the type 
of drug and its 
pharmacokinetics, 
samples are taken and 
drug levels or 
metabolites are 
measured at specific 
intervals. 
• Objective 
• Individualised 
  
• Variations can be due to 
factors other than non-
adherence. 
• White-coat adherence 
• Expensive 
• No information about 
reasons for non- 
Directly observed 
therapy 
Patients are observed 
when taking the 
prescribed medicines 
on specific times. 
• Most accurate 
 
• Not practical for routine 
use 
• Patients can hide dose in 
mouth 
• Contrary to the concept 
of informed adherence 
 
Indirect    
Repeat Prescription 
Ordering Data 
 
The frequency of 
ordering repeat 
prescription from GP 
over a defined period 
and checking if amount 
of medicines ordered 
covers that period.   
• Practical 
• Non-invasive 
• Inexpensive 
• Ability to measure 
adherence rate 
• Good as a scanning 
tool for potential 
non-adherers 
• Can identify 
potential non-
adherence to 
specific medicines 
   
• Reports rates only 
• Patients do not always 
“cash” their prescription 
• Patient may still be not 
taking their medicines 
despite ordering repeat 
prescriptions. 
• No information about 
reasons for non-
adherence 
 
Medication Events 
Monitoring System 
(MEMS®) 
The cap of the 
medicines bottle is 
fitted with a special 
microprocessor which 
records number of 
times of bottles 
opening.  
• Accurate  
• Non-invasive 
• Ability to measure 
adherence rate 
• Can observe 
behaviour pattern 
• Suitable for studies  
• Provide a profile of 
medication taking 
rather than simply 
detailing how 
much was taken. 
• Not practical (not all 
medicines are in bottles) 
• Expensive. 
• Patients may still not 
take their medicines. 
• No information about 
reasons for non-
adherence 
• Can enhance adherence 
by  acting as a 
behavioural intervention 
(Horne, 2001; Osterberg & Blaschke, 2005; Ho et al., 2009) 
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As non-adherence is a behaviour, the act of measurement itself can influence the 
behaviour. When patients are aware that their medicines-taking behaviour is being 
monitored, their adherence might be stimulated simply by drawing their attention to it 
(Horne, 2001). Therefore, the findings may be less likely to reflect routine medicines-
taking behaviour.  
 
It is apparent that the most practical and commonly used methods in the literature to 
measure adherence are: patient self-report, repeat prescription data, pharmacy refill 
records, or use of electronic lids to measure doses e.g. medication event monitoring 
systems (MEMS®) (WHO, 2003; Horne et al., 2005; NICE, 2009; Hansen et al., 2009). 
The latter three are most relied on to quantify adherence especially in research. They 
are also useful to identify patients who may need additional support with their 
medicines. Patients with low levels of adherence can also be identified by monitoring 
return of unused medicines (NICE, 2009). However, while these tools are useful for 
screening, research and audit purposes, they are very limited in identifying barriers to 
adherence that would enable the formulation of individualised interventions. Their 
findings need to be examined to identify complementary information they provide to 
enable healthcare professionals to do something about non-adherence (Steiner & 
Prochazka, 1997; Hansen et al., 2009; NICE, 2009). 
 
Asking patients to describe their medicines-taking behaviour is the simplest and most 
commonly used method to assess adherence (Horne, 2001). Some researchers 
undermined this approach due to its tendency to overestimate adherence, but it is a 
valid, practical and useful indicator of non-adherence and sheds more light on barriers 
to adherence than many other tools (Horne, 2001). In routine clinical practice and to 
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involve patients in decision making, self-report methods are considered most 
appropriate (NICE, 2009). They are also probably the closest the researcher can get to 
the actual medicines-taking behaviour of the patient. NICE (2009) identifies self-report 
as the most suitable method for reporting adherence in clinical context. Therefore, the 
rest of this review will focus on self-report methods.  
 
2.2 Self-reporting adherence assessment tools  
Patients’ self-reports are an inexpensive and pragmatic method to assess adherence in 
clinical practice. Their reliability is limited by several factors including memory and 
social desirability, that is, patients not admitting to non-adherence to avoid the 
disappointment of the prescriber (Horne, 2001). However, despite their limitations, 
generally reported non-adherence behaviour, in particular, using this method is 
considered reliable and accurate (Graber et al., 2004; Dimatteo, 2004; Shi et al., 2010; 
Shi et al., 2010a). Each method to measure adherence has its own advantages and 
failings which limit accuracy, reliability or practical application. Available tools are 
generally indicators of adherence rather than exact, quantitative measures of 
medicines-taking behaviour (Horne et al., 2005). Self-report methods represent a fair 
compromise in which accuracy and comprehensiveness is balanced against practicality, 
reactivity, ethical and cost implications (Horne et al., 2005). It is widely accepted that 
reports of low adherence by self-report scales are usually useful in practice and more 
accurate than reports of high adherence (Morisky et al., 1986).  Table 2.2 summarises 
some of the advantages and disadvantages of self-report adherence assessment tools. 
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Table  2.2 – A summary of the advantages and disadvantages of using self-report to assess 
adherence. 
 
Advantages Disadvantages 
• Simple 
• Inexpensive 
• Identifies non-adherence 
• Validated tools can be used to measure 
levels of adherence 
• Practical and easy to administer 
• Suitable for clinical settings 
• Truthfulness of those reporting non-
adherence  
• Gathers important information which can 
inform the support needed (e.g. situational 
and behavioural factors) 
 
• Overestimates adherence 
• Patients may exaggerate their adherence if they 
believe that reports of non-adherence will 
disappoint their clinician 
• Inaccurate self-reporting due to: 
o Recall bias 
o Social desirability bias 
o Errors in self-observation 
• Remembering can be a problem  
(specifying time period can help) 
• The wording and the way the questions are 
asked can influence outcome.  
• Inadequate reliability and poor distributional 
properties (i.e. restricted range and skewness). 
(Horne et al., 2005; Osterberg & Blaschke, 2005; Bangsberg, 2006; NICE, 2009) 
 
 
Self-reported adherence is usually an overestimation when compared to other indirect 
methods such as MEMS® or repeat prescription data (Bangsberg, 2006; Simoni et al., 
2006). It is thought that adherence rates identified by self-reported methods are 
usually 10 to 20% higher than the rates obtained with other methods (Bangsberg, 
2006; Simoni et al., 2006). These often cited disadvantages to self-reported adherence 
measures could have possibly arisen from inadequate attention to administration and 
measurement issues as will be discussed in Section 2.2.3 (Voils et al., 2011). 
 
Patients’ self-reports can effectively measure adherence in a very simple and practical 
way and readily identify adherence-related behaviours at the point of care (Osterberg 
& Blaschke, 2005). Self-report measures include questionnaires, diaries and interviews 
and they are considered the most appropriate for use in clinical practice to 
continuously monitor medicines-taking behaviour (Horne et al., 2005; NICE, 2009). 
Self-reporting methods should enable better understanding of the type of non-
adherence (intentional vs. unintentional) as well as possible barriers to adherence. This 
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should in turn provide a better picture about an individual patient’s adherence support 
needs. 
Some studies argue that the use of self-report daily diary methods might be most 
accurate for certain conditions such as cystic fibrosis (Modi et al., 2006). While this is 
correct for study purposes, for long-term use such methods are costly in terms of 
clinicians’ time and increase the burden on patients (Daniels et al., 2011). Interviews 
are also less practical, time consuming and cannot be easily administered.    
 
Valid and reliable scales, questionnaires or surveys are the most frequently reported 
type of self-report tools in the literature (Graber et al., 2004; Dimatteo, 2004; NICE, 
2009; Shi et al., 2010; Shi et al., 2010a).  They offer the advantage of assessing 
adherence in ‘naturalistic’ studies (e.g. following up a group of chronically ill patients) 
and have the highest potential for widespread application in clinical practice (Garber et 
al., 2004; Horne et al., 2005; NICE, 2009). A number of validated medication adherence 
scales have been described in the literature (see Section 2.2.3 and Appendix 1 for a full 
description of sample of these tools). However, no gold standard exists, and no single 
scale is appropriate for every scenario as will be detailed in Section 2.2.3 (Horne 2001; 
NICE 2009; Shi et al., 2010; Shi et al., 2010a).  
 
There is increasing interest in combining information from self-report with other 
adherence indicators such as repeat prescription data or prescription-redemption 
rates to produce amalgamated assessments of adherence and cross-check self-report 
methods (Horne, 2001; Horne et al., 2005). Such an approach is particularly important 
in interventional studies to enhance adherence.  
Literature Review                                                                                                  The Heart Medicines Survey 
 
 
34 
Self-reporting of medicines-taking behaviour has many advantages. The most relevant 
to this research is that it is easy and practical to use in clinical settings and can gather 
useful information to inform the formulation of individualised interventions to 
improve adherence. Selecting the right self-report adherence assessment 
questionnaire requires understanding of validity, reliability and other basic 
characteristics of these tools.  
 
2.2.1 Validity and reliability of self-report adherence assessment 
questionnaires  
 
The validity of the self-report questionnaires establishes whether the instrument 
measures what it is supposed to measure (Braker et al., 1994).  This is often 
established by checking the tool against other measures of adherence such as MEMS
®
, 
dosage counts and clinical markers (e.g. blood pressure). The MEMS
® 
is considered by 
some as the ‘imperfect gold standard’ that self-report adherence assessment 
questionnaires are often checked against (Shi et al., 2010a). The association and 
agreement between adherence levels identified by self-report questionnaires and 
other measures such as MEMS
®
 is reported using correlation coefficients such as the 
Pearson’s correlation coefficient (rp), the Spearman’s correlation coefficient (rs) or 
kappa coefficient (к) (Krousel-Wood et al., 2009; Shi et al., 2010a).  
 
Reliability of an assessment tool refers to the degree of consistency or reproducibility 
of the measurement and acceptability to the respondent (Barker et al., 1994). This is 
usually assessed using tests like the “test-retest reliability” where the questionnaire is 
administered twice and the findings are compared (Barker et al., 1994). The other 
most commonly used statistic is Cronbach's α (Barker et al., 1994; Machin et al., 2007; 
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Field, 2009). It measures the internal consistency and content validity of the 
questionnaire and assesses the degree to which individual items in the questionnaire 
represent the construct being measured (Machin et al., 2007; Field, 2009). A 
Cronbach's α value of 1 indicates a perfect correlation between the items that make up 
the scale, whereas, a value of 0 indicates no correlation between those items (Machin 
et al., 2007). For research purposes a Cronbach’s α value of 0.60 is considered 
marginal, and values should be higher than 0.7 to 0.8 (Braker et al., 1994; Bland & 
Altman, 1997). Further details are in Appendix 15. Complete correlation (α =1) could 
indicate that most of the questions can be discarded as all the information is contained 
in one of them (Machin et al., 2007).  Studies also report: sensitivity of the instrument 
which is the proportion of true positives (predicted non-adherent and found to be non-
adherent) and specificity which is the proportion of true negatives (predicted adherent 
and found to be adherent) (Marston, 2010).  
 
A systematic review examined the concordance of self-report methods (interviews 
(57%), questionnaires (27%), and diaries (17%)) with other measures of medicines 
adherence (Garber et al., 2004). The self-report measures showed higher adherence 
rates compared to other tools in most non-concordant cases. Concordance varied 
substantially by type of self-report measures. Questionnaires and diaries were more 
concordant with other methods compared to interviews (Garber et al., 2004). 
Generally, self-report questionnaires concorded with other electronic measures, 
although some variation in the level of agreement was found (Garber et al., 2004).  
 
 
Another recent meta-analysis examined the correlation between adherence rates 
measured by MEMS
®
 and self-reported questionnaires (Shi et al., 2010). The mean 
Literature Review                                                                                                  The Heart Medicines Survey 
 
 
36 
adherence levels identified by MEMS
®
 were 75% (range 53%-93%) versus 84% by self-
reported questionnaires (range 68%-95%). The correlation between the two 
approaches ranged from 0.24 to 0.87. The pooled correlation coefficient for the 11 
studies was 0.45 (p = 0.001, 95% CI: 0.34-0.56). The authors concluded that self-
reported questionnaires give a good estimate of medication adherence because they 
at least moderately correlated with adherence measured by MEMS
®
 (Shi et al., 2010).  
 
 
Shi et al. (2010a) reviewed the association between medication adherence self-report 
questionnaires and medication monitoring devices. The review identified that the 
majority of articles (68%) reported significant to high correlation between self-report 
questionnaires and monitoring devices. Therefore, self-report can be used to measure 
patient-reported adherence. Most of the trials used the MEMS
®
 monitoring system as 
a comparator. The most commonly used self-report questionnaires were the 
Adult/Pediatric AIDS Clinical Trial Group (AACTG /PACTG) (24%), the 4-item Morisky 
(10%), Brief Medication Questionnaire (BrMQ) (10%) and the Visual Analogue Scale 
(VAS) (7%) (Shi et al., 2010a). Generally self-report questionnaires appeared to report 
on average 15% higher rate of medicines adherence than electronic monitoring 
devices (Shi et al., 2010a). Self-report questionnaires used for assessing adherence in 
patients with cardiovascular disease were: 4 item Morisky, VAS, BrMQ, ASRQ 
(adherence self-report questionnaire) and another two unnamed tools which were not 
described clearly in the original sources (Rudd et al., 1993; Hope et al., 2004; Shi et al., 
2010a). More details about these tools can be found in Appendix 1 and in Section 2.3.   
 
Hansen et al. (2009) compared the three most commonly used adherence assessment 
tools in practice: self-report, prescription refill records and electronic lids. Factors that 
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might impact on measurement agreement were explored. The review focused on two 
similarly designed intervention trials to examine agreement among these adherence 
assessment tools. The self-report methods were a single question (did you take 
medications as intended (i.e., on schedule and regularly) during the past 4 weeks?) and 
the 4-item Morisky. All three methods provided similar estimates of overall adherence 
levels. However, refill and electronic measures were in highest agreement (Hansen et 
al., 2009). 
 
2.2.2 Improving self-report measures 
Different considerations and approaches can be used to reduce some of the limitations 
of self-report questionnaires. The first limitation of social-desirability can be addressed 
by diminishing the social pressure on patients to report high adherence (Rand & Wise, 
1994; NICE, 2009). Questions should be phrased in a non-threatening manner and 
without blaming the patient for non-adherent behaviour (NICE, 2009).  Assuring 
confidentiality, anonymity and explaining that there are no right or wrong answers can 
also minimise social-desirability bias (Rand & Wise, 1994; NICE, 2009). Incorrect 
wording of the questionnaire items can exacerbate this problem such as the use of the 
word ‘careless’ in the 4-item Morisky or the Adherence to Refills and Medications scale 
(ARMS) (Morisky et al., 1986; Kripalani et al.,  2009). Such use describes non-
adherence as a ‘careless’ behaviour which might be misinterpreted as judgmental and 
make patients reluctant to report their non-adherent behaviour truthfully (Horne et 
al., 2005). The use of statements to preface the items in the tool can also be very 
useful to minimise social-desirability. Various tools use this approach e.g. the 8-item 
Morisky (MMAS-8) and The Medication Adherence Report Scale (MARS) (Horne & 
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Weinman, 2002; Morisky et al. 2008). Here is an example of a preface statement 
(Horne & Weinman, 2002):  
 
‘Many people find a way of using their medicines which suits them. This may differ 
from the instructions on the label or from what their doctor had said. Here are some 
ways in which people have said they use their medicines. For each statement, please 
tick the box which best applies to you’ 
 
The recall bias can be reduced by mentioning a specific time period (e.g. in the last 
month) to make it easier for the patient to remember (Horne, 2001; NICE, 2009). Tools 
which explore a wide range of possible medicines-taking behaviours are more likely to 
capture non-adherent behaviour than those which focus on one aspect (e.g. 
forgetfulness, reducing dose, stopping a medicine etc.) (NICE, 2009).    
 
It is recommended that the patient should be asked to answer questions in the form of 
scale items with a range of responses rather than a Yes/No responses (Horne, 2001; 
NICE, 2009). This should improve the quality of information obtained from this method 
of assessment as patients are being graded according to their relative standing on the 
adherence dimension, not as an exact measure of when and how they took their 
medicines (Horne, 2001). The Likert scales answers can also give the opportunity to 
learn about the frequency of non-adherent behaviour rather than just the presence of 
non-adherence.  
 
 
Horne et al. (2005) argues that if the questionnaire items combine reports of non-
adherence with reasons for non-adherence it can lead for further problems. A 
statement like ‘I take less medication if I am feeling better’ might be difficult for 
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patients to interpret in certain circumstances such as if they take less medicines, but 
not because they feel better (Horne et al., 2005). The importance of making this 
distinction was also highlighted by Voils et al. (2011) when they reviewed the various 
self-reported measures of medicines non-adherence in the context of hypertension. It 
was identified that these measures can be improved by using “effect indicators” to 
assess the extent of non-adherence and “causal indicators” to assess reasons for non-
adherence.  Voils et al. (2011) also emphasises the need to assess adherence 
longitudinally. This is to establish if the extent to which medication non-adherence is 
transient or stable. They conclude that paying attention to these issues can improve 
the assessment of self-reported non-adherence and allow more accurate conclusions 
to be made about medicines taking behaviour (Voils et al., 2011). This will undoubtedly 
inform the design of patient-tailored interventions to improve adherence. 
 
2.2.3 Characteristics of self-reporting assessment questionnaires 
The review of literature clearly identifies various types of self-report assessment tools 
with different features. The tools differ in length; some tools have a single question, 
and others have more than 30 questions. Some tools quantify or measure non-
adherence and shed some light on barriers to adherence. Others mainly explore 
possible barriers with no quantification of non-adherence. The intentional and 
unintentional types of non-adherence are not covered by all tools. Some focus mainly 
on unintentional non-adherence, others explore mainly intentional non-adherence and 
few explore both elements. Certain questionnaires explore current or recent non-
adherence behaviour and others attempt to “predict” the likelihood of non-adherence 
behaviour based on the exploration of beliefs and other psychological aspects such as 
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self-efficacy. Certain scales were developed for specific conditions and are not generic. 
Table 2.3 summarises a sample of the wide range of self-report tools that were 
frequently reported in the literature and their main features. Full details about some of 
these tools can be seen in Appendix 1.  
 
The tools also varied in terms of their validity and reliability in different contexts. For 
example: the VAS and ASRQ had poor correlation with MEMS
®
 for identifying non-
adherent patients with cardiovascular disease (Zeller et al., 2008). However, VAS 
showed good correlation with MEMS
®
 in HIV patients (Oyugi et al., 2004). The MARS 
scale has been used in several studies and in various settings to assess self-report of 
medicines adherence such as in bipolar disorder, renal transplant and respiratory 
disease (Butler et al., 2004; George et al., 2005; Bowskill et al., 2007 Mahler et al., 
2010). However, it exists in a few versions with a range of four to nine items (Horne & 
Weinman, 1999; Horne et al., 2001; Horne & Weinman, 2002). Different versions were 
used in different studies, though the five item version is the more commonly used and 
validated (Ediger et al., 2007; Mahler et al., 2010). The internal consistency 
(Cronbach’s α) of MARS ranged from 0.60 to 0.90 and the test–retest reliability (rp) also 
ranged from 0.61 to 0.97 in different studies (Mahler et al., 2010). 
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Table  2.3 – Summary of some of the most frequently mentioned self-report adherence 
assessment tools and their main features. 
 
 
Self-report Tool Disease Specific 
/ Generic 
Quantify  
adherence 
Screening for 
barriers to 
adherence 
Intentional / 
unintention
al aspect 
Beliefs / 
psychological 
aspects  
4 and 8 -items 
Morisky   
Generic 
(wide range of 
conditions) 
Yes (scores 
& different 
levels) 
Yes, some. 
(Current 
behaviour) 
Yes, brief, 
both.  
Behaviour 
more than 
belief 
The Medication 
Adherence Report 
Scale (MARS) 
Generic 
(different versions,  
5-9 items) 
Yes 
Yes, some.  
(Current 
behaviour) 
Yes, brief, 
both. 
Behaviour 
more than 
belief 
ASK-20 adherence 
barrier survey 
Generic 
(Asthma, depression 
& diabetes, 20 
items) 
No 
Yes, extensive.  
(Current 
behaviour / 
possible future 
impact) 
Yes, both. 
Yes, (not as 
detailed as other 
tools).  
Adherence 
Estimator™ (AE) 
Generic 
(3 items) 
Yes 
(Likelihood of 
future 
adherence) 
Yes.  
(Predictive tool) 
Intentional 
only 
Yes. (Benefit, 
harm) 
Belief about 
Medicines 
Questionnaire 
(BMQ) 
Generic 
(18 items) 
No. Yes. 
Mainly 
Intentional 
Yes. (4 aspects of 
belief) 
Brief Medication 
Questionnaire 
(BrMQ) 
Generic 
(9 items) 
Yes. Yes. Yes, both.  No. 
Medication-Taking 
Questionnaire 
(MTQ) 
Hypertension 
(12 item) 
No. Yes. 
Mainly 
intentional  
Yes 
(hypertension &  
treatment) 
Medical 
Prescription 
Knowledge 
questionnaire 
(MPK) 
Diabetes 
type 2 
(4 item) 
No. 
Limited 
(Mainly issues 
with specific anti-
hyperglycaemics) 
Mainly 
knowledge. 
No. 
Maastricht Utrecht 
Adherence in 
Hypertension 
questionnaire 
(MUAH) 
Hypertension  
(40 items) 
Yes Yes Yes Yes 
Brief Evaluation of 
Medication 
Influences and 
Beliefs 
(BEMIB) scale 
schizophrenia (& 
related 
psychotic disorders) 
(8 items) 
Yes Yes  Yes, both. Yes 
(Morisky et al., 1986; Morisky et al., 2008; Horne & Weinman, 1999; Hahn et. al., 2008; McHorney, 2009; Horne et al., 1999; 
Svarstad et.al, 1999; Johnson &Rogers, 2006; Prado-Aguilar et al., 2009; Wetzels et al., 2006; Dolder et al., 2004) 
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Some of the tools might be more appropriate in specific settings. For example: the 
BrMQ tool was validated against MEMS
®
 with good correlation (Svarstad et al., 1999; 
Shi et al., 2010a). The sensitivity was reported to be 90% and its specificity was 100% 
(Svarstad et al., 1999). But it is rather a lengthy tool for patients who are on large 
number of medicines as the tool expects the patient to provide full detail about every 
single medicine and this could explain its lack of popularity (McHorney, 2009). Such a 
tool may be useful in a comprehensive medicines review settings, rather than a routine 
assessment or screening setting.  
 
2.3 Self-report adherence assessment tools in cardiology 
patients   
 
A literature review was carried out to identify self-report adherence assessment tools 
used in patients with CAD. The following databases were searched: Ovid Medline 
(1946 to June 2009), EMBASE (1980 to June 2009), British Nursing Index and Archive 
(1985 to June 2009), PsycINFO (1806 to June 2009) and Pharmline (1978 to June 2009). 
The initial search used the following combinations of keywords: (medication, 
medicines, drug), (compliance, adherence, persistence), (self-report), (questionnaire, 
survey, scale, measure, assess) and (coronary heart disease, coronary artery disease). 
The search was limited to articles in English and all repeated references were excluded.  
 
The research strategy revealed two self-report adherence assessment tools that were 
used in CAD: the Single question tool by Gehi et al. (2007) and the ARMS tool by 
Kripalani et al. (2009). 
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These tools did not cover all aspects of barriers to adherence and were not thoroughly 
investigated except in one trial each. Therefore, a second literature search was 
conducted for all self-report adherence assessment tools used in patients with 
Cardiovascular Disease (CVD). The broadening of the search captured tools which had 
been used in cardiology patients. The tools had to be transferable and adaptable to 
CAD patients. All disease specific tools were, therefore, excluded.  
 
Seven different tools were identified. The content of all tools were compared including 
validity and reliability data. It was clear at this stage that the element of intentional 
non-adherence, specifically beliefs about medicines, was not covered by these tools. 
Therefore, a third search identified two generic tools which could be used to explore 
patients’ beliefs about medicines and intentional non-adherence in specific. Tables 2.4, 
2.5 and 2.6 summarise these findings.     
 
Table  2.4 – Self-report adherence assessment tools used in patients with CAD as identified by 
the literature review. 
 
 
Self-report 
Tool 
Description Conditions 
Used In 
Outcome Practical 
issues 
Validity and 
Reliability 
Adherence 
to Refills 
and 
Medication 
Scale 
(ARMS) 
12 item, Likert 
scale 
 
No time period 
over which 
adherence 
measured 
 
 
Coronary heart 
disease and 
Hypertension 
• Rate 
• Some 
intentional 
• Barriers 
Forgetting  
Prescription 
Refill  
Designed for 
use in 
patients with 
low literacy 
 
12 items + 
uses words 
like “careless” 
Covers few 
barriers. 
 
Checked against 4 
items Morisky 
(rs=0.651) and 
Prescription Refill 
with significant 
correlation (r=0.323), 
Cronbach’s α = 0.814. 
 
Single 
Question 
(Gehi et al.) 
1 item, Likert 
scale 
Assesses 
adherence over 
the last month 
Coronary heart 
disease 
• Rate 
• No barriers 
No barriers 
Can adapt to 
report for 
single 
medicines 
Checked against 
mortality, significant 
association (p=0.03). 
(Kripalani et al.,  2009; Gehi et al., 2007) 
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Table  2.5 - Self-report adherence assessment tools used in patients with cardiovascular 
disease as identified by the literature review. 
 
 
Self-report 
Tool 
Description Conditions 
Used In 
Outcome Practical 
issues 
Validity and 
Reliability 
Adherence 
Self Report 
Questionnaire 
(ASRQ) 
6 item 
Participants 
indicate which 
of the 6 items 
describe their 
medication 
compliance. 
 
No time period 
over which 
adherence 
measured 
Hypertension, 
diabetes or 
dyslipidaemia  
• Rate 
• Very 
limited info 
about 
barriers 
Short, can be 
adapted to CAD. 
Patients could 
have more than 
one statement 
describing their 
behaviour  
 
Checked again MEMS® 
in different trials. With 
both significant and 
insignificant 
associations were 
reported.  
Sensitivity = 46% 
Specificity = 66% 
Medical 
Outcome 
Study (MOS) 
5 item, Likert 
scale 
 
Assesses 
adherence over 
the last month  
Hypertension, 
diabetes, 
Dyslipidaemia 
• Rate 
• Very 
limited info 
about 
barriers 
Not consistent 
with current 
thinking about 
Adherence and 
concordance 
Checked against 
prescription refill 
records with some 
association (rs=0.261, 
p=0.05) 
4-item 
Morisky 
4 item, 
Dichotomous 
scale 
 
No time period 
over which 
adherence 
measured 
Outpatient 
hypertension, 
patients 
taking ACEI or 
lipid lowering 
agents + other 
conditions 
(e.g. HIV, 
Crohn’s)  
• Rate 
• Barriers 
forgetting 
• Intentional 
element 
Uses 
terminology like 
“careless”  
 
Limited 
information on 
barriers 
Checked against blood 
pressure with 
significant correlation 
rp=0.58 (p<0.01), 
sensitivity = 81% 
Specificity = 44% 
Cronbach’s α = 0.61 
8-item 
Morisky 
(MMAS-8) 
8 item, 
Dichotomous 
and one Likert 
scale item 
 
One item 
previous day, 
previous 2 
weeks. 
Hypertension  • Rate 
• Barriers 
forgetting, 
different 
context 
• Intentional 
element 
Removed 
terminology like 
“carless” 
 
More info on 
barriers 
 
Still concise  
Checked against blood 
pressure control with 
significant association 
(p<0.05), Cronbach’s α 
= 0.83  
Sensitivity = 93% 
Specificity = 53% 
Checked against 
prescription refill data 
with significant 
association 
(Concordance was 75% 
or higher). 
Brief 
Medication 
Questionnaire 
(BrMQ) 
9 item, 
Continuous  
 
Asks about 
previous week. 
Hypertension, 
diabetes, 
dyslipidaemia 
• Rate 
• Barriers 
Forgetting, 
beliefs, access 
to medicines  
 
Regimen, 
belief, recall & 
access screen.  
Can be lengthy 
as it asks about 
each medicine 
in detail. 
 
 
 
Belief screen 
mainly looks at 
side-effects and 
bothersome 
Prescription refill 
records, poor 
correlation: belief 
screen (rs= 0.213), 
regimen (rs=.091) 
Regimen Screen against 
MEMS® good 
correlation rp=0.67. 
Sensitivity = 90% 
Specificity  = 100% for 
>80% adherence 
Visual 
Analogue 
Scale (VAS)  
1 item, 
Continuous  
Previous month 
Hypertension, 
diabetes and 
dyslipidaemia  
• Rate 
• No 
barriers 
Very limited 
info. But can 
use to measure 
adherence for 
each medicine. 
1 month scale checked 
against MEMS®, 
significant correlation  
(rs = 0.77) 
(Zeller et al., 2008; Hamilton, 2003; Morisky et al., 1986; Morisky et al., 2008; Svarstad et al., 1999; Cook et al., 
2005) 
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Table  2.6 - Self-report adherence assessment tools to assess beliefs about medicines as 
identified by the literature review 
 
Self-report 
Tool 
Description Conditions 
Used In 
Outcome Practical 
issues 
Validity and 
Reliability 
Adherence 
Estimator ™ 
(AE)  
3 item 
Likert scale 
 
Predicting 
intentional 
non-adherent 
behaviour 
 
Generic, 
patients had 
different 
chronic 
conditions 
including 
cardiovascular 
disease, 
diabetes, 
osteoporosis, 
asthma and 
dyslipidaemia.  
  
• Rate 
• Barriers around 
belief in benefit 
worry about harm 
and cost. 
Very practical 
to use. 
Transferrable. 
 
Validated in 
America where 
cost issues are 
more relevant. 
 
Validated in an 
already identified 
intentionally non-
adherent patients. 
Sensitivity was 88% – 
of the non-adherers. 
Specificity was 59%. 
 
Predictive validity 
against pharmacy 
refills over 9 months. 
Significant 
associations were 
observed   0.655, 
0.598, and 0.484 in 
the low-, medium-, 
and high-risk groups. 
Beliefs about 
Medicines 
Questionnaire 
(BMQ) 
18 items 
Likert scale 
 
No time scale. 
 
Explores 
beliefs.  
 
Two scales:  
BMQ-Specific 
scale (specific 
necessity + 
specific 
concern) 
 
BMQ-General 
scale (General 
overuse + 
general harm) 
 
Wide range of 
conditions 
• No direct rates 
of adherence 
• Possible 
predictions 
• Assesses 
participants’ 
beliefs about 
medicines that 
they are 
currently using 
or prescribed 
• Assesses 
participants’ 
beliefs and 
attitudes to 
medicines in 
general. 
Very useful 
information 
about 
understanding 
people’s beliefs 
& perceptions 
about 
medicines. 
 
Beliefs about 
medicines are 
more likely to 
be associated 
with intentional 
non-adherence 
 
 
Lengthy (18 
items)  
 
Various studies 
showed that non-
adherent patients had 
one or more of the 
following when they 
completed the BMQ: 
Low necessity score, 
high concern scores, 
high overuse score, 
high general harm 
score, compared to 
adherent patients.      
(McHorney, 2009; McHorney et al., 2009; Horne et al., 1999; Horne & Weinman, 1999) 
 
It became apparent from the literature review that there was no single self-report 
adherence assessment tool that covers all dimensions and aspects of non-adherence 
behaviour. Therefore, it is more likely that an amalgamation of several tools will be 
needed to be used to be able to explore the medicines-taking behaviour in enough 
depth to inform the formulation of interventions. Supplementing these tools and 
Literature Review                                                                                                  The Heart Medicines Survey 
 
 
46 
combining some of them may be the best way to achieve an accurate assessment of 
adherence and enable tailoring to patient needs (Hawkshead & Krousel-Wood, 2007).  
 
2.3.1 Selecting a self-report adherence tool for CAD patients   
Several factors should be considered when selecting an adherence scale. These 
include: the administration length of the tool, reliability and validity, ability to detect 
barriers to adherence, the type of non-adherence (intentional vs. unintentional) 
detected, transferability, generalizability, ability to assess beliefs about medicines, 
sensitivity and specificity, as well as the diseases in which it has been validated (NICE, 
2009; Lavsa et al., 2011). All points considered in Sections 2.2.1 and 2.22 relating to 
validity, reliability and improving self-report tools should also be taken into account. 
 
Only two tools were validated in CAD patients; the Single Question (SQ) and ARMS 
tools (Gehi et al., 2007; Kripalani et al., 2009). The SQ tool is practical and had good 
validity against cardiovascular events. However, it only reports the rate of non-
adherence. It is very similar to the VAS tool which had good validity against MEMS
®
. 
The advantage of this tool is that it can be adapted to ask the same question for every 
single CAD secondary prevention medicine without burdening the patients with many 
questions as was seen in the BrMQ (Svarstad et al., 1999). This can help in identifying 
adherence levels to individual medicines. The SQ will be a good tool to use to quantify 
the level of non-adherence, but is insufficient on its own to explore barriers to 
adherence.     
 
Despite its good validity against the 4-item Morisky scale, the ARMS tool is lengthy and 
uses terminology which may be misunderstood by patients and increase social-
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desirability (Kripalani et al., 2009). It builds on the older version of Morisky which has 
been revised to a much improved 8-item version (Morisky et al. 2008). It covers 
barriers to repeat prescriptions, which should be included while screening for barriers.  
 
The ASRQ and MOS had poor validity and sensitivity compared to other tools e.g. 
MMAS-8 (Hamilton, 2003; Zeller et al., 2008). The MOS also seems to check for 
compliance rather than adherence and it portrays the patient as someone who has to 
follow the orders of the prescriber (Hamilton, 2003).   
 
The Morisky adherence assessment scales are among the most widely used self-
reported medication adherence measures (Gao & Nau, 2000; Erickson et al., 2001; 
Shalansky et al., 2004; Sakthong et al., 2009).  Despite its popularity the 4-item Morisky 
has poor psychometric properties, and measures the presence of non-adherent 
behaviour without taking its frequency into account (Morisky et al., 1986). It also uses 
terminology which can increase social-desirability (Morisky et al., 2008). The MMAS-8 
is a much improved newer version with better psychometric properties compared to 
the old version and addresses previous limitations (Sakthong et al., 2009). Non-
adherence is explored with a non-threatening and non-judgmental way to tackle the 
social-desirability and encourage patients to answer truthfully. It has good validity and 
reliability and is useful for quantifying non-adherence levels and identifying some 
barriers. However, it does not explore enough barriers to adherence (e.g. swallowing).  
 
The BrMQ is good for extensive medicines review as it screens for regimen, belief, 
recall, and access to medicines (Svarstad et al., 1999). Its overall scoring system is not 
simple and it can be very lengthy if the patient takes many medicines. The belief 
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screen only explores “side-effects” and “medicine(s) bothersome”. The access screen is 
very good as it explores several barriers to adherence including: ability to open 
medicines bottles, reading the label, swallowing, and ordering repeat prescriptions 
(Svarstad et al., 1999). These are very important barriers that should be included when 
exploring patient’s medicines-taking behaviour.       
 
Exploring patients’ beliefs about medicines is very important to understanding 
medicines-taking behaviour (Horne & Weinman, 1999). None of the tools explore this 
aspect in enough depth like the BMQ. Therefore, it would be a good tool to use, 
though it is rather lengthy. The AE is a good short, practical, validated and reliable tool 
in detecting intentional non-adherence (McHorney, 2009). Its predictive feature is 
attractive in clinical practice as it can be used to identify patients who are likely to 
need adherence support in advance. The tool was developed in the United States of 
America, where the paying for medicines is different to that in the United Kingdom. 
However, cost of medicines for patients who are not exempt from paying prescription 
charges in the UK may be similar and therefore worth exploring.  
 
Based on the above findings, in this research a number of adherence assessment and 
exploratory tools will be used to enable better exploration of the various dimensions 
of medicines-taking behaviour. This will also enable comparison of the different tools 
and inform practice. Those tools will include:   
• SQ - a modified version, asking about each CAD secondary prevention medicine 
• The MMAS-8 
• The BMQ 
• The AE 
 
Full details about these tools are provided in the following sections. 
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As discussed earlier in relation to the BrMQ, the assessment of access to medicines is 
essential. Therefore, there should also be screening for problems in opening bottles or 
blister packs, reading labels, swallowing and issues with ordering repeat prescription.   
 
2.3.1.1 The MMAS-8 assessment tool  
The MMAS-8 scale contains 8 items and was built on the theory that there are many 
causes to medicines non-adherence (see Figure 2.1) (Morisky et al., 2008). So it asks 
the patients questions around these causes. For example, questions around 
remembering such as “Do you sometimes forget to bring medications with you when 
travelling?”, questions around the complexity of the regimen such as “Do you feel 
hassled by sticking to your treatment plan?”.  The MMAS-8 items measure specific 
behaviours and are not each a determinant of adherent behaviour (Morisky et al., 
2008). The scale uses the following preface to minimise social-desirability: 
 
“You indicated that you are taking medication for your (identify health concern). 
Individuals have identified several issues regarding their medication-taking behaviour 
and we are interested in your experiences. There is no right or wrong answer. Please 
answer each question based on your personal experience with your (health concern) 
medication. Interviewers may self-identify regarding difficulties they may experience 
concerning medication-taking behaviour.” 
 
Patients answer yes or no to items 1–7 and choose one of 5 options to answer 
questions 8. Items 1,2,3,4,6 and 7 score “1” if the patient answers “no” and “0” if they 
answer “yes”. This is reversed in question 5. Question 8 scores “1” for “Never” and “0” 
for “Always”. “Almost never” scores “0.75”, “Sometimes” scores “0.5” and “Quite 
often” scores 0.25 (Morisky et al., 2008; Morisky, 2009, pers. comm.). 
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Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
Yes No
8. How often do you have difficulty remembering 
to take ALL your heart medications ?                                                                                                                                                                                        
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6. When you feel like your heart condition is under control, do you 
sometimes stop taking your medications ?
7. Do you ever feel hassled about sticking to your heart treatment 
plan ? 
1. Do you sometimes forget to take your heart medicines ? 
2. Over the past 2 weeks, were there any days when you did not 
take your heart  medications ?
3. Have you ever cut back or stopped taking your medication 
without telling your doctor because you felt worse when you took 
it ?
4. When you travel or leave home, do you sometimes forget to 
bring along your medications?
5. Did you take your heart medications yesterday ? 
Question Please Tick Box
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure  2.1 – The MMAS-8 scale (Morisky et al., 2008). 
 
The total score ranges from 0 to 8, where higher scores indicate higher adherence. The 
ranges are classified and interpreted as can be seen in Table 2.7. 
 
Table  2.7 – Interpretation of the MMAS-8 total scores 
 
Total MMAS-8 Score Interpretation 
8 patient is likely to be adherent 
6 to <8 medium adherence 
< 6 low adherence 
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2.3.1.2 The Adherence Estimator 
TM 
(AE) 
The AE is a brief three item proximal screener for the likelihood of intentional non-
adherence to medicines used in chronic disease (McHorney, 2009). The tool contains 
three proximal drivers of adherence: perceived concerns about medicines, perceived 
need for medicines, and perceived affordability of medicines. The tool was designed 
with the involvement of intentionally non-adherent population. These drivers were 
identified and cross-validated in nearly 2000 adult patients using two rounds of 
psychometric approaches (McHorney, 2009). The researchers used a synthesis of 
psychometric results obtained from classical and modern psychometric test theory 
(McHorney, 2009).  
 
As can be seen in Figure 2.2 each one of the three questions has a weighted Likert 
scale. Each response to each question is given a weight. The summation of these 
weights produces a total score which can be easily interpreted to categorise the 
patients into one of three groups: 
 
1) Low risk for adherence problems, >75% probability of adherence (Score=0)  
2) Medium risk for adherence problems, 32-75% probability of adherence (Score=2-7) 
3) High risk of for adherence problems, <32% probability of adherence (Score ≥ 8) 
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Statements 
Agree 
completely 
Agree 
mostly 
Agree 
somewhat 
Disagree 
somewhat 
Disagree 
mostly 
Disagree 
completely 
I am convinced of the 
importance of my prescription 
medication 
0 0 7 7 20 20 
I worry that my prescription 
medication will do more harm 
than good to me 
14 14 4 4 0 0 
I feel financially burdened by 
my out-of-pocket expenses for 
my prescription medication 
2 2 0 0 0 0 
 
Figure  2.2 - The Adherence Estimator self-scoring algorithm (McHorney, 2009). The total 
number of points are added up from each ticked box and interpreted as explained above. 
 
The tool was also validated for its ability to predict non-adherent patients against 
pharmacy claims (cashed prescriptions) in nearly 1600 patients (McHorney et al., 
2009). The study showed that patients’ propensity to adhere to their medicines using 
the AE was statistically associated with several measures of adherence as derived from 
pharmacy claims over a 9-month period (McHorney et al., 2009). 
 
2.3.1.3 The Single Question scale  
The SQ adherence assessment tool was used in the Heart and Soul Study by Gehi et al. 
(2007). In this study patients with stable CAD were asked in an outpatient setting to 
answer one question “In the past month, how often did you take your medications as 
the doctor prescribed?”. Patients were given a Likert scale to answer this question and 
the possible responses were: “All of the time” (100%), “Nearly all of the time” (90%), 
“Most of the time” (75%), “About half the time” (50%),  or “Less than half the time” 
(50%) (Gehi et al., 2007). The cut-off point for non-adherence was defined as 75% by 
the authors. They cited that the reason for this was that the small number of 
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participants in the latter categories (75% and 50%), non-adherence was defined as 75% 
of the time or less. The study found that patients who were classed to be non-
adherent by this SQ scale (≤75%) had a greater than 2-fold increased rate of 
subsequent cardiovascular events, including coronary heart disease death, myocardial 
infarction, and stroke (Gehi et al., 2007). The tool can be modified to make it measure 
adherence to individual secondary prevention medicines.  
 
2.3.1.4 Beliefs about Medicines Questionnaire (BMQ) 
Beliefs about medicines are powerful predictors of adherence to medicines’ behaviour 
and exploring patients’ beliefs is therefore very important for the purpose of this study 
(Horne & Weinman, 1999). The BMQ was developed by Horne et al. (1999) to 
understand the beliefs and perceptions that patients have about medicines. The BMQ 
has two different scales and each scale has two subscales as follows (Horne et al., 
1999):  
• The BMQ-Specific scale  - assesses participants’ beliefs about medicines that they 
are currently using or prescribed (e.g. Secondary prevention medicines for CAD) 
o The specific necessity subscale – measures the level of belief that a patient 
has about the necessity of their medicines. 
o The specific concern subscale – measures the level of concern that a 
patients have about their medicines.      
• The BMQ-General scale – assesses participants’ beliefs and attitudes to medicines 
in general. 
o The general overuse subscale – measures the level of beliefs participants 
have about over prescribing or over using medicines by doctors.  
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o The general harm subscale – measures the level of beliefs participants have 
about the harmfulness of medicines in general. 
The first 2 subscales contain 5 questions each. The latter two subscales contain 4 
questions each. Each question has a 5 items Likert scale ranging from “strongly agree” 
to “strongly disagree”. 
 
Various studies have shown association between one or more of the BMQ subscales 
and adherence to medicines (Horne & Weinman, 1999; Ross et al., 2004; Khanderia et 
al., 2008). For example hypertensive patients who believe in the necessity of 
medication were more likely to be adherent (odds ratio 3.06; 95% CI: 1.74-5.38; 
p<0.001) (Ross et al., 2004).  A similar finding was seen in haemophilia patients 
(Llewellyn et al., 2003). However, perceptions of the necessity of treatment were not 
always associated with adherence to treatment in patients. This was found in patients 
with diabetes whose concerns regarding the use of treatments outweighed the 
benefits of regularly taking medicines (Horne et al., 1999). Strong concern about 
potential medicines adverse effects scores on the BMQ were found to be associated 
with higher self-reported non-adherence (Bane et al., 2006). 
 
Following coronary artery bypass graft (CABG), non-adherent patients were in stronger 
agreement on the General Overuse (p = 0.01) and General Harm (p = 0.04) scales 
(Khanderia et al., 2008). The adjusted odds of adherent behaviour were significantly 
lower, with an increasing General Overuse score (odds ratio 0.83; 95% CI: 0.72 - 0.95; p 
= 0.007) (Khanderia et al., 2008).  
 
Literature Review                                                                                                  The Heart Medicines Survey 
 
 
55 
2.4 Aims and objectives of the study 
This study is conducted to investigate medicines-taking behaviour among patients with 
CAD. The main focus was on adherence to CAD secondary prevention medicines. The 
study’s primary aim is:  
 
To investigate the prevalence and possible factors contributing to self-reported non-
adherence to secondary prevention medicines in patients living within West Yorkshire 
and nearby areas who have a well-established diagnosis of CAD. 
 
The following were the primary objectives of this study:  
• Assess self-reported non-adherence to collective and individual secondary 
prevention medicines.  
o Aspirin, clopidogrel, statins, beta-blockers, ACEI, ARBs. 
• Compare the findings, practicality, sensitivity and reliability of three different 
instruments (questionnaires) which assess self-reported non-adherence; MMAS-8, 
Adherence Estimator™, and the Single Question approach. 
• Identify barriers contributing to non-adherence to inform and change practice. 
• Survey the prevailing individual beliefs and attitudes to use of medication among 
patients with established CAD. 
The secondary objectives were:  
• Identify the level of secondary prevention medicines prescribing and use in 
patients with stable CAD. 
• Develop a practical approach to address non-adherence among this population. 
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3 Methodology   
This chapter will describe how this research was designed and conducted based on the 
findings of the literature review and the stated aims and objectives. The methods used 
to conduct this study will be detailed together with the rationale, approach and tools 
used to interpret and analyse the results.  
 
3.1 Study design and rationale 
This was a cross-sectional study designed to understand the current medicines-taking 
behaviour among a selected patient population with established CAD. It was also a 
prevalence and hypothesis generating study which attempted to explore the levels of 
non-adherence to CAD secondary prevention medicines and the factors influencing the 
medicines-taking behaviour of CAD patients. A quantitative method was used in order to 
quantify the levels of self-reported non-adherence to secondary prevention medicines 
and reasons for non-adherence. The study included multiple self-report adherence 
assessment and exploratory tools to capture wider aspects of non-adherence behaviour 
and compare the tools’ performance and findings. To enable the administration of these 
tools a special questionnaire, “The Heart Medicines Survey”, was developed for data 
collection (see Appendix 2). The questionnaire method is widely used in cross-sectional 
studies. Compared to other methods that can be used to administer self-report 
questionnaires, such as interviews and telephone calls, this was the most practical and 
efficient approach, as discussed in Section 3.1.2.  
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The analysis of the findings of the survey intends to generate hypotheses to enable 
better ways of identifying non-adherent patients and tackle contributing factors to non-
adherence in practice. 
 
The time line for designing and conducting this study can be seen in Figure 3.1. The 
Heart Medicines Survey was designed based on the findings of the literature review to 
answer the primary and secondary aims and objectives of the study. This is discussed in 
Section 3.2. The target population was identified from the on-going West Yorkshire 
ENCOURAGE (Epidemiology of Northern Cardiovascular Outcomes and Underlying Risk 
of Atherosclerosis due to Genes and Environment) programme database (see Section 
3.3). Full protocols and necessary documentation were prepared as discussed in Section 
3.4 and can be seen in Appendices 3, 4, 5, 6 and 7. As the study was taking place in the 
NHS, a full application to the NHS Research & Ethics Committee (NHS REC) was made. 
Applications were also made to the Leeds Teaching Hospitals Research and 
Development (R&D) unit and the University of Bradford Research Ethics committee. All 
relevant bodies approved the study as can be seen in Appendix 9. A special Microsoft 
Access® database, called RANI-1, was built to hold the data electronically before the 
study started. Full description of the RANI-1 data base can be seen in Appendix 11. 
Patients who met the inclusion criteria of the study were identified as detailed in 
Section 3.3. The study was started in Jan 2010. Patients were contacted by post in 
groups of 20-40. All returned questionnaires were entered into the RANI-1 database. 
Detailed examination of each single questionnaire was carried out in patches after data 
was entered into the database as described in Section 3.7. Last entry into the database 
was made in January 2011. Complete analysis of data was completed by September 
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2011. Thank you letters were sent to all patients participating in the study with suitable 
information leaflets in Oct 2011 (see Appendices 10 and 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.1 – Summary of the major steps in designing and conducting the study.  
Jun 2009 
Jul 2009 
Aug 2009 
Sep 2009 
Oct 2009 
Sept 2011 
July 2011 
Jan 2010 
Jan 2011 
Start 
Last Entry 
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3.1.1 Advantages of the questionnaire tool and approaches used to 
improve limitations  
 
The study employed self-report postal questionnaires for data collection. This is an 
efficient method of data collection from large number of patients. It is also a very 
practical tool and can be easily replicated in practice. As this research was intended to 
inform practice, approaches that could be duplicated and used in practice were 
selected. Questionnaires have the flexibility to be designed to meet the research 
question and provide an organised data gathering tool which can easily be entered in a 
database and analysed (Matthews & Ross, 2010). Compared to other self-report 
methods, such as interviews, questionnaires enable quicker data collection in a short 
period of time.   
 
The questionnaire method gave participants the chance and time to consider the 
questions on their own. They could look up their medicines in their own time, complete 
parts of the questionnaire or all of it as it suited them. As participants were completing 
the questionnaire on their own, they probably would have been more likely to feel 
comfortable expressing their opinions about their medicines on paper than to share it 
face to face with healthcare professionals (Braker et al., 1994).    
 
One of the main problems that survey - or questionnaire-based studies - face is low 
response rate. It was demonstrated by various researchers that non-responders may 
differ from responders in important ways which can result in study bias (Matthews & 
Ross, 2010). Therefore, it was important to maximise the response rate to reduce such 
potential bias. If high response rate was not achieved, the sample would be viewed as 
Methodology                                                                                                         The Heart Medicines Survey 
 
 
60 
self-selecting (Smith, 2010). Various measures were employed in advance to address 
this limitation. A covering letter which summarised the purpose of the study, what it 
involved and the benefits gained from the information provided by participants was 
enclosed with the first communication (see Appendix 5). A patient information leaflet 
was also enclosed to clarify frequently asked questions and explain the relevance of the 
study to patients with CAD (see Appendix 6). A full explanation of confidentiality and 
reassurance were provided and it was made clear to potential participants that they 
would be able to withdraw from the study at any time. This could reduce reluctance to 
take part in the study (Smith, 2010). A free phone number was also provided to enable 
patients to contact the researcher if they had any questions or queries about the study. 
To eliminate any ambiguities in the questionnaire it was piloted among a number of 
healthcare professional colleagues.  Table 3.1 summarises some of the other limitations 
of self-reporting questionnaires and suggested possible approaches to minimise these 
limitations.  
 
Table  3.1 – Further limitations of postal questionnaires and considerations to reduce these 
limitations. 
 
 
Limitation Considerations  
• Postal questionnaires may take long time 
to be returned or patients may forget 
about them.  
• Limited access for the researcher to in-
depth experience. 
• Certain people might be excluded. 
Example, patients unable to read or write 
and those with a language barrier.  
• Costs – including printing, envelops, 
administration time, postage (posting 
and return envelopes), data entry time.   
• Send patients a reminder 
 
 
• Provide patients the opportunity to 
provide extra comments 
• Identify patients with literacy or 
language barriers in advance and 
offer alternatives (e.g. translations) 
• Cost is still acceptable compared to 
other methods (e.g. interviews). Use 
2
nd
 class stamps or free post scheme.  
(Content adopted from Matthews & Ross, 2010; Smith, 2010) 
 
More details on the limitations and ways to improve self-report questionnaires were 
provided in Section 2.2. 
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3.1.2 Other methods that could have been used 
Other methods could have been used in this study to collect the data. The interview 
method using a structured or a non-structured questionnaire style would have had some 
advantages. This method would have enabled further exploration of interesting 
responses and the collection of more in-depth data about the reasons for non-
adherence. Participants would also have been able to clarify with the researcher any 
issues that they would prefer to talk about rather than write down in a questionnaire. 
Interview methods, however, are very labour intensive, time consuming, more costly 
and may require more resources. Such methods would have needed several researchers 
to be able to interview big number of patients.  
 
Collecting the data using telephone calls would have been another option. This method 
would have had the advantage of collecting data in a shorter time, if resources were 
available, rather than waiting for patients to return the questionnaires. The researcher 
would have had the opportunity to discuss with patients adherence related issues or 
explore further interesting answers. Patients would have had the opportunity to ask 
questions and clarify any ambiguous issues. Such a method can be cheaper and enable 
contacting more patients compared to the interview method. However, with the limited 
resource available the researcher would have needed to spend longer time collecting 
the data, and would have needed to make two phone-calls at least to enable patients to 
prepare themselves for the interview. In addition, contacting patients during a suitable 
time would have been another challenge. The frankness of the responses could have 
been influenced by the time of the call and the presence and absence of other people 
around the participant (Smith, 2010). It would also have been necessary to contact 
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patients in advance and provide them with all the necessary documentation (e.g. 
information about the study, consent form).  
 
The use of electronic questionnaires was another method which was explored by the 
researcher. Such a method would have been a very efficient way of conducting the 
research in terms of time, data collection, data entry and contacting patients. Such an 
approach would have required the participants to have internet access and ability to use 
e-mails and web browsers. Furthermore, the researcher would have needed the e-mail 
addresses of all participants and such information was not available. Due to 
confidentiality issues the researcher would have needed to develop a special secure 
website which enabled patients to access it and enter their personal details and answers 
to the questionnaire. This was not practical at this stage. However, this approach will be 
explored for future research related to this area.  
 
3.2 The structure and design of the Heart Medicines 
Survey questionnaire  
 
The Heart Medicines Survey questionnaire was designed to answer the primary and 
secondary research questions. The design and content of the questionnaire are a very 
important part of the research as they determine the questions and the answers that 
the researcher will be working with (Matthews & Ross, 2010). Based on the findings of 
the literature review four adherence assessment and exploratory tools were included to 
understand the various aspects of medicines-taking behaviour and enable comparison 
of the tools (see Section 2.3.1). The MMAS-8 and SQ tools estimate levels of self-
reported non-adherence. The MMAS-8 also explores possible reasons for non-
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adherence. The AE screens for likelihood of levels and reasons of intentional non-
adherence. The BMQ explores in more detail patients’ beliefs about medicines. Figure 
3.2 shows the overall structure of the Heart Medicines Survey (see also Appendix 2). 
 
 
Figure  3.2 – The structure of the Heart Medicines Survey. 
 
The questionnaire was composed of 5 parts. Part 1 aimed to identify what medicines the 
patient was taking and assess their basic knowledge of the indication of each secondary 
prevention medicine. This was of value when analysing the results of the survey in terms 
of the number, types, frequency and knowledge of the indication for the medicines 
prescribed. This part also asked about GTN use as it could be an indicative of how well 
patient’s angina was controlled. Parts 2, 3 and 4 used the pre-validated self-report 
adherence assessment tools to evaluate adherence to CAD secondary prevention 
medicines. Part 3 also explored four potential or possible barriers to adherence based 
on the BrMQ (see Section 2.3.1). These were practical problems that patients might 
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have faced when handling medicines and could have contributed to non-adherence. 
They included: opening medicine bottles or blister packs, reading the label, swallowing 
the medicine and ordering repeat prescriptions. Patients were asked to identify any 
issues with these “Possible Practical Problems” using a Likert scale to give them a better 
chance to express the extent of the problem, if present. This also helped the researcher 
better distinguish between respondents according to the scale.  
 
The SQ in Part 4 was modified to explore levels of non-adherence to individual CAD 
secondary prevention medicines. The single question nature of this tool made it easier 
to utilise for this purpose without burdening the patient with a lengthy survey.  The 
modification involved the listing of the different classes of secondary prevention 
medicines in a table as can be seen in Appendix 2. The patient was asked to estimate 
their level of adherence in the previous month to each one of these medicines. This 
approach enabled the collection of additional information about non-adherence to 
individual secondary prevention medicines.  
 
Part 5 included the BMQ and an open question to enable the respondents to answer in 
their own way and add any other issues that they wished to share with the researcher 
about their medicines. An open question at the end of the questionnaire sends a 
message to the respondents that their opinions were valued (Matthews & Ross, 2010).  
Each part of the questionnaire began with a statement explaining the purpose of the 
questions and providing instructions on how to answer them. Jargon was avoided and 
language used was familiar to patients whenever possible. The introductory statement 
and the questions were worded in a way to minimise them coming across as judgmental 
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or insensitive which could have made patients feel embarrassed or ashamed to report 
their medicines-taking behaviour (Matthews & Ross, 2010). 
 
More details about the 4 tools used in the questionnaire can be seen in Sections 2.3.1.1 
to 2.3.1.4. 
  
3.2.1 Agreement with authors of adherence assessment tools. 
The researcher sought permission from the developers of these tools. The MMAS-8 tool 
is copyrighted and the author was contacted and permission was granted. The AE was 
also copyrighted and the author requested a signed agreement for using the tool. The 
developer of the BMQ, Prof. Rob Horne, was informed of the intentions of the 
researcher to use this tool. No official agreements were requested. The SQ tool was not 
copyrighted. See Appendix 14 for communications with authors and use agreement. 
 
3.3 Target population  
The study targeted patients with established CAD in West Yorkshire and nearby areas 
who had been prescribed a minimum of one CAD secondary prevention medicine for at 
least three months. The study ran in conjunction with the ENCOURAGE programme 
which is managed by the Cardiovascular Research Unit at the Yorkshire Heart Centre, 
Leeds. The programme frequently invites patients in the region to take part in various 
cardiovascular studies. Over the years it built a database of patients who have given 
consent allowing the unit to contact them whenever needed to offer them the 
opportunity of participating in cardiovascular research studies. Patients on the database 
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regularly receive the ENCOURAGE Newsletter to update them on recent developments 
in heart disease.  
The ENCOURAGE database provided a practical and convenient way to access patients 
with CAD in the region with the limited resources and time frame of the study. Because 
the Yorkshire Heart Centre at the Leeds General Infirmary is one of the largest in the 
country and provides secondary care for Leeds and also tertiary care for West Yorkshire 
and part of North Yorkshire, there was a good representation of the different parts of 
the region (LTHT, 2011). In prevalence studies it is important that the sample is 
representative of the relevant population in order to be able to make inferences 
(Marston, 2010).   
 
3.3.1 Sampling 
Eight hundred patients within the ENCOURAGE cohort expressed specific interest after 
the April 2009 Newsletter mail shot in assisting in heart related health-care 
improvement projects. A purposive sample of 696 patients was chosen by screening 
respondents to check if they met the inclusion criteria of the study as detailed in Table 
3.2.  All patients who met the criteria were contacted in batches of 20-40 inviting them 
to participate in the study. Patients were sent a covering letter explaining what patients 
needed to do to participate, a study patient information leaflet, consent form, the Heart 
Medicines Survey and prepaid envelope. Patients were asked to sign the consent form, 
complete the survey and post it back using the prepaid envelope if they were interested 
in taking part in the study. Those who were not interested did not need to do anything. 
Forms are found in Appendices 2, 4, 5 and 6.   
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Table  3.2 – Inclusion and exclusion criteria of the study. 
 
Inclusion criteria 
1. Individual patients within the ENCOURAGE cohort who have recently expressed a specific 
interest in being involved in heart related healthcare improvement projects. 
 
2. Well-established CAD 
(CAD defined as documented or reported MI, CABG, PTCA, or angina (positive exercise test)) 
 
3. Prescription of at least one secondary prevention medicine for at least 3 months. 
(Secondary prevention medicines are: aspirin / clopidogrel, statins, beta blockers, ACEI / ARBS). 
 
4. Able to independently give informed consent.  
Exclusion criteria 
1. Patients who did not want to be contacted for further studies. 
 
2. Patients who are not part of the ENCOURAGE programme. 
 
  
If it had been feasible with the number of patients available a random sampling 
approach would have been adopted. The advantage of random sampling is that all 
members of the population have an equal probability of being a member of the selected 
sample and bias is reduced (Marston, 2010). It is important to emphasise, however, that 
all sampling frames have their own potential problems and measures should be taken to 
minimise bias as much as possible.  
 
3.3.2 Sample size 
The decision on the sample size for this study was based on two factors:  
Better representation and practicalities - The sample size for surveys should ensure 
sufficient numbers of the groups that needed to be compared (if sample is not random) 
(Matthews & Ross, 2010). Generally, the larger the sample in survey research, the more 
accurate the estimates when applied to the wider population and the narrower the 
confidence intervals (Smith, 2010).  Other factors which influenced the sample size were 
time, practicality, availability of resources, and the ease of access to the sampled cases 
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(Matthews & Ross, 2010). The researcher considered the time scale for completing this 
study and the resources available and decided based on these factors, that 500 patients 
would be reasonable.   
 
A follow up study - The design of this study was part of the ADHERE Study (see Section 
1.1). The power calculations used to determine the sample size for the ADHERE study 
determined the sample size for RANI-1. A statistician was consulted on the design and 
the power of the ADHERE study. The sample size needed to conduct the study was 40 – 
60 patients for each arm (of 3 arms). That is a total of 120 – 180 patients.  That is a 
power of 90% and an alpha of 0.05 to be able to detect 1 unit change in the MMAS-8 
score. Because the levels of non-adherence in the literature are estimated to be around 
30 – 50%, it was estimated that screening 500 patients for non-adherence would be 
sufficient to identify around 150 – 250 non-adherent patients to take part in the 
ADHERE study.  
 
3.4 Ethical considerations   
This healthcare research study needed a formal ethics approval because it was 
conducted on NHS premises and involved contacting patients and retaining identifiable 
patient information. Any ethical appraisal of a study should consider three different 
perspectives according to the Foster Framework (Smith, 2010): 
1. The worthiness and value of the study and whether the aims are likely to be 
achieved. 
a. The importance of the study 
b. Are the methods chosen the best way of answering the research question 
c. How beneficial will the findings be to patients and the healthcare system 
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2. Is what the study is asking participants to do reasonable and justified. 
a. The time and effort required from the participants 
b. The risk the participants are exposed to by enrolling in the study  
c. Are the needs / special needs of participants taken into account? 
 
3. Respecting the rights of the participants 
a. Full information provided to participants to enable them to have full 
understanding and opportunity to ask questions.  
b. Genuine informed consent to participate and ability to withdraw from the 
study easily. Enough time to consider their decision.  
c. Anonymity and confidentiality of data 
 
As can be seen from the detailed NHS REC and R&D application forms, all the above 
issues were addressed (see Appendix 8). Full ethical approval documents are in 
Appendix 9. The University of Bradford Ethics Committee also approved this study. All 
relevant documents (e.g. protocol, consent form, patient information leaflet, covering 
letter, thank you letter etc.) are in Appendices 3 to 10.  
 
3.5 Conducting the study  
After the study was granted NHS REC and R&D approvals it was started in Jan 2010. As 
described in the sampling section, a purposive sample was selected from the 
ENCOURAGE database.  The mortality status of those patients was checked on the NHS 
Patient Summary Records before they were contacted (i.e. patients were still alive 
according to the system). Figure 3.3 is a flow diagram which describes how the study 
was conducted. An entry was made in the RANI-1 database (see Appendix 11) of all the 
patients who were contacted (see Section 3.3.1). All returned questionnaires and 
consent forms were examined. If the consent form was not completed correctly or was 
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missing, the patient was contacted to address any queries about consent or missing 
documentation. Once consent was established the patient’s GP was contacted by post 
to inform them of their patient’s participation in the study. See Appendix 7 for GP letter.  
 
All returned forms were handled with full confidentiality. The paper version was stored 
in a safe cabinet within the research unit. The cabinet was securely locked and accessed 
only by the research team as per protocol (see Appendix 3). The data were then entered 
electronically into the database on the secure server by the support clerk. The patient’s 
progress in the study was marked accordingly. 
 
The researcher carried a detailed examination of each single questionnaire in batches 
after data were entered into the database. The last entry into the database was made in 
Jan 2011. The review of all returned questionnaires was completed in June 2011. During 
the review of the questionnaires the researcher considered the following: 
1) The accuracy of data entry. 
2) Level 1 medicines review (see Appendix 12).  
3) Assessment of patient’s knowledge.  
4) Examination of the overall adherence status of the patient according to the 
scores of the different scales and considering any missing data. 
5) Reviewed the comments made by patients.  
6) Completed the analysis summary on the RANI-1 database (see Appendix 11). 
 
From June 2011 to Sept 2011 a full analysis of the overall findings of the survey were 
conducted as described in the data interpretation and analysis Section 3.6. Thank you 
letters were sent to all patients participating in the study with suitable information 
leaflets in Oct 2011. For more information about the leaflets that were provided see 
Appendix 13. 
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Figure  3.3 – A flow diagram which describes how the study was conducted. 
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3.6 Data interpretation and analysis  
This section will detail the assumptions and approaches used while interpreting and 
analysing the findings of study. Full statistical analysis was conducted on the dataset.  
Statistical analysis included the use of simple descriptive statistics which enabled the 
presentation and understanding of the characteristics of the dataset. Bivariate statistical 
investigations were used to identify any associations between variables. Multivariate 
analysis was followed mainly by using logistic regression. The full detail of statistical 
tools and principles used can be found in Appendix 15. Detailed statistical output and 
analysis can be found in Appendix 16. Frequency and categorisation analysis was also 
carried out on the last part of the questionnaire and will be detailed in Section 3.6.7. 
The RANI-1 Microsoft Access® database was used to code all questions and answers and 
various reviews of overall data was conducted using the functions in the database to 
establish familiarity with the dataset. Microsoft Excel® 2010 was also used to conduct 
various frequencies and interpretative analysis. The SPSS v.19 (IBM, Chicago IL) was 
employed to conduct all statistical analyses. The mind mapping software IHNC 
CmapTools was used during exploration of patients’ comments, thematic and frequency 
analysis.  
 
3.6.1 Organising and presenting the data and using descriptive statistics 
3.6.1.1 Demographics 
The demographics of the sample according to age, gender, post code, ethnicity and 
marital status were described. The data on ethnicity and marital status were obtained 
from the ENCOURAGE database. Patients were grouped according to their post codes. 
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Post codes were also grouped according to the following categories: Leeds, West 
Yorkshire (other than Leeds) and outside West Yorkshire. This grouping aimed to explore 
the geographical spread of the sample.  
 
The patients’ marital status was incomplete, as around 45% of patients did not identify 
their current marital status in the database. This was only identified after the analysis. 
Therefore, the marital status analysis was conducted by collapsing the categories into 
two; married vs. non-married during bivariate analysis. This produced larger cell counts 
to see if the chi-square test assumptions hold (Marston, 2010; Smith, 2010). 
 
3.6.1.2 Comorbidities and cardiac history 
All available information about patients’ cardiac history, medicines, identifiable 
comorbidities relevant to CHD was identified, grouped and presented. These variables 
were used in the exploratory analysis comparing groups of adherent and non-adherent 
patients. Patients identified their angina, MI, angioplasty and bypass (CABG) procedure 
when they expressed interest in being contacted. No exact dates were provided of when 
the events or procedures took place. None of these claims were verified against the 
medical notes as it was not practical to review the medical records of 503 patients.  
 
Patients’ medicines were reviewed and two comorbidities relevant to CAD and/or 
medicines taking analysis were identified. These were diabetes (controlled with 
medicines) and hypothyroidism (controlled by levothyroxine). Patients who were 
prescribed anti-diabetic medicines were assumed to have diabetes. Those who were 
prescribed levothyroxine were assumed to have hypothyroidism.   
Methodology                                                                                                         The Heart Medicines Survey 
 
 
74 
Patients recruited into this study participated in the past in various studies conducted in 
the Cardiovascular Research Unit. Patients’ participation in previous studies was 
identified. This information shed light on the cardiac history of the sample.  This will be 
elaborated on in the Results and Discussion Chapters.  
 
3.6.1.3 Number and frequency of prescribed medicines  
Descriptive statistics were presented of the number of medicines prescribed according 
to patients’ reporting in Part 1 of the questionnaire. The descriptive statistics presented 
for the purpose of exploring the dataset were for the following variables: number of 
medicines prescribed, number of individual daily doses and the number of daily 
administrations. The number of daily doses was calculated in order to account for 
medicines with more than once a day doses and enable comparing the impact of the 
frequency of medicines taking on adherence. The number of daily administrations 
represented the total number of times the patient had to take a medicine regardless of 
the number of medicines taken at the point of administration. More than one medicine 
may have been taken at each administration time. 
 
3.6.1.4 Secondary prevention medicines 
Special attention was paid to the secondary prevention medicines because they were at 
the centre of this study.  The frequency of each single class of secondary prevention 
medicines and all prescribed combinations were explored. The total number of doses 
and the total number of administration times per day were also presented. 
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3.6.1.5 Patients’ knowledge of secondary prevention medicines indications 
The patients’ knowledge about the indication of their secondary prevention medicines 
was divided into 3 categories: “specific” knowledge if the patient reported the indication 
and gave a correct description which distinguished the class of medicine e.g. 
antiplatelets, “general” knowledge if the patient identified that the drug is for the heart, 
and “none” if the patient was unsure about the indication, provided incorrect 
information or left blank. The researcher decided on these categories as part of the 
review of the returned questionnaires.  For the purpose of analysis the categories about 
knowledge were also grouped into two categories: “knowledgeable” which included 
patients who reported “specific” knowledge about the secondary prevention medicines 
and “not knowledgeable” which included patients who were identified to have “general” 
or “none” level of knowledge about secondary prevention medicines.   
 
The overall patients’ knowledge about all the secondary prevention medicines that they 
were prescribed was calculated as follows: after allocating each secondary prevention 
medicine with a score of 1 to 3 (1 = having “specific” knowledge about the medicine, 2 = 
“general”, and 3 = no knowledge was reported), all scores were added and the average 
was calculated for each patient. This was used to compare overall knowledge of 
secondary prevention medicines between different groups.  
 
3.6.1.6 GTN 
Patients were asked to report if they had GTN spray or tablets used to manage their 
angina. Those who reported that they did possess GTN were also asked to report the 
frequency of GTN use. Descriptive statistics were used to summarise these data.  
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Because patients reported the frequency of GTN use in different ways; as number of 
times per day, per week and per month, a cumulative monthly description of GTN use 
was calculated and presented to enable easier comparison.  Daily and weekly 
frequencies were converted into monthly frequencies. 
 
3.6.1.7 Possible practical problems 
The four possible practical problems that could impact on adherence were examined. 
The frequencies of the results were summarised under each one of the 4 Likert scale 
options. The results were also presented by grouping the 4 categories into the following 
categories: “There is a problem” included patients who identified the barrier to be 
always or sometimes a problem and “Need a solution / alternative” included patients 
who identified that the barrier was not a problem but preferred an alternative or the 
barrier was sometimes or always a problems and a solution was needed. The 
associations between the four barriers and non-adherence identified by various scales 
were examined.   
 
3.6.1.8  Descriptive statistics used 
Descriptive statistics were used to summarise the data. Frequencies on each variable 
were reported and presented in different formats e.g. tables, bar charts, pie charts as 
can be seen in the Results Chapter. Depending on data type (nominal, ordinal, scale), 
appropriate summary statistics were chosen to describe each set of data (variable). For 
central tendencies: mean was used for normally distributed variables and median for 
data which was not normally distributed. In normally distributed data the mean equals 
median (Marston, 2010). To describe the spread of normally distributed data, standard 
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deviation was used.  For variables which were not normally distributed interquartile 
range (lower quartile, and upper quartile), minimum and maximum were reported. 
Because the second quartile equals the median, it was not reported (Marston, 2010). 
The normal distribution of continuous parametric data was tested using the Probability–
Probability plot (P-P plot), Kolmogorov-Smirnov test (K-S test) and a histogram. These 
data can be seen in Appendix 16. Wherever missing data was identified and valid 
percentages were reported. 
 
3.6.2 Adherence assessment tools – scoring and exploration 
The MMAS-8 and AE scales were scored in accordance with the described scoring 
systems in Sections 2.3.1.1 and 2.3.1.2. However, additional considerations for these 
scales are highlighted here. The SQ and BMQ scoring considerations are described 
below.  
 
3.6.2.1 The MMAS-8  
The internal consistency and uni-dimensionality of the construct of the MMAS-8 scale 
was examined using Cronbach's α statistics and Factorial Analysis. This aimed to identify 
any problems in any of the 8 questions used by the scale which could impact on the 
findings. 
  
3.6.2.1.1 Reliability and consistency of the MMAS-8 
Cronbach's α statistic was used to measure the internal consistency, reliability and 
content validity of the MMAS-8. This aimed to explore any problematic questions in this 
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tool and assess the degree to which individual items in the questionnaire represented 
the construct being measured (Field, 2009).  As discussed in Section 2.2.1 the value of 
Cronbach's α varies from zero to 1. A value of 1 indicates a perfect correlation between 
the items that make up the scale, whereas, a value of 0 indicates no correlation 
between those items (Machin et al., 2007).  Cronbach's α indirectly indicates the degree 
to which a set of questions in the instrument measures a single unidimensional latent 
construct (Field, 2009). If there is a suspicion that an instrument is capturing several 
dimensions (i.e. different constructs), then factorial analysis is used to investigate the 
internal structure of the instrument (Barker et al., 1994).   
 
Question 5 was a reverse-phrased item used to reduce response bias, and had to be 
reversed before conducting the analysis (Field, 2009). For research purposes a 
Cronbach’s α value of 0.60 was considered marginal, and more than 0.7 to 0.8 was 
preferred for good internal consistency (Braker et. al., 1994; Bland & Altman, 1997). If 
there are several subscales within a questionnaire, one should calculate Cronbach’s α 
for each subscale individually (Field, 2009). All cases of missing values in any one of the 8 
questions were excluded by the analysis. Full SPSS output can be seen in Appendix 16. 
The researcher evaluated the impact of each item in the scale on the value of 
Cronbach’s α. Items which increased the value of Cronbach’s α were removed and 
Cronbach’s α was recalculated. The process was repeated until the largest Cronbach’s α 
value was achieved. If the removal of an item caused insignificant increase in Cronbach’s 
α value, it was retained (see Results Chapter). 
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3.6.2.1.2 Factor analysis (Principal Component Analysis (PCA)) 
The aim of this analysis was to explore the dimensions or constructs in the MMAS-8 
scale.  Factor analysis is useful to explore the data and generate hypotheses (Dytham, 
2011). Subsets of variables with large correlation coefficients between them indicate 
that such variables may be measuring aspects of the same underlying dimension (factor, 
latent variables) (Field, 2009).  
 
Full interpretation can be seen in Appendix 15 and full SPSS output can be seen in 
Appendix 16. Multicolinearity, sampling adequacy (Kaiser-Meyer-Olkin (KMO) statistic), 
and identity matrix (the Bartlett’s test of sphericity) were all considered. Please see 
Appendices 15 and 16 for more detail. 
 
Factorial analysis uses eigenvalues associated with the factors. The eigenvalue 
associated with each item before extraction, after extraction and after rotation were 
generated. The eigenvalues associated with each factor represented the variance 
explained by that particular linear component and was displayed as a percentage of 
variance (Field, 2009). Eigenvalues showed how evenly (or otherwise) the variances of 
the matrix were distributed. The dimensions of the data were examined by looking at all 
the eigenvalues for the dataset. The eigenvalue associated with a variate indicated the 
substantive importance of that factor. Factors with large eigenvalues were retained. 
Kaiser’s criterion of retaining factors with eigenvalues >1 was used.  
 
To discriminate between factors, orthogonal factor rotation was used (factors are 
rotated while keeping them independent or unrelated). Any factor loading of >0.29 was 
considered important. Reverse phrasing questions give a negative factor loading and 
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therefore need to be reversed (Field, 2009). Therefore, question 5 was reversed. Full 
SPSS output was presented in Appendix 16 and only a table of the main findings will be 
shown in the Results Chapter 
 
3.6.2.2 Adherence Estimator  
Further analysis of item 3, which is related to cost of medicines, was conducted. This 
was because patients over 60 and those with certain medical conditions were at the 
time of the study exempt from paying prescription charges. This item was analysed 
taking age and co-morbidities into account. It was not possible to establish for certain all 
those patients who were under 60 and were exempt from paying prescription charges. 
However, all identifiable reasons available to the researcher were used in the analysis.  
 
3.6.2.3 Single Question scale   
The original and modified SQ scale asked patients to answer the “single question” using 
a Likert scale (Gehi et al., 2007).  No percentages were included on the questionnaire. 
The answers were converted to percentages as described earlier in Section 2.3.1.3. 
Frequencies of the answers for each class of the secondary prevention medicines were 
calculated. The medicines list provided by patients in Part 1 of the questionnaire was 
compared to their answers in Part 4. All calculations were based on the number of 
patients who answered the SQ part and listed these medicines in Part 1 of the 
questionnaire. All patients who answered the SQ part about a medicine that they did 
not include in Part 1 were excluded unless their comments clarified the discrepancy. 
Please see Appendix 16. 
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The original authors of the SQ tools used 75% (“most of the time”) as a cut-off point in 
identifying their non-adherent group.  The cut-off point of 75% in the SQ scale was not 
validated or chosen based on comparing it to a “gold standard” adherence assessment 
method. Furthermore, these Likert scale assigned percentages were subjective and not 
necessarily a true representation of the percentage of adherence. So “most of the time” 
could mean a different percentage to different people. These assigned percentages 
were not tested or verified by the researchers. Every patient who selected any choice 
other than “All of the time” (100%) had some kind of non-adherence. Therefore, the 
analysis will consider two cut-off points; 75% which was used in the original study and 
found to correlate with mortality and 90% which represents any kind of non-adherence. 
No sensitivity or specificity tests were reported for the SQ scale. Hence, both cut-off 
points were explored.  
 
3.6.2.4 The Beliefs about Medicines Questionnaire  
In Part 5 of the survey patients were asked 18 questions related to 4 categories of 
beliefs about medicines. The questions were grouped under the 4 categories: specific 
necessity, specific concern, general harm, and general overuse. The first 2 categories 
contained 5 questions each. The latter two categories contained 4 questions each. 
Each question had a Likert scale ranging from “strongly agree” to “strongly disagree”. 
Each option in the Likert scale was assigned a number as follows: 
• Strongly disagree = 1 
• Disagree = 2 
• Uncertain = 3 
• Agree = 4 
• Strongly agree = 5 
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The frequency of answers, total score for each question, average score for each 
question, total score for each category and average for each category were calculated 
and reported. All these values were also calculated for adherent and non-adherent 
patients and compared using appropriate statistical methods to identify any statistically 
significant differences. Horne & Weinman (2002) used a similar approach in their studies 
and limitations in using parametric statistics to analyse Likert scales are discussed 
below.   
 
3.6.2.4.1 Analysing Likert scales using parametric statistics 
Frequency analysis is usually the first tool used in reporting Likert scale answers. Some 
authors question the validity of assigning numerical values (1-5) due to the non-linearity 
of the Likert scale (Smith, 2010). Such self-reported data should probably be treated as 
ordinal because the intervals between values cannot be presumed equal, though many 
scientists do analyse it as if it was continuous (Field, 2009). It has become common 
practice in literature to assume that Likert type data can be analysed using statistics for 
interval level measurement (e.g. mean, standard deviation) (Jamieson, 2004). Such use 
is justified by arguing that sample size and distribution are more significant than level of 
measurement to determine if it is appropriate to use parametric statistics (Jamieson, 
2004). Norman (2010) argues that though the use of parametric tests on Likert scales 
can, strictly speaking, increase the chance of “wrong conclusions”, one needs to ask the 
question “by how much?”. He affirms that if the chance of such error is not much (or 
none at all) then such violation of using parametric statistics on ordinal data can be 
justified and that it is not more than an issue of robustness (Norman, 2010). He 
conducted various parametric statistical tests on Likert scale data and showed that 
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fearing to come to the “wrong conclusions” is almost non-existent and therefore the use 
of parametric statistics on Likert scale data is fully acceptable (Norman, 2010). 
 
Due to the large sample size of the study and the above discussion, parametric statistics 
were occasionally used in the analysis of the Likert scale data. However, the researcher 
did also conduct non-parametric statistical analysis of the findings and any major 
differences were pointed out. For the BMQ non-parametric statistics were presented in 
the Results Chapter. Parametric statistics of the scale were calculated for comparison 
and can be found in Appendix 16.     
   
3.6.3 Missing data 
Identifying missing data is very important and therefore the approach adopted to 
handle missing data is described here. The analysis of missing data can reveal various 
issues related to the questionnaire, patients and the area being investigated in general. 
For example: patients may miss questions that they did not know how to answer them 
or felt uncomfortable to answer, questions which were not clear could also have been 
intentionally missed (Smith, 2010). However, a full analysis of missing data will not be 
presented in this write up as it is beyond its scope.    
 
Patients who did not answer a whole part of the questionnaire were excluded from the 
analysis of that part. Below is a description of how partially answered parts of the 
questionnaire were handled. Excluding all patients who had partial answers would have 
wasted valuable information. 
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MMAS-8 scale – In cases where patients partially answered this part, the researcher 
assumed best case scenario and the missing response was given a score in favour of 
adherence, so all missing questions were scored “1”. This approach is similar to the 
“intention to treat” approach, where the analysis was testing how the overall findings 
would look, if the patients were assumed adherent in any partially missing data. The 
alternative approach was to score the answered items and adjust to a scale of 0 – 8. So 
for example a patient who answered 7 questions and had a total score of 7, their 
adjusted score would (7x1.144) = 8. However, this approach was unlikely to produce any 
different results to the earlier approach except that some patients may be ranked 
differently in the non-adherence categories. The levels of adherence according to 
MMAS-8 were also calculated with adjusting partial responses in favour of non-
adherence and non-adherence to compare the significance of the approach on changing 
outcome. 
  
Adherence Estimator - Patients who answered at least one question in the scale were 
assigned a score of zero for every missing response (i.e. in favour of adherence).  
 
BMQ - As some patients missed some questions in the BMQ, the “n” for each question 
was calculated. For ease of comparison and analysis the mean and standard deviation of 
the answers for each question and the overall category were calculated.  
 
3.6.4 Comparing groups 
The attributes of the adherent and non-adherent groups according to various scales 
were compared according to the set of variables identified to describe the sample 
population. The three main categories used in the comparison were as follows: 
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• Demographics of the adherent vs. non-adherent groups 
o Age, gender, post code, ethnic origin and marital status. 
• Co-morbidities and cardiac history of both groups 
o Diabetes, angina, MI, angioplasty, CABG and trial background. 
• Medicines related variables  
o Number of overall medicines, doses per day, administration per day, GTN 
possession, GTN use, GTN monthly use, the type of secondary prevention 
medicines, number of secondary prevention medicines, number daily doses 
and number of daily administrations of secondary prevention medicines, and 
overall and individual knowledge about secondary prevention.  
 
Appropriate statistical tests were used to identify if differences were statistically 
significant as described below. Detailed comparisons of all variables were tabulated in 
Appendix 16. Only statistically significant differences were reported in the relevant 
sections in the Results Chapter.   
 
3.6.4.1 Bivariate analysis statistics  
Bivariate analysis was used to explore relationships between variables. Cross-
tabulations were used to look at categorical variables and explore possible associations 
between the variables and adherence. Two sided tests were used. The null hypothesis 
was that there was no difference between the adherent and non-adherent groups in 
regards to the variable being tested. The following tests were applied: 
• chi-square test (χ
2 
test) for categorical data.  
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• Fisher’s exact test was used when the assumptions of the chi-square test were 
violated (i.e. if less than 5 cases were expected in any of the cells). 
• Independent samples t-test to compare the means of parametric variables which 
had normal distribution.   
• Mann-Whitney U test is the equivalent of the independent samples t-test for non-
parametric or not normally distributed data.  
• Kruskal-Wallis H test is a non-parametric test which is similar to Mann-Whitney U 
test, but was used when more than two groups were being compared. 
 
p-values (2-sided) were calculated using the above various statistical methods. p-values 
of <0.05 were considered statistically significant and indicated that the null hypothesis 
of no difference or no association was rejected. All p-values <0.001 were reported as 
<0.001 rather than the actual value (Marston, 2010). All p-values reported were two-
sided because both directions of the effect or trend were considered possible. This was 
based on non-directional hypotheses, where it was assumed that the effect of the 
variables on adherence could have gone either way (i.e. increase or decrease 
adherence) (Howitt & Cramer, 2011).      
 
3.6.5 Comparing scales  
The results of the survey were further analysed to compare the consistency and 
differences between the 3 adherence measurement tools (MMAS-8, AE and SQ). This 
should inform future studies on best tools to use to assess adherence among CAD 
patients. 
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In the absence of a “gold standard” to compare the tools to, the findings of the AE and 
SQ tools were compared to the MMAS-8 and any Factors identified within it. The 
sensitivity and specificity of the SQ was calculated against the MMAS-8 findings using 
cross-tabulation. Because the AE predicted intentional non-adherence behaviour, its 
“prediction” was compared to the findings of both the MMAS-8 and SQ.  The positive 
predictive value and negative predictive values were calculated for the AE. The 
sensitivity and specificity of AE were calculated using the findings of both the MMAS-8 
and SQ. More details are provided in Appendix 15. 
    
3.6.5.1 Kappa statistic 
Kappa statistic (Cohen’s Kappa) was used to quantify the level of agreement between 
the 3 adherence assessment scales.  The 95% confidence interval (CI) for this statistic 
was calculated manually using the equation (Estimate ± 1.96 x SE) where SE is standard 
error. The interpretation and conclusion about the kappa statistic outcome was in 
accordance with the recommendations made by Landis and Koch (1977) for all 
statistically significant Kappas:  
к < 0  Poor agreement 
к = 0.0 – 0.20 Slight agreement 
к = 0.21 – 0.40 Fair agreement 
к = 0.41 – 0.60 Moderate agreement 
к = 0.61 – 0.80 Substantial agreement 
к = 0.81 – 1.00 Almost perfect agreement 
 
It is usually desirable to have a kappa statistic >0.60. The p-value for kappa is not always 
reported since the null hypothesis of no association is not always logical (Marston, 
2010). 
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3.6.6 Interpreting overall results 
Three adherence scales were used to measure levels of non-adherence. The MMAS-8 
and SQ scales identified current behaviour and any underway non-adherence to 
secondary prevention medicines. The AE explored propensity to non-adherence based 
on the major drivers of intentional non-adherence. All three scales findings were 
brought together and all patients who were identified to be non-adherent by the 
MMAS-8 or the SQ scales were explored to identify the reasons for their non-adherence. 
Where data was missing for one of the two scales the conclusion on level of adherence 
was used based on the other scale. The AE scores for the non-adherent patients 
identified by the MMAS-8 or SQ were also explored. A summary of the reasons for non-
adherence was generated. The percentage of non-adherent patients due to the cost of 
medicines was calculated separately taking into account patients who did not seem to 
be exempt from paying for their prescriptions. The BMQ of the non-adherers was also 
compared to the adherers.    
 
3.6.6.1 Building a regression model 
Regression analysis is one of the most commonly used multivariate statistical methods 
in the analysis of quantitative data. The aim was to identify variables (independent) that 
can be predictive of the dependent variable (non-adherence). To further explore the 
relationships between the different variables and patients’ adherent and non-adherent 
status multiple logistic regression was used.  The null hypothesis in the logistic 
regression model for each variable would be that there is no relationship between the 
dependent variable and the independent variable being examined in the model 
(Marston, 2010). Full description of this statistic is in Appendix 15. 
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Independent variables were systematically included in the logistic regression model. 
Based on the researcher’s clinical knowledge, literature review, and the bivariate 
comparisons which were carried out to compare the adherent and non-adherent groups 
the following variables were individually tested using the SPPS logistic regression 
function to check for the relationship between them and the probability of non-
adherence: 
 
 
• Age 
• Gender 
• Diabetes 
• Angina Status 
• MI Status 
• Bypass Status 
• Angioplasty Status 
• Trial background 
• Specific Necessity Score 
• Specific Concern Score 
• General Overuse Score 
• General Harm Score 
• Number of medicines 
• Number of doses per day 
 
• Number of administrations per day 
• GTN use 
• GTN monthly use 
• Being on any one of the 6 secondary 
prevention medicines 
• Number of secondary prevention medicines 
per day 
• Number administrations of secondary 
prevention medicines per day 
• Knowledge about individual secondary 
prevention medicines 
• Overall average knowledge about secondary 
prevention medicines 
• Needing solution or alternative to the four 
possible barriers to adherence. 
 
Three regression models were built for the following dependent variables: Non-
adherence according to MMAS-8 (excluding Qn5) or SQ, non-adherence according to 
Factor 1, and non-adherence according to Factor 2. Details on the variables included in 
each of the three models after univariate analysis can be found in Appendix 15.  
 
The following variables had a p-value of <0.25 in the univariate analysis for non-
adherence according to MMAS-8 (excluding Qn5) or SQ and were retained to include in 
the multivariate model:  
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• Age 
• Gender 
• Diabetes 
• Bypass Status 
• Angioplasty Status 
• Specific Necessity Score 
• Specific Concern Score 
• General Overuse Score  
• General Harm Score 
• Number of doses per day 
• Number of administrations per day 
• Being on statins, ACEI, aspirin 
• Number administrations of secondary 
prevention medicines per day 
• Knowledge about aspirin, ACEI, BB 
• Overall average knowledge about 
secondary prevention medicines 
• Needing solution or alternative to 
reading labels, getting repeat 
prescriptions. 
 
A correlation matrix (using Spearman’s co-efficient) for all variables considered for the 
model was created and reviewed for any evidence of collinearity. The variables related 
to the knowledge about certain secondary prevention medicines were excluded as 
patients who were not on that specific medicine could not be judged as if they knew or 
did not know about that medicine which would create vast number of missing values 
which would limit the data available for model estimation. However, the average of 
overall knowledge about the indication of secondary prevention medicines was 
retained.   
 
The literature does not support the theory testing of each single variable in this study. 
Therefore, three various approaches of model building were used to enable further 
exploration of associations and missing any independent variables (see Appendix 15 and 
16). The model which was considered more comprehensive, clinically meaningful, and 
explained more of the observed data was used and presented in the Results Chapter. 
The dependent variable was coded as 0 and 1 and the category most important (non-
adherence) was coded as 1 (Marston, 2010). Variables with non-significant p-values 
(>0.05) were removed. Important statistics were reported for the overall model such as 
the model’s χ
2
 and p-value which indicated whether the model was significant or not (p-
value needs to be <0.05), the Hosmer and Lemeshow Test (HLT) p-value to explain the 
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overall goodness-of-fit of the model (p-value needs to be >0.05) and the overall 
prediction ability of the model (the higher the percentage the better) (Field, 2009; 
Marston, 2010).   
 
Logistic regression reports odds ratios. The dependent variable is more likely to occur 
when the odds ratio is greater than one, and less likely to occur when less than 1 
(Marston, 2010). In continuous independent variables the odds ratio is for one unit of 
change (Marsden, 2010). The confidence intervals were quoted with each odds ratio. 
When they did not include 1 then the difference is statistically significant.  
 
Only relevant values from the final table of the logistic regression were reported and the 
rest of the output was populated in Appendix 16. The tables in Appendix 16 contained 
the log odds ratio (B), standard error for log odds ratio (SE), the Wald statistic, degrees 
of freedom (df), p-value (Sig.), odds ratio (Exp(B)), and 95% confidence interval for the 
odds ratio. The summary tables in the Results Chapter will only contain odds ratios, 95% 
confidence intervals and p-values.    
 
3.6.6.1.1 Interactions  
An interaction effect is the effect of two or more variables in combination on the 
outcome. The independent variables interact if the effect of one of the variables on the 
outcome differs depending on the level of the other variable (Field, 2009). Interaction is 
also known as a conditional relationship in which the relationship between two variables 
depends on the specific values of a third variable (Argyrous, 2011). Interactions were 
explored wherever the researcher suspected the existence of such effect. For example, 
gender, age and adherence.   
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3.6.7 Analysis of patients’ comments  
Due to the qualitative nature of patients’ comments and answers to the last question in 
the questionnaire a different analytical method was used. Frequency analysis of 
patients’ comments was identified to be most suitable for this purpose. The content and 
frequency of comments were reviewed in order to identify key ideas or themes using 
segmentation, categorisation and re-linking of aspects of the data (Matthews & Ross, 
2010).   
All comments made by patients were studied thoroughly because data familiarization is 
key to analysing qualitative data (Howitt & Cramer, 2011). A list of topics or issues 
identified by patients was generated and grouped together to examine for initial 
themes. All comments were charted and further analysis was carried out to identify 
themes, categories and sub-categories. Links between all these components were also 
examined and established. The overarching themes were checked to see if they were 
inclusive. The IHMC CmapTools software v. 5.03 was used to assist in mapping the initial 
themes and other emerging categories and subcategories. The software was invaluable 
in grouping the various emerging themes and linking relevant topics / issues. After the 
major themes, categories and subcategories were presented; the researcher identified 
comments made by adherent and non-adherent patients and made them 
distinguishable for the benefit of the analysis.  
As the data generated by this part of the questionnaire were not collected in a 
structured way such as an interview or structured questions, the analysis was a 
categorisation and frequency analysis of patients’ comments. These comments were 
useful in providing complementary and explanatory detail for the quantitative analysis.  
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4 Results 
 
In this chapter data from the constituent sections of the study will be presented in 
order to facilitate the interpretation of the results.  Basic descriptive statistics will be 
used first to illustrate the quantitative elements of the results, followed by more 
analytical statistics to explore associations, correlations and relationships. Chapter 3 
contains more detail on data interpretation and analysis. Figure 4.1 summarises how 
the results are presented and analysed in this chapter. Detailed description of the 
statistical tools used can be found in Appendix 15. Further detailed statistical analysis 
is presented in Appendix 16.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.1 – Chapter overview to demonstrate the structure and organisation of the data. 
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4.1 Response rate 
Out of the 696 questionnaires posted to patients from the ENCOURAGE data base, 503 
were completed and returned. The response rate was 72%.  All questionnaires were 
reviewed by the principal investigator as described in Chapter 3. Respondents were 
older than non-respondents (median age in years (Q1, Q3) = 70 (64, 74) versus 67 (61, 
74), respectively. p-value (2-sided) = 0.001 (Mann-Whitney U test)). The distribution of 
gender was the same among respondents and non-respondents.    
 
4.2 Patient demographics 
Table 4.1 describes the demographic profile of the participants according to age, 
gender, post code (of residence), ethnicity and marital status. The median age of the 
participants was 70 years. Males constituted 80% of the sample. Approximately 43% of 
the sample was from Leeds, 47% were from the rest of West Yorkshire (excluding 
Leeds) and 11% were from outside West Yorkshire. The majority of the participants 
were white (92%). Information about patients’ marital status was incomplete as 
discussed in Section 3.6.1.1. 
 
The age distribution of the sample is shown in Figure 4.2. The age of around 75% of the 
patients falls in the 6
th
 and 7
th
 decade. Fifty percent of participants were 70 years or 
older.     
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Table  4.1 – Demographics of the participants according to age, gender, post code, ethnicity 
and marital status (N=503). 
 
 
 Number Percentage 
Age(years)   
Median (Q1, Q3) 70 (63, 75)  
Min, Max   38, 92  
Gender   
F 100 20% 
M 403 80% 
Post Code   
Leeds (LS) 214 42.5% 
   
WF 108 21.5% 
BD 63 12.5% 
HD 38 7.6% 
HX 27 5.4% 
West Yorkshire (excluding LS) 236 47% 
   
YO 38 7.6% 
HG 9 1.7% 
BB 2 0.4% 
DN 2 0.4% 
HU 1 0.2% 
OL 1 0.2% 
 Other (outside of WY) 53 10.5% 
Ethnicity   
White 462 91.8% 
South Asian 2 0.4% 
Mixed Race 1 0.2% 
Unknown 38 7.6% 
Marital Status   
Single 10 2% 
Married 247 49.1% 
Widow / Widower  10 2% 
Divorced/Separated 10 2% 
Not Known 226 44.9% 
   
Q1 = Lower quartile, Q3 = upper quartile, LS=Leeds, WF=Wakefield, BD=Bradford, HD=Huddersfield, YO=York, HX=Halifax, 
HG=Harrogate, BB=Blackburn, DN=Doncaster, HU=Hull, OL=Oldham, WY=West Yorkshire 
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Figure  4.2 – Age distribution of the sample (N=503). The percentages on the graph represent 
the patients in each age decade. 
 
 
4.3 Patients’ cardiac history and comorbidities  
The cardiac history and comorbidities relevant to CHD and medicines-taking analysis 
are described in Table 4.2. This information was based on the details provided by 
patients when they expressed interest in taking part in the study (see Sections 3.6.1.2 
and 3.6.1.3 for more detail). Table 4.3 summarises studies conducted in the 
Cardiovascular Research Unit that participants were enrolled on in the past. Ninety 
three percent of the sample participated in the Family Heart Study or OPERA which 
indicates that they should have been on secondary prevention medicines for more 
than 5 years.   
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Table  4.2 – Cardiac history and procedures as reported by patients prior to completing the 
survey and relevant comorbidities identified from review of patients’ medicines (N=503). 
 
 
Condition / procedure Status 
Number of 
patients 
Percentage 
(N=503) 
Angina Yes  65 13% 
 No 188 37% 
 Unknown 250 50% 
MI Yes 349 69% 
 No 154 31% 
Angioplasty Yes 286 57% 
 No 217 43% 
CABG Yes  192 38% 
 No 311 62% 
Diabetes (on anti-diabetics) Yes 62 12% 
 No 441 88% 
Controlled by:    
PO (only)  40  
INJ (only)  9  
Both  13  
Age less than 60 years  8  
Hypothyroidism (on levothyroxine) Yes 32 6% 
 No 471 94% 
Age less than 60 years  6  
MI=Myocardial Infarction, CABG = Coronary artery bypass grafting, Diabetes= controlled with anti-diabetic medicines, PO=oral 
anti-diabetic medicines, INJ=injectable anti-diabetic medicines (insulin and other).  
 
 
 
 
Table  4.3 – Description of the trials that patients had participated in and associated 
information about patients’ cardiac history (N=503). 
 
 
Trial 
No. of patients 
(percentage) 
Relevant Cardiac History 
Family Heart Study 
(Samani et. al., 2005) 
285 (56.7%) 
Launched 2001. Patients with CAD defined as MI, 
CABG, PTCA, or angina (positive exercise test), with 
validated onset before the age of 66. 
   
OPERA Study 
(Sainsbury et. al., 2005) 
183 (36.4%) 
Launched 2005. Patients undergoing acute or 
elective PTCA at the Leeds General Infirmary. 
   
Candidates for SIGNIFY 
study 
(Ferrari, 2009) 
35 (7.0%) 
Launched 2009. Documented stable CAD without 
clinical signs of heart failure. CAD based on previous 
documented MI, PCTA, CABG, or imaging evidence 
and positive exercise test positive at least 3 months 
before enrolment.  
  CAD=Coronary artery disease, MI=Myocardial Infarction, CABG= Coronary artery bypass graft, PTCA= Percutaneous transluminal 
coronary angioplasty. OPERA = Markers of myocardial injury in patients undergoing percutaneous angioplasty, SIGNIFY= Study 
assessInG the morbidity–mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease 
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4.4 Medicines used by patients in the sample 
This section reports the number of medicines used by patients, the number of daily 
doses and administrations, GTN use, and secondary prevention medicines use.  
4.4.1 Number of medicines  
The median (Q1, Q3) number of different medicines reported in Part 1 of the 
questionnaire by patients was 7 (5, 9). Figure 4.3 is a histogram showing the 
distribution of the overall number of medicines used by patients in the study. 
Approximately 55% of patients were prescribed 4 to 7 medicines and 81 (16%) patients 
were on 5 medicines.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.3 – The frequency and distribution of the overall number of medicines prescribed to 
patients in the study according to their reporting in Part 1 of the questionnaire (N = 503). 
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4.4.2 Frequency of daily medicines doses and administrations 
Table 4.4 shows the medicines administration reported by patients in the study 
categorised according to daily frequencies. Fifty percent of patients were prescribed all 
their medicines for once daily administration, and 37% reported taking at least one of 
their medicines twice daily (and none more than twice daily). The total number of daily 
doses is presented in Figure 4.4. The median number of individual doses per day was 6. 
Figure 4.5 highlights the total number of administration times per day with a median of 
2 (see Section 3.6.1.3).  
 
Table  4.4 – Frequency of daily medicines administration as reported by participants (N= 503). 
 
 
Description  
No. of patients who 
meet the criteria 
Percentage 
(N=503) 
Takes all medicines Once Daily (OD) only 250 50% 
Takes at least one medicine Twice Daily (BD)  
(But not >BD)  
189 37% 
Takes at least one medicine more than BD  64 13% 
Total 503 100% 
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Figure  4.4 – Frequency and distribution of individual daily doses (N = 503).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.5 – Frequencies and distribution of the total number of daily administrations of 
medicines as reported by patients in the sample (N = 503). 
Median number of daily doses = 6 
Min = 1 
Max = 24 
Percentiles   25 = 5 
        75 = 9 
Median number of administration times = 2 
Min = 1 
Max = 4 
Percentiles   25 = 5 
        75 = 3 
Mean (±SD) = 2.41 ± 0.817  
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4.4.3 Secondary prevention medicines  
The number of patients prescribed each class of secondary prevention medicines is 
shown in Table 4.5. The number of individual daily doses of secondary prevention 
medicines is shown in Figure 4.6. Figure 4.7 shows the number of daily administration 
times. The different combinations are described in Tables 4.6 and 4.7. Only 263 (52%) 
patients were prescribed at least four of the secondary prevention medicines.  One 
hundred and seventy (34%) patients were prescribed three secondary prevention 
medicines and 53 (11%) were prescribed only two secondary prevention medicines. 
Table 4.8 shows that 15 (3%) patients were prescribed only one secondary prevention 
medicine. One patient reported that they were not on any secondary prevention 
medicines. Another patient indicated that they no longer take their secondary 
prevention medicines without identifying which ones they were prescribed.       
 
Table  4.5 – Secondary prevention medicines prescribed for patients in this sample; ranked 
according to the most commonly prescribed (N=503). 
 
Name of Heart Medicine 
No. of patients 
on the drug 
Percentage 
Statin 476 94.6% 
Aspirin 439 87.3% 
BB 356 70.8% 
ACEI 293 58.3% 
ARBs 104 20.7% 
Clopidogrel 59 11.7% 
BB = beta blockers, ACEI = angiotensin converting enzyme inhibitors, ARBs = angiotensin receptor blockers 
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Figure  4.6 – Frequency and distribution of the number of individual daily doses of secondary 
prevention medicines as reported by patients in the sample (N = 503). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.7 – Frequency and distribution of the number of daily administration times for 
secondary prevention medicines reported by participants (N = 503). 
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Table  4.6 – Frequency of the different combinations of secondary prevention medicines 
prescribed for patients in this sample (N = 503). 
 
Combination No. of patients 
Number of patients on FIVE secondary prevention medicines. 
• Aspirin & Clopidogrel 
• ACEI or ARBs 
• BB 
• Statin 
27 
(5.4%) 
Number of patients on FOUR secondary prevention medicines.  
• Aspirin or Clopidogrel 
• ACEI or ARBs 
• BB 
• Statin 
236 
(46.9%) 
Total (on at least four medicines) 263 (52.3%) 
Number of patients on THREE secondary prevention medicines.  
Combination 1 (No BB) 
• Aspirin or Clopidogrel 
• ACEI or ARBs 
• Statin 
82 
(16.3%) 
Combination 2 (No ACEI or ARBs) 
• Aspirin or Clopidogrel 
• BB 
• Statin 
60 
(11.9%) 
Combination 3  (No Aspirin or Clopidogrel) 
• Statin 
• BB 
• ACEI 
22 
(4.4%) 
Combination 4 (No Statin) 
• Aspirin or Clopidogrel 
• BB 
• ACEI 
6 
(1.2%) 
Total (on three only, any combination) 170 (33.8%) 
Number of patients on TWO secondary prevention medicines.  
Combination 1 (No BB & ACEI) 
• Aspirin or Clopidogrel 
• Statin 
33 
(6.6%) 
Combination 2  (No BB & Aspirin or Clopidogrel) 
• ACEI or ARBs 
• Statin 
9 
(1.8%) 
Combination 3  (No BB & Statin) 
• Aspirin or Clopidogrel 
• ACEI or ARBs 
7 
(1.4%) 
Combination 4 (No Statin & ACEI) 
• Aspirin OR Clopidogrel 
• BB 
3 
(0.6%) 
 Combination 5 (No Aspirin or Clopidogrel & ACEI) 
• Statin 
• BB 
1 
(0.2%) 
Total (on two only, any combination) 53 (10.6%) 
BB = beta blockers, ACE I = angiotensin converting enzyme inhibitors, ARBs = angiotensin II receptor antagonists 
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Table  4.7 – Number of patients prescribed only ONE of the secondary prevention (N=503). 
 
Name of Heart Medicine 
No. of patients 
on the drug 
Percentage 
Statin 6 1.2% 
Aspirin 5 1% 
BB 1 0.2% 
ACEI 2 0.4% 
ARBs 1 0.2% 
BB = beta blockers, ACE I = angiotensin converting enzyme inhibitors, ARBs = angiotensin II receptor antagonists 
 
 
4.4.3.1 Knowledge of secondary prevention medicines indication 
Table 4.8 summarises participants’ level of knowledge of secondary prevention 
medicines indications as described in Section 3.6.1.5.  
 
 
Table  4.8 – Patients’ level of knowledge about the indication of each of the prescribed 
secondary prevention medicines on a scale of 1 – 3 (N=503). 
 
Name of 
Heart 
Medicine 
No. of 
patients on 
the drug 
Level of Knowledge of Indication 
Specific (1) General (2) None (3) n 
Aspirin 439 230 52.4% 144 32.8% 63 14.4% 439 
Statin 476 316 66.7% 77 16.2% 83 17.5% 474 
Clopidogrel 59 28 47.5% 17 28.8% 14 23.7% 59 
BB 356 128 36.4% 139 39.5% 85 24.1% 352 
ACEI 293 110 37.8% 106 36.4% 75 25.8% 291 
ARBs 104 46 44.2% 25 24.0% 34 32.7% 104 
BB = beta blockers, ACE I = angiotensin converting enzyme inhibitors, ARBs = angiotensin II receptor antagonists 
1=have “specific” knowledge about indication, 2 = have “general” knowledge and 3 = have “none” knowledge reported. 
 
 
The “knowledgeable” vs. “not knowledgeable” categorisation as explained in Section 
3.6.1.5 is shown in Table 4.9. This classification is used later in the comparative 
analysis. The overall patients’ knowledge about the indications of all the secondary 
prevention medicines that they were prescribed was calculated as described in Section 
3.6.1.5. The sample’s overall knowledge of secondary prevention medicines’ indication 
is as follows: mean ± SD = 1.7 ± 0.65, median (Q1, Q3) = 1.6 (1, 2). 
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Table  4.9 – Patients’ knowledge about the indication of each of the secondary prevention 
medicines they were prescribed (N=503). 
 
Name of Heart 
Medicine 
No. of patients 
on the drug 
Level of Knowledge of Indications 
Knowledgeable 
Not 
Knowledgeable n 
Statin 476 316 66.7% 160 33.8% 474 
Aspirin 439 230 52.4% 207 47.2% 439 
Clopidogrel 59 28 47.5% 31 52.5% 59 
ARBs 104 46 44.2% 59 56.7% 104 
ACEI 293 110 37.8% 181 62.2% 291 
BB 356 128 36.4% 224 63.6% 352 
BB = beta blockers, ACE I = angiotensin converting enzyme inhibitors, ARBs = angiotensin II receptor antagonists 
“knowledgeable” =  reported indication and gave accurate description to distinguish the class of medicine, “not knowledgeable” = 
not reported indication, wrong indication, unsure about indication, or said it is for the heart. 
 
 
 
4.4.4 GTN use 
Seventy three percent of patients were prescribed a GTN spray or tablet and 49% of 
them used their GTN as shown in Table 4.10. The frequency of GTN use was not 
reported by 38% of those who reported using it. The median (Q1, Q3; min, max) 
number of times GTN used was 3 times per day (2, 4; 1, 8) among those who reported 
GTN use daily, 3 times per week (2, 4; 1, 6) among weekly users and 2 usages per 
month (1, 3; 1, 10) among monthly users. Cumulative Monthly GTN is shown in Figure 
4.8. 
 
Table  4.10 – Summary of the GTN possession and use among patients in the study (N=503). 
 
Possession of a GTN   n = 503 
Yes 366 73% 
No 128 25% 
Missing 9 2% 
Total 503  
GTN use (for those who possess GTN)  n = 366 
Yes 180 49% 
No 178 49% 
Missing 8 2% 
Total 366  
Frequency of reported GTN use  n = 180 
Daily 15 8% 
Weekly 41 23% 
Monthly 56 31% 
Missing 68 38% 
Total  180  
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Figure  4.8 – Cumulative Monthly GTN use by all patients who reported frequency of their GTN 
use (n = 112). Daily and weekly use was aggregated to monthly use. 
 
 
 
There was no statistically significant correlation between cumulative monthly GTN use 
and number of secondary prevention medicines prescribed, reported angina status, 
MI, angioplasty or CABG.  
 
 
 
 
 
 
 
n = 112 
mean = 17 
SD = ± 33 
median = 4 
Min = 1 
Max = 224 
Percentiles  25 = 2 
    75 = 12 
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4.5 Levels of adherence according to the adherence 
scales 
 
In this section the findings of each of the adherence assessment scales will be 
presented.   
 
4.5.1 Results of the Morisky Medication Adherence Scale – 8 (MMAS-8)     
 
 
This part of the questionnaire was completed by 500 patients. Missing data were 
handled as described in Section 3.6.3. Three patients did not answer any question on 
the MMAS-8 scale and will therefore be excluded from the analysis. Table 4.11 shows 
the overall results of the MMAS-8 including individual item responses. As can be seen 
from Table 4.12, the level of adherence was 49%; 40% of patients had medium 
adherence and 11% had low adherence. These levels were calculated after adjusting 
partial responses in favour of non-adherence. The overall summary of responses for 
the non-adherent patients is shown in Table 4.13. After adjusting missing data in 
favour of adherence, only 8 patients shifted from being classed non-adherent to the 
adherent category. Other changes can be seen by comparing Table 4.12 to Table 4.14 
which shows the levels of non-adherence according to the MMAS-8 after adjusting 
missing responses in favour of adherence.  
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Table  4.11 – Overall results for MMAS-8 for both adherent and non-adherent patients (n = 
500) (3 patients did not answer any of the scale’s questions).  
 
Question Yes No n 
1. Do you sometimes forget to take your heart 
medicines? 
92 (18.4%) 405 (81.0%) 497 
2. Over the past 2 weeks, were there any days 
when you did not take your heart 
medications? 
29 (5.8%) 470 (94.0%) 499 
3. Have you ever cut back or stopped taking 
your medication without telling your doctor 
because you felt worse when you took it? 
31 (6.2%) 465 (93.0%) 496 
4. When you travel or leave home, do you 
sometimes forget to bring along your 
medications? 
26 (5.2%) 469 (93.8%) 495 
5. Did you take your heart medications 
yesterday? 
450 (90.0%) 48 (9.6%) 498 
6. When you feel like your heart condition is 
under control, do you sometimes stop 
taking your medications? 
5 (1%) 492 (98.4%) 497 
7. Do you ever feel hassled about sticking to 
your heart treatment plan? 
41 (8.2%) 456 (91.2%) 497 
8. How often do you have difficulty 
remembering to take ALL your heart 
medications?                                                                                                                                      
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64.6% 
136 
 
27.2% 
33 
 
6.6% 
5 
 
1% 
0 
 
0% 
497 
 
 
 
 
 
Table  4.12 – The levels of adherence and non-adherence according to the MMAS-8 Score after 
adjusting missing data in favour of non-adherence i.e. unanswered question scored 0 (n = 500). 
 
Morisky Adherence Status  
Adherent (MS = 8) 245 (49%) 
Non-adherent (MS <8) 255 (51%) 
n 500    
  
Level of Adherence   
High Adherence (MS = 8) 245 (49%) 
Medium Adherence (MS - 6 to 8) 202 (40%) 
Low Adherence (MS <6)  53 (11%) 
n 500 
MS = Morisky Score 
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Table  4.13 – MMAS-8 results for non-adherent patients after adjusting missing answers in 
favour of adherence (n=247) (Green shading indicates response considered non-adherence). 
 
 Yes No n
*
(missing) 
1. Do you sometimes forget to take your 
heart medicines? 
92 (37.3%) 155 (62.7%) 245(2)  
2. Over the past 2 weeks, were there any 
days when you did not take your heart 
medications? 
29 (11.7%) 218 (88.3%) 246(1) 
3. Have you ever cut back or stopped 
taking your medication without telling 
your doctor because you felt worse 
when you took it? 
31 (12.6%) 216 (87.4%) 244(3) 
4. When you travel or leave home, do you 
sometimes forget to bring along your 
medications? 
26 (10.5%) 221 (89.5%) 245(2) 
5. Did you take your heart medications 
yesterday? 
198 (80.2%) 49 (19.8%) 246(1) 
6. When you feel like your heart condition 
is under control, do you sometimes stop 
taking your medications? 
5 (2%) 242 (98%) 244(3) 
7. Do you ever feel hassled about sticking 
to your heart treatment plan? 
41 (16.6%) 206 (83.4%) 246(1) 
8. How often do you have difficulty 
remembering to take ALL your heart 
medications?                                                                                                                 
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(mis
sing) 
73 
 
29.5% 
136 
 
55.1% 
33 
 
13.4% 
5 
 
2% 
0 
 
0% 
245 
(2) 
 
 
*n = number of patients who answered this question before adjusting. 
 
 
 
Table  4.14 – Adherence levels according to MMAS-8 Score after adjusting for partial responses 
and scoring them in favour of adherence (n=500). 
 
Morisky Adherence Status  
Adherent (MS = 8) 253 (51%) 
Non-adherent (MS <8) 247 (49%) 
n 500  
  
Level of Adherence   
High Adherence (MS = 8) 253 (51%) 
Medium Adherence (MS - 6 to 8) 195 (39%) 
Low Adherence (MS <6)  52 (10%) 
n 500  
MS = Morisky Score 
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Figure 4.9 shows the distribution of MMAS-8 scores for non-adherent patients after 
adjusting for missing responses in favour of adherence. Twenty three percent of non-
adherent patients had a score of 7.75 which indicates that they only answered “almost 
never” to Question 8 instead of “never”.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.9 – Distribution of MMAS-8 scores among Non-adherent patients identified by the 
MMAS-8 scale after adjustments in favour of adherence (n= 247). 
 
 
The MMAS-8 scale explores various types of reasons for non-adherence. Questions 1, 4 
and 8 (Qn1, Qn4 and Qn8) mainly address forgetfulness. Questions 2 and 5 (Qn2 and 
Qn5) can be due to forgetfulness or other intentional non-adherence reasons. In Table 
4.15 responses were grouped, where possible, to understand reasons behind non-
adherence according to the MMAS-8 scale. The most common reason for non-
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adherence was forgetfulness. Seventeen percent of patients were hassled about their 
medicines and 13% stopped their medicines after feeling worse on them without 
informing their doctor. 
    
Table  4.15 – The reasons for non-adherence among non-adherent patients who were 
identified by the MMAS-8 scale (n=247). 
 
Reason Frequency  
(1) Forgetfulness of any type (questions 1,4,8) 182 (74%) 
Forgetfulness when travelling (question 4) 26 (11%) 
(2) Did not take medicine in the last 2 weeks OR yesterday.  (forgetfulness or 
other reason) (questions 2, 5) 
75(30%) 
Not taken in the last 2 weeks (question 2) 29 (12%) 
Not taken yesterday (question 5) 49 (20%) 
(3) Hassled about medicines 41 (17%) 
(4) Stopped medicine(s) after feeling worse on medicine (without telling doctor) 31 (13%) 
(5) Stopped medicine(s) after feeling condition under control  5 (2%) 
 
4.5.1.1 Issues with Question 5 in the MMAS-8 scale 
Qn5 in the MMAS-8 was reversed (i.e. if the patient answered no = non-adherence, yes 
= adherence) with respect to Qn1, Qn2, questions3 (Qn3), Qn4 and question 7 (Qn7). 
This sometimes caused confusion and certain patients may have answered it 
incorrectly. An account of the number of patients who could have been wrongly 
classified as non-adherent based only on Qn5 of the MMAS-8 is as follows:  
The number of patients who answered Qn5 with “No” was 49. Of those patients 
14 answered “Yes” to at least one of the other questions in the MMAS-8 scale. 
This means that 35 patients were classed to be non-adherent based only on Qn5. 
To reduce the risk of incorrectly classifying those patients as non-adherent, Qn5 
will be excluded from further analysis.  
 
After excluding Qn5, the scoring of MMAS-8 was recalculated. The number of non-
adherent patients was found to be 211 (42%) as opposed to 247 (49%) (adjusted in 
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favour of adherence) without excluding Qn5. The levels of non-adherence were: 
medium adherence 162 (32%) and low adherence 49 (10%). Before excluding Qn5 the 
levels were: 195 (39%) and 52 (10%) respectively.    
 
4.5.1.2 Reliability of MMAS-8 - Cronbach's α  
Cronbach's α (alpha) was calculated for MMAS-8 to check for internal consistency in 
identifying non-adherent patients in the sample as described in Section 3.6.2.1.1 and 
Appendix 15. Full statistical SPSS output can be seen in Appendix 16. As can be seen in 
Table 4.16 the calculated Cronbach's α for all 8 items was 0.495, which reflects low 
internal consistency and “unidimensionality”. It is noteworthy that n for this 
calculation was 486 and 17 cases were excluded from the analysis because the 
reliability test employs “listwise deletion” i.e. the case is excluded if any data is missing 
in the tested variables (any of the 8 questions). Table 4.16 also shows the correlation 
between each item in the scale and the overall scale. Any question with a correlation 
of <0.3 indicates lack of consistency with the rest of the questionnaire. A negative 
value indicates a negative correlation with the total score of the questionnaire. Qn3, 
Qn5, question 6 (Qn6) and Qn7 have poor correlation with the overall finding of the 
scale. Qn5 negatively correlates with the overall scale. 
 
Table  4.16 – The correlation between each item in the MMAS-8 scale and the total score for 
the scale and Cronbach’s α for all 8 items (n = 486). 
 
MMAS- 8 Question Correlation with the total score 
Question (1) 0.408 
Question (2) 0.373 
Question (3)   0.182* 
Question (4) 0.308 
Question (5) - 0.108† 
Question (6)   0.172* 
Question (7)   0.193* 
Question (8) 0.546 
Cronbach's α (N items = 8) 0.495 
*correlation value is <0.3, † negative correlation. 
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Table 4.17 shows the predicted change to Cronbach’s α if any one of the 8 items was 
excluded from the scale. Removing Qn5 increases Cronbach's α value significantly from 
0.495 to 0.602. This means that removing Qn5 improves the reliability of this scale. The 
correlation of each question to the overall scale and Cronbach's α were recalculated 
after removing Qn5 (see Table 4.18). 
 
Table  4.17 – Changes in Cronbach’s α for the MMAS-8 scale if any item was excluded (n=486). 
 
MMAS- 8 Question Cronbach's α if Item Excluded 
Question (1) 0.362 
Question (2) 0.410 
Question (3) 0.477 
Question (4) 0.434 
Question (5) 0.602 
Question (6) 0.487 
Question (7) 0.476 
Question (8) 0.384 
 
 
Table  4.18 – The correlation between each item in the MMAS-8 scale and the total score for 
the scale and Cronbach’s α for all 7 items after removing Qn5 (n = 487). 
 
MMAS- 8 Question Correlation with the total 
Question (1)  0.484 
Question (2)  0.399  
Question (3)    0.195* 
Question (4)  0.343  
Question (6)    0.163* 
Question (7)    0.205* 
Question (8)  0.601  
Cronbach's α (N items = 7)  0.602 
*correlation value is <0.3 
 
 
A Cronbach's α value of <0.7 indicates reduced internal consistency and this could be 
explained by the diverse themes covered by the scale. Qn3, Qn6 and Qn7 have a 
correlation of <0.3 which indicates lack of consistency with the rest of the 
questionnaire. However, as can be seen in Table 4.19 removing Qn3, Qn6 and Qn7 
individually will cause negligible increases in Cronbach's α value.   
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Table  4.19 - Changes in Cronbach’s α for the MMAS-8 scale if any item of the 7 remaining was 
excluded (n=486). 
 
MMAS- 8 Question Cronbach's α if Item Excluded 
Question (1) 0.500 
Question (2) 0.538 
Question (3) 0.604 
Question (4) 0.557 
Question (6) 0.606 
Question (7) 0.608 
Question (8) 0.504 
 
 
The MMAS-8 scale had medium reliability after removing Qn5 (Cronbach's α = 0.602). 
Due to the poor correlation between Qn3, Qn6 and Qn7 with the overall score of the 
questionnaire, Cronbach's α value was recalculated in the absence of all of these three 
questions. Cronbach's α for MMAS-8 for Qn1, Qn2, Qn4, and Qn8 was increased to the 
value of 0.681 (n=493). Any further item deletion reduced Cronbach's α value to 
<0.681.  If all missing values were replaced with a score in favour of adherence to 
make n= 500. Cronbach's α (including Qn5) = 0.501, Cronbach's α (excluding Qn5) = 
0.610, Cronbach's α (excluding Qn5, Qn3, Qn6 and Qn7) = 0.678.  
 
Due to these findings further exploration by conducting a factorial analysis is needed 
to identify if the scale is “unidimensional” or contains other constructs that should be 
considered when analysing the results.  
 
4.5.1.3 Factor analysis of MMAS-8 
An exploratory factorial analysis was conducted on the 8 questions as described in 
Section 3.6.2.1.2 and Appendix 15. The analysis was carried on 486 patients following 
the principle of listwise deletion. Full SPSS output can be seen in Appendix 16.  The 
determinant of the correlation matrix was 0.345 which means that multicolinearity is 
not a problem for this data (Field, 2009). The questions correlate and none of the 
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correlation coefficients were particularly large (>0.9), so there was no need to 
eliminate any questions. The KMO was 0.698 indicating good sampling adequacy and 
factor analysis should yield distinct and reliable factors (Field, 2009). Bartlett’s test of 
sphericity results were  χ
2 
= 518.204, p < 0.001 and therefore the original matrix is not 
an identity matrix (Field, 2009).  
 
Initial eigenvalues identified 8 components (equal to the number of questions). 
Kaiser’s criterion of retaining factors with eigenvalues >1 was used. The extraction 
identified two constructs or factors. The communilaties table (see Appendix 16) 
indicates the proportion of variance explained by the underlying factors. Qn1 has a 
common associated variance of 72.5% whereas Qn5 had only 8.9%. Before rotating: 
Qn1, Qn2, Qn4, and Qn8 load highly onto the first factor; and Qn3, Qn6 and Qn7 load 
highly onto the second factor. Qn5 does not seem to load onto either of the factors.  
SPSS used the extraction method of principal component analysis and the rotation 
method of Varimax with Kaiser Normalization.  Rotation converged in 3 iterations and 
the same questions were loaded onto the same factors. However, the values of loading 
for most of the questions were bigger. Table 4.20 shows factor loading after rotation. 
The two constructs identified were as follows:  Factor 1 - includes Qn1, Qn2, Qn4 and 
Qn8 which focus mainly on non-intentional i.e. forgetfulness, and Factor 2 – includes 
Qn3, Qn6 and Qn7 which focus more on intentional non-adherence. While Qn3 and 
Qn6 reflect intentional non-adherence, Qn7 possibly has both intentional and non-
intentional components.  
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Table  4.20 - Summary of exploratory factor analysis results for MMAS-8 scale (n=486). The 
green shaded areas are the questions with high factor loading (>0.4). 
 
  Item 
Factor 1 
(Unintentional /  
Forgetfulness non-
adherence) 
Factor 2 
(Intentional / Hassle 
non-adherence) 
1. Do you sometimes forget to take your 
heart medicines? 
0.85 0.05 
2. Over the past 2 weeks, were there any 
days when you did not take your heart 
medications? 
0.69 0.02 
3. Have you ever cut back or stopped 
taking your medication without telling 
your doctor because you felt worse 
when you took it? 
0.05 0.67 
4. When you travel or leave home, do you 
sometimes forget to bring along your 
medications? 
0.50 0.26 
5. Did you take your heart medications 
yesterday? 
-0.27 0.13 
6. When you feel like your heart condition 
is under control, do you sometimes 
stop taking your medications? 
-0.13 0.63 
7. Do you ever feel hassled about sticking 
to your heart treatment plan? 
0.10 0.65 
8. How often do you have difficulty 
remembering to take ALL your heart 
medications? 
0.80 0.18 
Eigenvalues 2.17 1.38 
% of variance 27.15 17.19 
Cronbach's α 0.681 0.324 
 
 
The calculation of Cronbach's α for Factor 2 shows very low internal consistency 
among the 3 questions. Removing item 6 from Factor 2 would increase Cronbach's α to 
0.329. Removing either item 3 or item 7 would reduce Cronbach's α to <0.180. This will 
be discussed further in the Discussion Chapter. 
 
4.5.1.4 Adherence levels according to the two Factors 
Factor 1 (unintentional / forgetfulness non-adherence) includes all patients who 
answered “yes” to one or more of the following questions: Qn1, Q2, Qn4 or Qn8 in the 
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MMAS-8 scale. Factor 2 (intentional / hassle non-adherence) includes those who 
answered “yes” to one or more of Qn3, Qn6 or Qn7. In Factor 2 six patients had one 
missing response to one of the three questions. Those were adjusted in favour of 
adherence. Figure 4.10 shows the distribution of the non-adherent group identified by 
MMAS-8 (excluding Qn5) (211 patients) according to Factor 1 and Factor 2. Forty (19%) 
of non-adherent patients had both elements of non-adherence (Factor 1 and Factor 2).     
 
 
Figure  4.10 – Venn diagram of non-adherent patients identified by the MMAS-8 and 
distributed to Factor 1 and Factor 2 (n = 211). 
 
 
4.5.2 Results of the Adherence Estimator scale  
Table 4.21 describes the overall results for the scale. Table 4.22 is an analysis for Item 
3 which is related to cost of medicines. As patients over 60 and those with certain 
medical conditions are exempt from paying prescription charges, the item was 
analysed taking age and relevant identifiable co-morbidities into account. It was not 
possible to establish for certain which patients who were both under 60 and exempt 
from paying for their medicines. However, all identifiable reasons available to the 
researcher were used in the analysis.  
40 (19%) 
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Table  4.21 – Overall results for the Adherence Estimator (n=498).  
(Five patients did not answer any question of the AE (one was <60 years old). Green cells are significant according to the AE scale (weight > 0)) 
 
 
Table  4.22 – Overall results for question 3 for Adherence Estimator ™ score for patients <60. (n=71) 
 
 Agree 
Completely 
Agree Mostly 
Agree 
Somewhat 
Disagree 
Somewhat 
Disagree 
Mostly 
Disagree 
Completely 
n 
I feel financially burdened by my 
out-of-pocket expenses for my 
prescription medication 
16 (22.5%)* 3 (4.2%) 13 (18.3%)* 7 (9.5%)* 5 (7.0%)* 27 (38.0%) 71 
 
* 15 patients ≥ 60 answered item 3 with other than “Disagree Completely”. Two aged 72 and 71 said “Agree completely” and the rest said “Agree Somewhat” or 
less. Four had just turned 60 – so they could have been recently paying for their prescription and have just become exempt. Nine were older than 60. Only one 
patient of the 9 gave a reason for answering this question. He commented that “erectile dysfunction medication should be free for a non-earning pensioner”. The 
other 8 made no comment.    
 
 
Agree 
Completely 
Agree Mostly 
Agree 
Somewhat 
Disagree 
Somewhat 
Disagree 
Mostly 
Disagree 
Completely 
n 
1. I am convinced of the 
importance of my prescription 
medication 
386 (77.8%) 83 (16.7%) 19 (3.8%) 6 (1.2%) 0 (0%) 2 (0.4%) 496 
2. I worry that my prescription 
medication will do more harm 
than good to me 
16 (3.4%) 22(4.7%) 47 (10.0%) 39 (8.3%) 96 (20.5%) 248 (53.0%) 468 
3. I feel financially burdened by my 
out-of-pocket expenses for my 
prescription medication 
18 (3.6%) 3 (0.6%) 17 (3.4%) 13 (2.6%) 8 (1.6%) 441 (88.1%) 496 
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Table 4.23 shows the probability of the level of intentional adherence and non-
adherence to secondary prevention medicines according to the AE. All missing cases 
were handled as was discussed in Section 3.6.3. Thirty percent of patients were 
predicted by the AE to have low to medium probability of adherence. The AE 
estimated that 10% of patients should have low probability of adherence.  
   
Table  4.23  – Probability of adherence levels according to the AE. 
(Assuming best case scenario – i.e. missing responses were converted in favour of adherence) 
  
AE Adherence Status   
Adherent (AES = 0) 351 (71%) 
Non-adherent (AES> 0) 147 (30%) 
n 498  
  
Level of Adherence   
High probability of adherence (>75%) (AES = 0) 351 (71%) 
Medium probability of adherence (32 – 75%) (AES = 2 to 7) 96 (19%) 
Low probability of adherence (<32%) (AES ≥ 8)  51 (10%) 
n 498 
AES = Adherence Estimator score.  
 
The distribution of scores for the non-adherent patients is presented in Figure 4.11. It 
is notable that the scores in the AE suggest possible reasons for non-adherence as 
summarised in Table 4.24. 
 
Table  4.24 – Summary of the interpretation of various AE scores in terms of the reasons 
underlying propensity to intentional non-adherence. 
 
Possible reason for propensity to intentional non-adherence 
AE Score Cost Worried about harm Not convinced of importance 
2    
4    
6    
7    
11    
14    
16    
20    
21    
23    
34    
 = indicates a stronger contribution from this element (Possible range 0 – 36) 
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Sixty eight percent of the predicted non-adherent group are only worrying that their 
medicines can cause more harm than good (scored 4 or 14 as in Figure 4.11). 
 
Figure  4.11 – Distribution of AE scores among probable non-adherent patients according to AE 
(n = 147). 
 
 
The reasons for propensity to intentional non-adherence according to the AE findings 
are shown in Table 4.25. Worrying about the harm of medicines ranked first.  The 
analysis of cost of medicines’ impact on adherence is shown in Table 4.26. 
 
 
Table  4.25 – Reasons for probable non-adherence according to AE (overall) 
Ranked according to higher frequency (n=147). 
 
Reason Frequency 
Worry that their medicines will do more harm than good  124 (84.4%) 
Not convinced enough about the importance of their medicines 27 (18.4%) 
Feel financially burdened by cost of medicines See Table 4.27 
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Table  4.26 – Analysis of question 3 in AE (cost of medicines being reason for non-adherence) 
by identifying the number of patients who are not exempt from paying a prescription charge. 
(Only patients aged <60 were included) 
 
 Number of patients 
Patients <60 yrs old in the sample AND who answered Q3 in AE 71 
Patients <60 yrs old who are not exempt (not diabetic or hypothyroid) 58 
Adherent patients according to question 3 in AE (and are not exempt) 41 (71% of 58) 
Non-adherent patients according to question 3 in AE 17* (29% of 58) 
One way Chi square test (assuming 50:50) p-value = 0.002 
*Two patients were excluded because they were exempt (one is diabetic and the second has hypothyroid) and still 
answered that cost is an issue. It is unclear why they identified cost as an issue. 
 
 
 
Fourteen of those none adherent according to AE had a score of 2, i.e. no other reason 
under the AE to be non-adherent except cost of medicines. One of those patients was 
a diabetic and therefore should have not identified cost as an issue. This means that 
22% (13/58) of patients who pay a prescription charge identified cost as the only 
possible barrier to their adherence according to the AE. Seven of them were found to 
be non-adherent by the MMAS-8 (excluding Qn5) scale. Four had both elements of 
non-intentional (forgetfulness) and intentional (medicines related) non-adherence. 
Two patients had only non-intentional (forgetfulness) reasons and one patient had 
only intentional (medicines related) non-adherence. Their median number of 
medicines was 5. 
 
 
4.5.3 Results of the Single Question scale  
Table 4.27 summarises the final findings of the SQ after addressing discrepancies 
between this part and Part 1 of the questionnaire. The overall “raw” results of this part 
are presented in Appendix 16. See Section 3.6.2.3 for more details. Only patients who 
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answered the SQ part and listed the secondary prevention medicine(s) in Part 1 of the 
questionnaire were included. 
 
Overall 482 out of 503 patients answered this part of the questionnaire. Table 4.28 
shows the level of adherence and non-adherence to individual secondary prevention 
medicines as reported by patients who responded to the SQ scale. Patients who were 
non-adherent to at least one of the secondary prevention medicines were classed as 
non-adherent. The original SQ scale used 75% as a cut-off point in identifying the non-
adherent patients. Accordingly, statins are the most non-adhered to medicines (3% 
non-adherence). However, patients who chose 90% also have some level of non-
adherence. Therefore, examining any non-adherence to the secondary prevention 
medicines (≤90%) shows that aspirin is the most non-adhered to secondary prevention 
medicine (9%) followed by statins (8%). The researcher introduced an additional cut-
off point of 90% to identify patients with medium adherence vs. those with low 
adherence (≤75%). For the purpose of this analysis two categories of non-adherence 
were created; SQ Medium adherence = non-adherence of 90% to at least one of the 
secondary prevention medicines and in the absence of any non-adherence of <90% to 
any of the other secondary prevention medicines. SQ Low adherence = non-adherence 
of ≤75% to any of the secondary prevention medicines. Table 4.29 describes the 
overall levels of adherence according to the SQ scale. The estimated level of non-
adherence according to the SQ scale if the 75% cut-off point was used is 5% (25/482). 
If the 90% cut-off point was used the level of reported non-adherence would be 13% 
(60/482). The contribution of aspirin, statins, clopidogrel, beta blockers, ACEI and ARBs to the 
SQ scale non-adherence was 62%, 67%, 7%, 30%, 22% and 5%, respectively. 
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Table  4.27 – Summary of patients’ answers to the modified Single Question Scale (n = 482). 
(21 patients did not answer this part of the questionnaire) 
 
 
 
In the past month, how often did you take your medications as the doctor prescribed? 
Name of Heart 
Medicine 
All of the time 
100% 
Nearly all of the time 
90% 
Most of the time 
75% 
About half the time 
50% 
Less than half the 
time 
<50% 
n
*
 
Aspirin 370 (90.9%) 27 (6.6%) 2 (0.5%) 5 (1.2%) 3 (0.7%) 407 
Clopidogrel   53 (93.0%) 3 (5.3%) 0 (0.0%) 1 (1.8%) 0 (0.0%) 57 
ACE Inhibitor  262 (95.3%) 9 (3.3%) 3 (1.1%) 0 (0.0%) 1 (0.4%) 275 
BB  321 (94.7%) 14 (4.1%) 2 (0.6%) 0 (0.0%) 2 (0.6%) 339 
Statin  409 (91.1%) 26 (5.8%) 7 (1.6%) 3 (0.7%) 4 (0.9%) 449 
ARBs  87 (96.7%) 3 (3.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 90 
ACE = Angiotensin Converting Enzyme, BB = Beta Blockers, ARBs = Angiotensin Receptor Blockers 
*
n = the number of patients who answered this part of the questionnaire and listed the drug in Part 1 OR declared intentional non-adherence 
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Table  4.28 – Levels of adherence and non-adherence to individual secondary prevention 
medicines according to the SQ scale (n = 482). 
 
  Adherence according to SQ scale 
Secondary Prevention 
Medicine 
n 100% 90% ≤75% ≤90% 
Aspirin 407 370 91% 27 7% 10 2% 37 9% 
Clopidogrel 57 53 93% 3 5% 1 2% 4 7% 
ACEI 275 262 95% 9 3% 4 1% 13 4% 
BB 339 321 95% 14 4% 4 1% 18 5% 
Statin 449 409 91% 26 6% 14 3% 40 8% 
ARBs 90 87 97% 3 3% 0 0% 3 3% 
ACEI = Angiotensin Converting Enzyme Inhibitors, BB = Beta Blockers, ARBs = Angiotensin Receptor Blockers 
 
 
 
Table  4.29 – Overall levels of adherence and non-adherence according to the modified SQ 
scale (n = 482). 
 
SQ Adherence Levels Number of Patients 
Number of patients with SQS of 100% for all their secondary 
prevention medicines  
422 (87.5%) 
Number of Patients with SQS of 90% for at least one of their 
secondary prevention medicines (none of the other 
medicines <90%)  - Medium Adherence 
35 (7.3%) 
Number of Patients with SQS of ≤75% for at least one of 
their secondary prevention medicines (none of the other 
medicines <90%) – Low Adherence   
25 (5.2%) 
Total 482 (100%) 
  
Missing (SQ part not answered at all from the 503)  21 
SQ = Single Question, SQS = Single Question Score 
 
 
Table 4.30 is a cross-tabulation of the number of the secondary prevention medicines 
prescribed as reported by patients and the number of the secondary prevention 
medicines not adhered to in each category. The total number of non-adherent patients 
was 60. Fifty three percent (32/60), 18% (11/60), 12% (7/60) and 17% (10/60) of non-
adherent patients did not adhere to 1, 2, 3 and 4 of their secondary prevention 
medicines respectively.  
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Table  4.30 – The number of secondary prevention medicines not adhered to, according to the 
number of secondary prevention medicines taken by patients. 
 
 No. of Secondary Prevention Medicines NOT adhered to  
No. of Sec Prev 
Medicines Taken 
by Patient 
0 1 2 3 4 
Total 
1 17 89% 2 11% 0 0% 0 0% 0 0% 19 
2 46 87% 4 8% 3 6% 0 0% 0 0% 53 
3 150 87% 12 7% 3 2% 7 4% 0 0% 172 
4 186 87% 13 6% 5 2% 0 0% 10 5% 214 
5 23 96% 1 4% 0 0% 0 0% 0 0% 24 
Total 422 88% 32 7% 11 2% 7 1% 10 2% 482 
 
 
 
4.6 Overall findings and comparing the adherence scales 
 
The MMAS-8 and SQ scales identified current behaviour and any contemporaneous 
non-adherence to secondary prevention medicines. The AE, on the other hand, 
explored propensity to non-adherence based on the major drivers of intentional non-
adherence. In this section the findings of all three scales will be brought together and 
compared. Agreement between the scales will also be explored.  
 
As can be seen in Figure 4.12, the level of non-adherence identified by MMAS-8 
(excluding Qn5) or SQ scale was approximately 44%. Where data was missing for one 
scale the conclusion on level of adherence was used based on the other scale. Only 
one patient could not be classified according to either scale. Figure 4.13 describes the 
number of patients who were predicted by the AE to be non-adherent and were 
identified to be non-adherent by the MMAS-8 (excluding Qn5) or the SQ scale. It also 
identifies the proportion of patients who had propensity to non-adherence according 
to the AE and were not identified by other scales to be non-adherent.  
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Figure  4.12 – Overall identified adherence vs. non-adherence according to MMAS-8 (excluding 
Qn5) or SQ scale (n=502). 
 
Only 39% of non-adherent patients were predicted by the AE. Forty two percent of 
patients who were predicted to be non-adherent by the AE were not identified to be 
so by any of the scales. 
 
 
Figure  4.13 – Venn diagram of non-adherent patients identified by the MMAS-8 (excluding 
Qn5) or the SQ scale and those patients who were identified by the AE to have propensity to 
non-adherence. 
 
 
 
n = 86 
39% (of 219) 
n = 133 
61% (of 219) 
n = 61 
42% (of 147) 
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Figure 4.14 shows the distribution of AE scores for the 86 patients who were identified 
by the AE to have propensity to non-adherence and were detected by the MMAS-8 
(excluding Qn5) or the SQ scale to be non-adherent.  
 
 
 
 
 
 
 
 
 
 
 
Figure  4.14 – Distribution of AE scores for non-adherent patients who were identified by AE to 
have propensity to non-adherence and were detected by the MMAS-8 (excluding Qn5) or SQ 
scale. 
 
 
Table 4.31 summarises the possible cumulative reasons for non-adherence in those 86 
patients based on the AE. The main reason for predicted intentional non-adherence 
among non-adherent patients was worrying that the medicines will cause harm (86%). 
Not being convinced about the importance of medicines was cited by 23% of patients. 
Cost was identified as a reason by 12 patients. All those patients were less than 60 
years old and did not have diabetes or hypothyroidism (except for one patient). One 
patient did have hypothyroidism and it is unclear why he cited cost as a reason (as they 
would be exempt from prescription charges).    
 
N = 86 
Mean = 8.52 
SD = ± 6.33 
Median = 4 
Min = 2 
Max = 34 
Percentiles =  25 = 4 
      75 = 14 
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Table  4.31 – Reasons for propensity to non-adherence according to AE in patients who were 
identified to be non-adherent by the MMAS-8 (excluding Qn5) or SQ scales. 
 
Factor 
Number of 
Patients (n=86) 
Worry that their medicines will cause harm  74 (86%) 
Not convinced enough about the importance 
of their medicines 
20 (23%) 
Feel burdened by the cost of their medicines* 12 (14%) 
*All patients in this category were <60 years old and not exempt, except for one patient who has hypothyroidism. 
 
 
4.6.1 Reasons for non-adherence according to the findings of various 
scales 
 
Table 4.32 summarises the overall reasons for non-adherence in the non-adherent 
group identified by MMAS-8 (excluding Qn5) or SQ scale. The biggest cause of non-
adherence was forgetfulness (83%). Worrying that medicines will do more harm than 
good was reported by nearly 34% of the non-adherers. Approximately 19% of non-
adherents were hassled with their medicines and nearly 14% stopped taking their 
medicines because they felt worse.  The percentage of non-adherent patients due to 
the cost of medicines was calculated separately as can be seen in the table (30%). 
Though 12 patients were identified to have cost of medicines as a cause for non-
adherence, one patient was excluded because of his exemption status 
(hypothyroidism). 
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Table  4.32 – Overall reasons of non-adherence among the non-adherent group identified by 
MMAS-8 (excluding Qn5) and SQ scale (n = 219). 
 
 n = 219 
Forgetfulness of any type (questions 1,4,8) 182 (83%) 
General forgetfulness (question 1 and 8)  179 (82%) 
Forgetfulness when travelling (question 4) 26 (11%) 
Worry that their medicines will do more harm than good 74(34%) 
Hassled about medicines 41 (19%) 
Stopped medicine(s) after feeling worse on medicine (without telling doctor) 31 (14%) 
Did not take medicine in the last 2 weeks (due to forgetfulness or other 
reason)  
29(13%) 
Not convinced enough about the importance of their medicines 20(9%) 
Stopped medicine(s) after feeling condition under control 5 (2%) 
 n = 37* 
Feel financially burdened by cost of medicines* 11 (30%) 
*Total non-adherent patients <60 and not exempt = 37. Percentage = 11/37 = 30% of those paying charges 
 
 
4.6.2 Comparing AE findings with MMAS-8 (excluding Qn5) scale and SQ 
The AE identified 30% of patients to have a medium to a high probability of non-
adherence. The predictions of the AE are compared to the findings of MMAS-8 
(excluding Qn5) scale, and Factor 1 and 2 elements (see Table 4.33).  
 
Only 39% of patients identified by MMAS-8 (excluding Qn5) to be non-adherent had 
been predicted by the AE. A similar percentage (37%) was found for Factor 1 findings. 
However, 63% of non-adherent patients who were identified by the Factor 2 element 
(intentional / hassle non-adherence) had been predicted by AE to be non-adherent. 
This could be explained by the intentional non-adherence element in Factor 2.   
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Table  4.33 - Cross-tabulation of predicted adherent and non-adherent findings of the AE 
against identified adherent and non-adherent findings of the MMAS-8 (excluding Qn5), Factor 
1, and Factor 2 (n=496). 
 
 Adherence Estimator   
 Probably Adherent 
(n=350) 
Probably non-adherent 
(146) χ
2
 
p-value* 
(2-sided) 
MMAS-8 (Excluding Qn5) 
(n=496) 
    
Adherent  223 (78%) 64 (22%) 16.697 <0.001 
Non-adherent 127 (61%) 82 (39%) 
     
Factor 2 (intentional / 
hassle) MMAS-8 (n=496) 
    
Adherent 326 (76%) 105(24%) 40.758 <0.001 
Non-adherent 24 (37%) 41 (63%) 
     
Factor 1 (unintentional) 
MMAS-8 (n=496) 
    
Adherent 234 (75%) 78 (25%) 7.966 0.005 
Non-adherent 116 (63%) 68(37%) 
     
* p-values were calculated using Chi-square test 
 
 
As explained in Sections 2.1, 2.2.1 and 3.6.5 there is no “gold standard” tool for 
measuring actual adherence behaviour and no single tool to detect all types of non-
adherence. To evaluate the performance of self-report adherence assessment tools 
researchers in this field often select an ‘imperfect gold standard’ tool to check against 
(e.g. MEMS® or other self-report tool). Therefore, the reported sensitivity, specificity, 
positive predictive and negative predictive values for a specific self-report tool is only 
relative to the ‘imperfect gold standard’ chosen
**
. If the findings of the MMAS-8 
(excluding Qn5) or SQ scale were used as a “gold standard” in identifying non-adherent 
patients, it is possible to calculate the positive and negative predictive values of the AE 
(as a screening tool). Table 4.34 is a breakdown of the predicted estimated level of 
                                                 
**
 And therefore somewhat imprecise compared to their use in other healthcare fields. In diagnostics, 
for example, they would only be calculated with regard to a definitive final outcome (i.e. whether the 
patient developed the disease according to a completely accurate diagnostic test). However, reporting 
these “imprecise” values is standard in the adherence literature, and in this thesis, as they are useful for 
comparing the performance of adherence assessment tools. This impreciseness should always be taken 
into account when interpreting and reporting these values. 
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adherence according to the AE and the number of patients who were identified to be 
adherent or non-adherent by the gold standard tools. Based on these figures the 
positive predictive value of the AE is 59% (86/147). That is the portion of patients who 
were found to be non-adherent of those who were predicted by the AE to have 
medium (52) to high (34) risk of adherence problems. More patients who were 
predicted in the high risk category were identified to be non-adherent than those in 
the medium risk category (67% vs. 54% respectively).  The negative predictive value 
for the AE was 63% (220/351). That is the proportion of patients who were found to be 
adherent of those predicted to have low risk of adherence problems. The sensitivity of 
the AE in predicting patients who are likely to be non-adherent in this sample was 40% 
(86/217 (two were missing)).The specificity of the AE in predicting adherent patients 
was 78% (220/281).     
 
Table  4.34 – Comparing the risk levels of propensity to adherence by the AE to the findings of 
self-reported adherence scales (n=498). 
 
AE estimate for adherence 
Identified to be 
non-adherent 
Identified to be 
adherent 
Total 
Low risk of adherence problems (>75% 
prob of adherence) 
131 (37%) 220 (63%) 351 
Medium Risk of adherence problems 
(32%- 75% prob of adherence) 
52 (54%) 44 (46%) 96 
High risk of adherence problems 
(<32% prob of adherence) 
34 (67%) 17 (33%) 51 
Total 217 281 498 
χ
2
 =21.023 , p = <0.001 (2-sided), prob = probability     
 
4.6.3 Comparing SQ findings with MMAS-8 (excluding Qn5) and AE 
 
Table 4.35 compares the findings of the SQ scale with other scales. The table shows 
that the SQ has lower sensitivity compared to the MMAS-8 (excluding Qn5) scale. The 
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SQ sensitivity was 25% (52/206). The SQ specificity was 97% (266/274). This lack of 
sensitivity is apparent for example in that 131 patients who said that they sometimes 
forgot to take their secondary prevention medicines according to Factor 1 findings 
were classed as adherent by the SQ scale. The intentional element of non-adherence 
(Factor 2) was seen more in the low adherence category of the SQ scale (20% in SQ low 
adherence vs. 11% in SQ medium adherence); whereas the unintentional element 
(Factor 1) was seen more in the medium adherence category (18% in SQ medium 
adherence vs. 10% in SQ low adherence).  
 
 
Table  4.35 - Comparing adherent and non-adherent findings of the SQ with the MMAS-8 
(excluding Qn5), Factor 1 and Factor 2 of MMAS-8, and Adherence Estimator. 
 
 Level of Adherence According to SQ scale  
 
Adherent Medium Adherence Low Adherence 
p-value* 
(2-sided) 
MMAS-8 (excluding  Qn5) 
(n=480) 
    
Adherent  266 (97%) 3 (1%) 5 (2%) <0.001 
Non-adherent 154 (75%) 32 (15%) 20(10%) 
Factor 2 (intentional / hassle) 
MMAS-8 (n=480) 
    
Adherent 376 (90%) 28 (7%) 12 (3%) <0.001 
Non-adherent 44 (69%) 7 (11%) 13 (20%) 
Factor 1 (unintentional) 
MMAS-8 (n=480) 
    
Adherent 289 (97%)  3 (1%) 6 (2%) <0.001 
Non-adherent 131 (72%) 32 (18%) 19 (10%) 
Adherence Estimator 
 
(n=478)     
Adherent 301 (89%) 24 (7%) 12 (4%) 0.037 
Non-adherent 117 (83%) 11 (8%) 13 (9%)  
* p-values were calculated using Chi-square test OR Fisher’s Exact test 
 
Table 4.36 focuses on the non-adherent patients identified by the scales and excludes 
the adherent patients according to any scale. The earlier discussion about the 
distribution of the intentional and non-intentional elements of non-adherence in the 
SQ scale becomes more apparent. Higher percentage of patients who were non-
adherent due to non-intentional cause (forgetfulness) was classified by the SQ as 
“medium adherers” (63% vs. 37% in the “low adherers” category). The intentional / 
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medicines related non-adherers or those who have high propensity to be intentionally 
non-adherent were found more among the SQ low adherence category (65% and 54% 
respectively).    
 
Table  4.36 - The distribution of non-adherent patients identified by both scales; the SQ scale 
and comparator scales. 
 
 Level of Adherence According to SQ scale  
 
Medium Adherence Low Adherence 
Total non-adherent 
according to both 
scales 
MMAS-8 (excluding Qn5)     
Non-adherent 32 (62%) 20(38%) 52 
    
Factor 2 (intentional / hassle) 
MMAS-8  
   
Non-adherent 7 (35%) 13 (65%) 20 
Factor 1 (non-intentional) 
MMAS-8  
   
Non-adherent 32 (63%) 19 (37%) 51 
    
Adherence Estimator TM     
Non-adherent 11 (46%) 13 (54%) 24 
    
 
 
 
4.6.4 Kappa statistic to examine agreement between scales. 
The Kappa statistic was used to examine the agreement between scales as described in 
Section 3.6.5.1 and Appendix 15. Full SPSS statistical results can be seen in Appendix 
16. All findings are summarised in Table 4.37. Overall the agreement between the 
scales was poor. The highest agreement was seen between Factor 1 and the SQ scale. 
Factor 2 had a fair agreement with the SQ scale when the 75% cut off point was used, 
and with the AE. This emphasises the intentional element of non-adherence in Factor 2 
and the SQ findings with a score of <90%. The agreement between the scales in their 
ranking was also explored and the calculations are presented in Table 4.38. The overall 
agreement was also poor.  
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Table  4.37 – Agreement between the scales (including Factor 1 and Factor 2) in detecting or 
identifying possible adherent vs. non-adherent patients. 
 
  Comparison n Value of к 95% CI p-value Conclusion 
MMAS-8 & SQ 480 0.192 0.133, 0.251 < 0.001 Slight agreement 
MMAS-8 (excluding Qn5) & SQ 480 0.245 0.176, 0.314 < 0.001 Fair agreement 
Factor 1 (MMAS-8) & SQ 480 0.288  0.212, 0.364 <0.001 Fair agreement 
Factor 2 (MMAS-8) & SQ 480 0.222 0.104, 0.340 <0.001 Fair agreement 
MMAS-8 (excluding Qn5) & SQ75 480 0.088 0.039, 0.137 <0.001 Slight agreement 
Factor 1 (MMAS-8) & SQ75 480 0.101 0.044, 0.158 <0.001 Slight agreement 
Factor 2 (MMAS-8) & SQ75 480 0.235 0.110, 0.360 <0.001 Fair agreement 
MMAS-8 (excluding Qn5) & AE 496 0.177 0.093, 0.261 <0.001 Slight agreement 
Factor 1 (MMAS-8) & AE 496 0.125 0.037, 0.213 0.005 Slight agreement 
Factor 2 (MMAS-8) & AE 496 0.253 0.165, 0.341 <0.001 Fair agreement 
AE & SQ 478 0.076 -0.008, 0.160 0.056 No agreement 
AE & SQ75 478 0.074 0.007, 0.141 0.011 Slight agreement 
AE = Adherence Estimator, SQ = Single Question, SQ75 = Single Question with 75% cut off point, к = Kappa, CI = Confidence 
Interval. Bolded values are best agreement within each set of comparisons. 
 
 
 
Table  4.38 - Agreement between the scales in ranking the identified or possible level of non-
adherence among patients. 
 
 
Comparison n 
Value 
of к 
95% CI p-value Conclusion 
MMAS-8 (excluding Qn5) rank & AE rank 496 0.103 0.029, 0.155 0.002 Slight agreement 
MMAS-8 (excluding Qn5) rank & SQ rank 480 0.169 0.112, 0.226 <0.001 Slight agreement 
SQ rank & AE rank 478 0.080 0.018, 0.104 0.010 Slight agreement 
AE = Adherence Estimator, к = Kappa, CI = Confidence Interval 
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4.7 Comparing groups of adherers vs. non-adherers 
according to findings  
 
The attributes of the adherent and non-adherent groups were compared as described 
in Sections 3.6.4 and 3.6.4.1. Detailed comparisons of all variables will be tabulated in 
Appendix 16. Only statistically significant differences will reported in this section and 
will be discussed later in the discussion chapter. 
 
4.7.1 Comparing groups of adherent vs. non-adherent according to 
MMAS-8 scale (excluding Qn5)  
 
When comparing the demographics of the adherent vs. non-adherent groups, only the 
difference in age was statistically significant. Overall the non-adherent group was 
younger than the adherent (see Table 4.39). All differences in other variables were not 
statistically significant. When comparing co-morbidities and cardiac history, the 
differences in patients’ angioplasty and CABG history were statistically significant. 
CABG patients were less likely to be non-adherent, whereas patients who had 
angioplasty were more non-adherent. The differences between the medicines related 
variables were statistically non-significant except for being prescribed aspirin and the 
knowledge about beta blockers. Patients who were prescribed aspirin were more likely 
to be non-adherent. Non-adherent patients were more knowledgeable about beta 
blockers than adherers.  
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Table  4.39 – Statistically significant differences between the adherent vs. non-adherent groups 
according to the MMAS-8 (excluding Qn5). 
 
Variable Adherent (n=289) Non-adherent (n=211) n 
Age* Median (Q1, Q3) 71 (65, 76) 67 (63, 73)  
500 
 
Min, Max 45, 92 38, 92 
CABG ** Yes 122 (42%) 68 (32%) 500 
 No 167 (58%) 143 (68%) 
Angioplasty** Yes 153 (53%) 132 (63%) 500 
 No 136 (47%) 79 (37%) 
On the 
following 
secondary 
prevention 
medicines 
Aspirin** 
Yes 241 (83%) 196 (93%) 
500 No 48 (17%) 15 (7%) 
 Adherent (n=206) Non-adherent (n=144) n 
Knowledge about 
secondary prevention 
medicines 
 
(K = “ Knowledgeable” vs. N 
= “not-knowledgeable”) 
BB** 
K 63(30%) 64 (44%) 350† 
N 
 
143(70%) 80 (56%) 
*p-value (2-sided) <0.05 (Mann-Whitney), **p-value (2-sided) <0.05 (Chi-square test), CABG = Coronary artery bypass grafting, BB 
= beta blocker, †not all patients were on BB and 2 did not complete the MMAS-8 part, hence n=350  
 
 
 
4.7.2 Comparing groups according to factor analysis findings  
Table 4.40 compares the groups of the adherers and none-adherers based on Factor 1 
(unintentional / forgetfulness).  Non-adherent patients were younger with a median 
age 67 compared to a median age of 71 among the adherent group. Females were 
more adherent than males. Patients who had diabetes controlled with anti-diabetics 
were more likely to be adherent than non-diabetics. Patients with a history of CABG 
were more likely to be adherent. The number of medicines that patients were 
prescribed was higher among adherers. Adherent patients had also higher number of 
medicines doses and administrations per day. Patients who were prescribed aspirin 
were more likely to be non-adherent. More non-adherent patients, prescribed beta 
blockers, were classified as “knowledgable” about beta blockers than adherent. 
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Table  4.40 – Comparison of various variables in the adherent vs. non-adherent groups 
according to Factor 1 (unintentional) in the MMAS-8 (n=500). 
 
Variable Adherent (n=314) Non-adherent (n=186) n 
Age* Median(Q1, Q3) 71 (65, 76) 67 (63, 73) 
500 
Min, Max 45, 92 38, 92 
Gender** 
Male 242 (77%) 160 (86%) 500 
Female 72 (23%) 26 (14%) 
Diabetes** Yes 48 (15%) 14 (8%) 
500 
No 266 (85%) 172 (92%) 
CABG ** Yes 134 (42.7%) 56 (30.1%) 
500 
No 180 (57.3%) 130 (69.9%) 
Number of 
Medicines*  
Median (Q1, Q3) 7 (5, 9) 6 (4, 9) 
500 
Min, Max 2, 19 2, 20 
Number of doses 
per day*  
Median (Q1, Q3) 7 (5, 10) 6 (5, 9) 
500 
Min, Max 1, 24 2, 22 
Total number of 
daily 
administrations* 
Mean (SD) 2.47 (± 0.86) 2.31 (± 0.74) 
500 Median (Q1, Q3) 2 (2, 3) 2 (2, 3) 
Min, Max 1, 4 1, 4 
On the following 
secondary 
prevention 
medicines 
Aspirin** 
Yes 265 (84%) 172 (92%) 500 
No 49 (16%) 14 (8%) 
 Adherent (n=221) Non-adherent (n=129) n 
Knowledge about 
individual secondary 
prevention medicines 
 
(K = “ Knowledgeable” vs. N 
= “not-knowledgeable”) 
BB** 
K 68 (31%) 59 (46%) 350
†
 
N 
 
153 (69%) 70 (54%) 
*p-value (2-sided) <0.05 (Mann-Whitney OR Independent samples t-test), **p-value (2-sided) <0.05 (Chi-square or Fisher’s Exact 
test), BB = beta blockers, †not all patients were on BB and 2 did not complete the MMAS-8 part, hence n=350 
 
Further analysis was carried out on the interactions between gender and marital 
status, and age and gender among the Factor 1 adherent vs. non-adherent groups. 
These can be found in Appendix 16. The analysis showed no statistically significant 
difference in adherence behaviour between married vs. non-married males or females. 
The distribution of the age of females was the same across the categories of adherent 
and non-adherent groups and the difference in the median age (72 vs. 68.5 
respectively) was not statistically significant. However, among males the median age of 
non-adherers was lower than that for adherers (66.5 vs. 71 respectively). This 
difference was statistically significant (p-value (2-sided) < 0.05).      
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The average overall knowledge of indication(s) of prescribed secondary prevention 
medicines among non-adherers was higher than that for adherers (mean ± SD = 1.6 
(±0.63) vs. 1.8 (±0.63) respectively, median (Q1, Q3) = 1.5 (1, 2) vs. 1.7 (1.3, 2) 
respectively). The difference was statistically significant (p-value (2-sided) <0.05, 
Mann-Whitney &Independent samples t-test), n = 498 (2 patients did not list any 
prescribed secondary prevention medicines).  
 
Tables 4.41 compares the adherent vs. non-adherent groups based on Factor 2 
(intentional/ hassle). The median age of non-adherers was lower than the adherers. 
Compared to adherers, non-adherers were more likely to have reported suffering from 
angina. Contrary to the previous findings non-adherent patients had a higher median 
of number of medicines. Patients who were prescribed aspirin were more likely to be 
non-adherent as seen previously and those who were prescribed beta blockers were 
more likely to be adherent.  
 
Table  4.41 – Comparison of various variables in the adherent vs. non-adherent groups 
according to Factor 2 (intentional / hassle) in the MMAS-8 (n=500). 
 
Variable Adherent (n=435) Non-adherent (n=65) n 
Age*  Median (Q1, Q3) 70 (64, 76) 67 (58, 72) 
500 
Min, Max 45, 92 38, 92 
Number of 
Medicines*  
Median (Q1, Q3) 6 (5, 9) 7 (5, 10) 
500 
Min, Max 2, 20 3, 19 
On the following 
secondary 
prevention 
medicines 
Aspirin** 
Yes 375 (86%) 62 (95%) 500 
No 60 (14%) 3 (5%) 
BB** 
Yes 315 (72%) 39 (60%) 500 
No 120 (28%) 26 (40%) 
Variable Adherent (n=217) Non-adherent (n=34) n 
Angina Status**  
Yes 49 (23%) 15 (44%) 251
†
 
No 168 (77%) 19 (56%) 
*p-value (2-sided) <0.05 (Mann-Whitney OR Independent samples t-test), **p-value (2-sided) <0.05 (Chi-square or Fisher’s Exact 
test, †not all patients reported whether they have angina or not, hence n=251.  
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4.7.3 Comparing groups of adherence vs. non-adherence according to 
AE 
 
Five patients did not complete this part of the questionnaires and therefore n=498.  As 
can be seen in Table 4.42 the median age among the predicted non-adherent group 
was lower than the adherent. CABG patients were less likely to be identified among 
the non-adherent, whereas angioplasty patients were more likely to be non-adherent. 
Predicted non-adherers were more likely to be experiencing angina.  
     
Table  4.42 – Comparison of various variables in the adherent vs. non-adherent groups 
according to the findings of the AE (n=498). 
 
Variable Adherent (n=351) Non-adherent (n=147) n 
Age* Median (Q1, Q3) 70 (64, 76) 67 (59, 74) 
498 
Min, Max 44, 92 38, 92 
CABG ** Yes 145 (41%) 45(31%) 498 
 No 206 (59%) 102(69%) 
Angioplasty** Yes 189(54%) 94(64%) 498 
 No 162(46%) 53(36%) 
Variable Adherent (n=177) Non-adherent (n=73) n 
Angina Status**  
Yes 39 (22%) 25 (34%) 
 
250
†
 
 
No 138 (78%) 48 (66%) 
*p-value (2-sided) <0.05 (Mann-Whitney OR Independent samples t-test), **p-value (2-sided) <0.05 (Chi-square or Fisher’s Exact 
test, †not all patients reported whether they have angina or not, hence n=250. 
 
 
4.7.4 Comparing groups of adherence vs. non-adherence according to 
SQ  
 
The cut-off point of 90% is used to identify all non-adherent patients according to the 
SQ scale. The findings are summarised in Table 4.43. The median age of the non-
adherent patients was lower than the adherent. The number of medicines and doses 
per day was lower among the non-adherent patients compared to the adherent. No 
other statistically significant differences were identified.  
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Table  4.43 – Comparison of various variables in the adherent vs. non-adherent groups 
according to the SQ scale (n=482). Patients with any level of non-adherence according to the 
SQ scale were classed as non-adherent. 
 
Variable Adherent (n=422) Non-adherent (n=60) n 
Age* Median (Q1, Q3) 70 (64, 76) 65 (59, 70)  
482 
 
Min, Max 38, 92 44, 84 
Number of 
Medicines*  
Median (Q1, Q3) 7 (5, 9) 5 (4, 8)  
482 
 
Min, Max 2, 20 2, 13 
Number of 
doses per day* 
Median (Q1, Q3) 7 (5, 10) 5 (4, 7) 
482 
Min, Max 1, 24 2, 15 
*p-value (2-sided) <0.05 (Mann-Whitney), **p-value (2-sided) <0.05 (Chi-square or Fisher’s Exact test. 
 
 
4.7.5 Comparing groups of adherence vs. non-adherence according to 
overall findings 
 
The characteristics of all non-adherent patients identified by MMAS-8 (excluding Qn5) 
or SQ scales were compared. As can be seen from Table 4.44 the non-adherent group 
was younger than the adherent.  CABG patients were less likely to be non-adherent, 
whereas patients who had angioplasty were more non-adherent. The differences 
between the medicines related variables were statistically insignificant except for 
being prescribed aspirin and the knowledge about BB. Patients who were prescribed 
aspirin were more likely to be non-adherent. Non-adherent patients were more 
knowledgeable about BB than the adherent.  
 
The average overall knowledge of indication(s) of prescribed secondary prevention 
medicines among non-adherers was higher than that for adherers (mean ± SD = 1.6 
(±0.62) vs. 1.8 (±0.66) respectively, median (Q1, Q3) = 1.5 (1, 2) vs. 1.7 (1.3, 2) 
respectively). The difference was statistically significant (p-value (2-sided) <0.05, 
Mann-Whitney &Independent samples t-test), n = 498 (2 patients did not list any 
prescribed secondary prevention medicines). 
Results Chapter                                                                                                   The Heart Medicines Survey 
 
141 
 
Table  4.44 – Comparison of various variables in the adherent vs. non-adherent groups 
according MMAS-8 (excluding Qn5) or SQ scales (n=502). 
 
Variable Adherent (n=283) Non-adherent (n=219) n 
Age* Median(Q1, Q3) 71 (65, 71) 67 (62, 73)  
502 Min, Max 45, 92 38, 92 
CABG** Yes 119 (42%) 72 (33%) 502 
 No 164 (58%) 147 (67%) 
Angioplasty** Yes 150 (53%) 136 (62%) 
502 
No 133 (47%) 83 (38%) 
On the following 
secondary prevention 
medicines 
Aspirin** 
Yes 237 (84%) 202 (92%) 502 
No 46 (16%) 17 (8%) 
 Adherent (n=202) Non-adherent (n=150) n 
Knowledge about 
individual secondary 
prevention medicines 
 
(K = “ Knowledgeable” vs. N 
= “not-knowledgeable”) 
BB** 
K 61 (30%) 67 (45%) 352
†
 
N 
 
141(70%) 83 (55%) 
*p-value (2-sided) <0.05 (Mann-Whitney OR Independent samples t-test), **p-value (2-sided) <0.05 (Chi-square or Fisher’s Exact 
test), BB = beta blockers, †not all patients were on BB and 2 did not complete the MMAS-8 part, hence n=352 
 
 
 
4.8 Possible practical barriers to adherence  
The four possible practical problems or barriers to adherence are examined as 
described in Section 3.6.1.7. Table 4.45 summarises the results for all patients who 
answered this part of the questionnaire. The answers were grouped in Table 4.46 to 
identify those patients who want an alternative for one or more of these four barriers;  
answers which indicate that one or more of these barriers are sometimes or always 
problematic are also grouped together. Having a problem opening bottles or blister 
packs was reported by 18% of patients, and 22% of those patients who answered this 
question want a solution or an alternative. Seven percent of patients have a problem 
reading the label, and similar percentages have problems swallowing medicines and 
getting repeat prescriptions.     
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Table  4.45 – Results of the possible practical barriers which can affect adherence. 
 
 
Possible Problem 
Always a 
problem 
for me 
Sometimes 
a problem 
for me 
Not a problem 
prefer alternative 
(solution) 
Not a 
problem to 
me at all n 
Opening the medicines 
bottle or blister pack  
16 (3%) 70 (14%) 24 (5%) 382 (78%) 492 
Reading the label on the 
medicines bottle or box 
9 (2%) 25 (5%) 6 (1%) 449 (92%) 489 
Swallowing my medicines 4 (1%) 30 (6%) 8 (2%) 449 (925%) 491 
Getting my repeat 
prescription  
4 (1%) 31 (6%) 16 (3%) 441 (90%) 492 
 
 
Table  4.46 – Patients who have a problem (always OR sometimes) with the four practical 
barriers and those who need a solution or an alternative. 
 
Possible Problem There is a 
problem 
Need a solution / 
alternative 
Total number of patients who 
answered this question 
Opening the medicines bottle 
or blister pack  
86 (18%) 110 (22%) 492 
Reading the label on the 
medicines bottle or box 
34 (7%) 40 (8%) 489 
Swallowing my medicines 34 (7%) 42 (9%) 491 
Getting my repeat prescription  35 (7%) 51 (10%) 492 
 
 
4.8.1 The effects of barriers to adherence on non-adherence identified 
by different scales  
 
The association of the four barriers with adherence was examined in Tables 4.47 and 
4.48. Patients who have problems with their repeat prescriptions or ask for a solution 
or an alternative are more likely to be non-adherent. Those asking for an alternative to 
reading the labels are also more likely to be non-adherent.    
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Table  4.47 – Adherent and non-adherent patients who have possible problems (always or 
sometimes) with the four practical categories. 
 
Possible Problem 
This is a 
problem 
MMAS-8 (excluding Qn5) or SQ 
p-value 
(2-sided) Adherent Non-Adherent 
Opening the medicines bottle 
or blister pack  
Yes = 86 45 (16%) 41 (19%) 
NS 
No = 406 233 (84%)  173 (81%) 
Reading the label on the 
medicines bottle or box 
Yes = 34 15 (5%) 19(9%) NS 
No = 455 261 (95%) 194 (91%) 
Swallowing my medicines Yes = 34 18(7%) 16 (7%) NS 
No = 457 256 (93%) 201 (93%) 
Getting my repeat prescription  Yes = 35 11(4%) 24(11%) 0.002 
No = 457 265(96%) 192(89%) 
NS = not significant, Chi-Square test was used to calculated p-values 
 
 
 
Table  4.48 – Adherent and non-adherent patients who need a solution or an alternative with 
one or more of the four categories of possible barriers to adherence. 
 
Possible Problem 
Need an 
alternative 
MMAS-8 (excluding Qn5) or SQ 
p-value 
(2-sided) Adherent Non-Adherent 
Opening the medicines 
bottle or blister pack  
Yes = 110 57 (20%) 53 (25%) 
NS 
No = 382 221(80%)  161 (75%) 
Reading the label on the 
medicines bottle or box 
Yes = 40 16 (6%) 24(11%) 0.029 
No = 449 260 (94%) 189 (89%) 
Swallowing my medicines Yes = 42 20(7%) 22(10%) NS 
No = 449 254(93%) 195(90%) 
Getting my repeat 
prescription  
Yes = 51 15(5%) 36(17%) <0.001 
No = 441 261(95%) 180(83%) 
NS = not significant, Chi-Square test was used to calculated p-values 
 
 
 
The association of these four barriers with non-adherence identified by Factor 1 and 
Factor 2 was also explored. Patients who need an alternative or a solution to getting 
repeat prescription were more likely to be non-adherent according to Factor 1 (see 
Table 4.49). Non-adherent patients according to Factor 2 were more likely to identify 
all four barriers as a problem or needing an alternative (see Table 4.50). 
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Table  4.49 – Possible barriers which were found to have a statistically significant effect on 
adherence vs. non-adherence according to the Factor 1. 
 
Possible Problem 
Need an 
alternative 
 Factor 1 (MMAS-8) – 
forgetfulness 
p-value 
(2-sided) Adherent 
Non-
Adherent 
Getting my repeat 
prescription  
Yes = 51 22(7%) 29(16%) 0.002 
No = 439 285(93%) 154(84%) 
Chi-Square test OR Fisher’s Exact test were used to calculate p-values 
 
 
 
 
Table  4.50 - Possible barriers which were found to have a statistically significant effect on 
adherence vs. non-adherence according to the Factor 2. 
 
Possible Problem 
This is a 
problem 
Factor 2 (MMAS-8) – 
intentional / hassle  
p-value 
(2-sided) Adherent 
Non-
Adherent 
Opening the medicines 
bottle or blister pack  
Yes = 86 66 (15%) 20 (32%) 0.001 
No = 404 362 (85%)  42 (68%) 
Swallowing my medicines 
Yes = 34 23(5%) 11(17%) 
0.002 
No = 455 401(95%) 54 (83%) 
Getting my repeat 
prescription  
Yes = 35 22(5%) 13(20%) 
<0.001 
No = 455 403(95%) 52(80%) 
Possible Problem 
Need an 
alternative 
Factor 2 (MMAS-8) 
p-value 
(2-sided) Adherent 
Non-
Adherent 
Opening the medicines 
bottle or blister pack  
Yes = 110 87 (20%) 23 (37%) 
0.003 
No = 380 341(80%) 39 (63%) 
Reading the label on the 
medicines bottle or box 
Yes = 40 30 (7%) 10(16%) 
0.015 
No = 447 395(93%) 52(84%) 
Swallowing my medicines Yes = 42 30(7%) 12(19%) 0.002 
No = 447 394(93%) 53(81%) 
Getting my repeat 
prescription  
Yes = 51 33(8%) 18(28%) <0.001 
No = 439 392(92%) 47(72%) 
Chi-Square test OR Fisher’s Exact test were used to calculate p-values 
 
 
 
 
4.9 Beliefs about medicines results 
The method of analysis of this section was described in Section 3.6.2.4.  Table 4.51 
summarises the overall answers. The highest percentage of answers for each question 
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is bolded. For example: approximately 48% of the sample strongly agrees that their 
“health at the moment depends on their medicines”. In the specific concern (SC) 
category 30% of the sample agrees that they “sometime worry about the long-term 
effects of their medicines”. In the general overuse (GO) category approximately 41% of 
patients are uncertain if “doctors use too many medicines”. Only 491 patients 
answered this part of the questionnaire. However, not all the questions in this tool 
were answered by each patient. Therefore, “n” is different for each question. For ease 
of comparison and analysis the mean and standard deviation of the answers for each 
question and the overall category were calculated as seen in Table 4.51.  
 
Table 4.52 compares the beliefs about medicines among the adherent and non-
adherent groups identified by MMAS-8 (excluding Qn5) or SQ scales. The answers to 
some questions within each category do not seem to differ between groups. However, 
the overall total score medians indicate that there is a difference in all four categories. 
Non-adherent patients agree less with the specific necessity (SN) category than 
adherers. On the other hand, they disagree less with the SC and GO categories than 
adherers. The biggest difference between adherent and non-adherent patients is in 
the SC category. This indicates that they have more concern about their medicines.    
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Table  4.51 – The overall results of the Beliefs about Medicines Questionnaire (BMQ). 
 
Strongly Agree (5) Agree (4) Uncertain (3) Disagree (2) Strongly Disagree (1) Median Q1, Q3 n 
S
p
e
c
i
f
i
c
 
N
e
c
e
s
s
i
t
y
 My health, at present, depends on my medicines 233 (47.6%) 186 (38.0%) 55 (10.9%) 13 (2.6%) 2 (0.4%) 4 4, 5 489 
My life would be impossible without my medicines  111 (23.7%) 111 (23.7%) 193 (41.2%) 45 (9.6%) 9 (1.8%) 3 3, 4 469 
Without my medicines I would be very ill  104 (21.4%) 119 (24.5%) 206 (42.5%) 47 (9.7%) 9 (1.9%) 3 3, 4 485 
My health in the future will depends on my medicines  156 (32.7%) 214 (44.9%) 81 (17.0%) 19 (4.0%) 7 (1.5%) 4 4, 5 477 
My medicines protect me from becoming worse  177 (36.0%) 231 (47.0%) 71 (14.5%) 6 (1.2%) 6 (1.2%) 4 4, 5 491 
   Median (Q1, Q3) SN totals = 19 (16, 22) Overall SN median  4 3.5, 5  
S
p
e
c
i
f
i
c
 
C
o
n
c
e
r
n
 
Having to take medicines worries me  24 (5.0%) 71 (14.9%) 59 (12.4%) 171 (35.8%) 152 (30.2%) 2 1, 3 477 
I sometimes worry about long-term effects of my medicines 51 (10.5%) 151 (30.1%) 89 (18.4%) 119 (24.5%) 75 (15.5%) 3 2, 4 485 
My medicines are a mystery to me 27 (5.6%) 79 (16.3%) 78 (16.1%) 204 (42.1%) 96 (19.8%) 2 2, 3 484 
My medicines disrupt my life  9 (1.9%) 29 (6.0%) 26 (5.4%) 211 (43.5%) 210 (43.3%) 2 1, 2 485 
I sometimes worry about becoming too dependent on my 
medicines 
28 (5.9%) 80 (16.8%) 71 (14.9%) 165 (34.7%) 131 (27.6%) 2 1, 3 475 
   Median (Q1, Q3)  SC totals = 11 (8, 14) Overall SC median 2 1.38, 3  
G
e
n
e
r
a
l
 
H
a
r
m
 
People who take medicines should stop their treatment for a 
while every now and again  
8 (1.6%) 17 (3.5%) 97 (19.8%) 168 (34.4%) 199 (40.7%) 2 1, 2.5 489 
Most medicines are addictive   9 (1.9%) 30 (6.3%) 160 (33.6%) 165 (34.7%) 112 (23.5%) 2 2, 3 476 
Medicines do more harm than good 8 (1.7%) 6 (1.2%) 70 (14.6%) 209 (43.5%) 188 (39.1%) 2 1, 2 481 
All medicines are poisons  7 (1.4%) 17 (3.5%) 104 (21.4%) 168 (34.6%) 190 (39.1%) 2 1, 3 486 
   Median (Q1, Q3)  GH totals = 8 (6, 10) Overall GH median 2 1, 2  
G
e
n
e
r
a
l
 
O
v
e
r
u
s
e
 
Doctors use too many medicines  16 (3.4%) 51 (10.9%) 191 (40.9%) 136 (29.1%) 73 (15.6%) 3 2, 3 467 
Natural remedies are safer than medicines 5 (1%) 12 (2.5%) 200 (41.1%) 138 (28.3%) 132 (27.1%) 2 1, 3 487 
Doctors place too much trust on medicines  6 (1.3%) 45 (9.5%) 146 (30.7%) 175 (36.8%) 103 (21.7%) 2 2, 3 475 
If doctors had more time with patients they would prescribe 
fewer medicines. 
19 (4.0%) 89 (18.5%) 177 (36.8%) 123 (25.6%) 73 (15.2%) 3 2, 3 481 
   Median (Q1, Q3)  GO totals = 10 (8, 12) Overall GO median 2.5 2, 3  
SN = Specific Necessity, SC = Specific Concern, GH = General Harm, GO = General Overuse 
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Table  4.52 – Comparing beliefs about medicines in the adherent vs. non-adherent group identified by the MMAS-8 (excluding Qn5) or SQ scales. 
 
Adherence MMAS-8 (excluding Qn5) or SQ scale 
Adherent  Non-adherent 
Median Q1, Q3 n 
 
Median Q1, Q3 n p-value (2 sided) 
S
p
e
c
i
f
i
c
 
N
e
c
e
s
s
i
t
y
 
My health, at present, depends on my medicines 5 4, 5 277 4 4, 5 212 0.002 
My life would be impossible without my medicines  4 3, 5 265 3 3, 4 204 0.005 
Without my medicines I would be very ill  3 3, 4 271 3 3, 4 214 NS 
My health in the future will depends on my medicines  4 4, 5 269 4 3, 4.75 208 0.002 
My medicines protect me from becoming worse  4 4, 5 274 4 4, 5 217 0.017 
 Overall SN Median 4 4, 5 281 4 3, 5 218 0.013 
 Overall SN score 20 17, 22 281 18 16, 21 218 0.004 
S
p
e
c
i
f
i
c
 
C
o
n
c
e
r
n
 Having to take medicines worries me  2 1, 3 266 2 2, 4 211 <0.001 
I sometimes worry about long-term effects of my medicines 3 2, 4 275 4 2, 4 210 <0.001 
My medicines are a mystery to me 2 1, 3 270 2 2, 3 214 0.023 
My medicines disrupt my life  1 1, 2 273 2 1, 2 212 <0.001 
I sometimes worry about becoming too dependent on my medicines 2 1, 3 268 2 2, 4 207 <0.001 
 Overall SC Median 2 1, 2 278 2 2, 3 216 <0.001 
 Overall SC score 10 7.75, 13 278 12.5 10, 16 216 <0.001 
G
e
n
e
r
a
l
 
H
a
r
m
 
People who take medicines should stop their treatment for a while every now & again  2 1, 2 275 2 1, 3 214 <0.001 
Most medicines are addictive   2 1, 3 266 2 2, 3 210 NS 
Medicines do more harm than good 2 1, 2 271 2 1, 2 210 0.035 
All medicines are poisons  2 1, 3 272 2 1, 3 214 NS 
 Overall GH Median 2 1, 2.5 276 2 1.5, 2.5 216 0.024 
 Overall GH score 8 6, 9 276 8 6, 10 216 0.014 
G
e
n
e
r
a
l
 
O
v
e
r
u
s
e
 Doctors use too many medicines  2 2, 3 266 3 2, 3 201 <0.001 
Natural remedies are safer than medicines 2 1, 3 275 2 1, 3 212 NS 
Doctors place too much trust on medicines  2 1, 3 266 2 2, 3 209 0.015 
If doctors had more time with patients they would prescribe fewer medicines. 3 2, 3 270 3 2, 4 211 0.004 
Overall GO Median 2.5 2, 3 276 3 2, 3 215 <0.001 
 Overall GO score 9 7, 11 276  10 8, 12 215 0.001 
NS = not significant. The non-parametric Mann-Whitney test was used to calculate the 2-sided p-value.  
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4.10 Building a regression model 
 
The regression models described in this section were built as described in Section 
3.6.6.1 and Appendix 15. SPSS output can be seen in Appendix 16. A model will be built 
for the non-adherent group identified by the MMAS-8 (F1, F2) or SQ scale. Another 
two models will be built to look at non-adherent patients identified by the Factor 1, 
and those identified by Factor 2 in the MMAS-8 scale.   
 
4.10.1 Building a logistic regression model for the MMAS-8 (excluding 
Qn5) or SQ scale non-adherence.  
 
In accordance with the criteria described in Section 3.6.6.1, the best model identified 
by the researcher is reported. The final model had the following statistics: the model’s 
χ
2
 = 65.408, p <0.001 which means that the model was significant. The Hosmer and 
Lemeshow Test (HLT) p-value = 0.169 indicating the overall goodness-of-fit of the 
model. The overall prediction was 67.4%. Table 4.53 is a summary of the final model.  
 
Table  4.53 – Final model, variables with significant association with non-adherence identified 
by MMAS-8 (excluding Qn5) or SQ scale. Multivariate logistic regression Analysis (p-values 
<0.05) (n=484). 
 
   Variable 
Odds 
Ratio 
95% CI  
Lower Upper 
 Age 0.96 0.94 0.98 
Gender (Male – Female)  0.56 0.34 0.93 
Specific Concern about SPM (score) 1.12 1.07 1.18 
Issues with Repeat Prescriptions 2.48 1.26 4.90 
Aspirin (Prescribed) 2.22 1.18 4.17 
CI = confidence interval, SPM = Secondary Prevention Medicines 
 
 
Interpretation of the model: 
 
• Every one year increase in age was associated with a 4% reduction in the risk of 
being non-adherent. 
• Being female was associated with 44% reduction in the risk of being non-adherent.  
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• Every one unit increase in the specific concern score was associated with 12% 
increase in the risk of being non-adherent.   
• Having a problem or needing alternatives with repeat prescriptions was associated 
with a 2.5 times increase in the risk of being non-adherent.  
• Being on aspirin was associated with a 2.2 times increase in the risk of being non-
adherent. 
 
 
4.10.2 Building a logistic regression model for various non-adherent 
groups 
 
The final model for Factor 1 had the following statistics: the model’s χ
2
 = 57.013, p 
<0.001 which means that the model was significant. The HLT p-value = 0.871 indicating 
good overall goodness-of-fit of the model. The overall prediction was 69.1%. The final 
model can be seen in Table 4.54. 
 
Table  4.54 – Final model, variables with significant association with non-adherence identified 
by Factor 1. Multivariate logistic regression Analysis (p-values <0.05) (n=492). 
 
   Variable 
Odds 
Ratio 
95% CI  
Lower Upper 
 Age 0.96 0.94 0.98 
Gender (Male – Female) 0.50 0.29 0.82 
Diabetic (No – Yes) 0.44 0.23 0.85 
CABG (No – Yes) 0.60 0.40 0.90 
Aspirin (Prescribed) 2.00 1.05 3.85 
Specific Concern about SPM (score) 1.08 1.03 1.13 
CI = confidence interval, SPM = Secondary Prevention Medicines 
 
Interpretation of the model: 
 
• Every one year increase in age was associated with reduction in the risk of being 
non-adherent due to forgetfulness by 4%. 
• Being a female was associated with a reduction in the risk of being non-adherent 
due to forgetfulness by 50%.  
• Being diabetic was associated with a reduction in the risk of being non-adherent 
due to forgetfulness by 56%. 
• Having CABG was associated with a reduction in the risk of being non-adherent 
due to forgetfulness by 40%. 
• Being on aspirin was associated with two fold increase in the risk of being non-
adherent. 
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• Every one unit increase in the score of specific concern was associated with 
increase in the risk of non-adherence by 8%. 
 
The final model for Factor 2 is presented in Table 4.55 and had the following statistics: 
the model’s χ
2
 = 90.585, p <0.001 which means that the model was statistically 
significant. HLT p-value = 0.820 indicating good overall goodness-of-fit of the model. 
The overall prediction was 86%. 
 
Table  4.55 – Final model, variables with significant association with non-adherence identified 
by Factor 2. Multivariate logistic regression analysis (p-values <0.05). (n=480) 
 
   Variable 
Odds 
Ratio 
95% CI  
Lower Upper 
 Age 0.96 0.93 0.99 
Specific Necessity for SPM (score) 0.90 0.82 0.99 
Specific Concern about SPM (score) 1.16 1.07 1.27 
General Overuse of Medicines (score) 1.16 1.03 1.32 
Beta Blocker (Prescribed)  0.48 0.25 0.90 
Aspirin (Prescribed) 4.60 1.25 16.96 
Issues with Repeat Prescriptions 3.68 1.75 7.74 
No. of Prescribed Medicines 1.18 1.07 1.31 
CI = confidence interval, SPM = Secondary Prevention Medicines 
 
Interpretation of the model: 
 
• Every one year increase in age was associated with a 4% reduction in being 
intentionally non-adherent. 
• Every one unit increase in the score of specific necessity was associated with a 
decrease in the risk of intentional non-adherence by 10%. 
• Every one unit increase in the score of specific concern was associated with an 
increase in the risk of intentional non-adherence by 16%. 
• Every one unit increase in the score of general overuse was associated with an 
increase in the risk of intentional non-adherence by 16%. 
• Being on beta blockers was associated with reducing the risk of being 
intentionally non-adherent almost by 50%. 
• Being on aspirin was associated with almost a 5 times increase in the risk of being 
intentionally non-adherent. 
• Having a problem or needing an alternative / solution to repeat prescriptions was 
associated with approximately 4 times increase in the risk of intentional non-
adherence.  
• Every one unit increase in the number of medicines was associated with a 14% 
increase in the risk of intentional non-adherence.   
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4.11 Additional comments by patients 
 
A total of 221 patients provided extra comments. There were 85 comments made by 
82 adherent patients and around 225 comments made by non-adherent patients. In 
this section the analysis of these comments will be presented and summarised.      
 
4.11.1 Analysis of patients’ comments  
 
Frequency and categorisation analysis was conducted as described in Section 3.6.7.  
The full analysis can be seen in the spider diagram presented in Figure 4.15. Comments 
of adherent and non-adherent patients (according to MMAS-8 (excluding Qn5) or SQ 
scale) were clearly separated in order to learn more about the reasons behind non-
adherence to medicines.  Seven major themes were identified from the analysis and 
they are as follows: 
1) Specific concerns about secondary prevention medicines 
2) General concerns about medicines 
3) General concern about healthcare professionals 
4) General concern about sexual health 
5) Satisfaction and happiness related to medicines and services 
6) Favouring alternative therapies 
7) Suggestions related to medicines and medicines related services  
 
Table 4.56 summarises the number and percentage of comments made under each 
theme by adherent and non-adherent patients. The majority of the comments made 
under the “specific concerns about secondary prevention medicines” were by non-
adherent patients (87%). This was the same for all other themes except for the 
“satisfaction and happiness related to medicines and services” theme where most 
comments were by adherent patients.  
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Figure  4.15 – Spider diagram representing the full analysis of patients’ comments 
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Table  4.56 – Summary of the number of comments made under each theme by adherent and 
non-adherent patients.  (Total number of comments = 310) 
 
Themes Number of 
comments  
Adherent Non-adherent  
1) Specific concerns about secondary 
prevention medicines 
97 13 (13%) 84 (87%) 
2) General concerns about medicines 108 30 (28%) 78 (72%) 
3) General concern about healthcare 
professionals 
11 0 (0%) 11 (100%) 
4) General concern about sexual health 9 2 (22%) 7 (78%) 
5) Satisfaction and happiness related to 
medicines and services 
50 35 (70%) 15 (30%) 
6) Favouring alternative therapies 4 1 (25%) 3 (75%) 
7) Suggestions related to medicines and 
medicines related services.  
31 4 (13%) 27 (87%) 
 
 
Figures 4.16 and 4.17 show the distribution of the comments made by both groups 
across the seven themes identified. The majority of the comments made by adherers 
were about “satisfaction and happiness” and “general concern about medicines”. The 
non-adherers commented most on “specific concerns about secondary prevention 
medicines” and “general concern about medicines”. Adherent patients had very few 
suggestions compared to those who were non-adherent (5% vs. 12%, respectively).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.16 – Distribution of adherent patients’ comments between the seven themes 
identified in the analysis. (Total number of comments = 85) 
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Figure  4.17 - Distribution of non-adherent patients’ comments between the seven themes 
identified in the analysis. (Total number of comments = 225) 
 
 
Tables 4.57 to 4.63 summarise in groups of categories and sub-categories the issues 
highlighted by adherent and non-adherent patients under each one of the seven 
themes. Most comments under the “specific concerns about secondary prevention 
medicines” theme were about statins, aspirin, and beta blockers (55%, 19%, and 14% 
respectively). The sub-categories show a great number of comments from patients 
about the side-effects of these medicines.  
 
Table 4.58 shows that the three top concerns that patients raised about medicines in 
general related to adverse effects, therapeutic issues (mainly around the length of 
time they should continue on this therapy), and pharmaceutical issues (mainly around 
packaging and presentation of medicines) (40%, 21%, and 13% respectively). 
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Table  4.57 – Breakdown of comments under the theme of “specific concerns about secondary 
prevention medicines” grouped in categories and sub-categories as identified by adherent and 
non-adherent patients.  (Total number of comments = 97) 
 
Theme, categories and sub-categories 
No. of 
comments 
Adherent Non-adherent 
1) Specific concerns about secondary prevention 
medicines 
97 13 (13%) 84 (87%) 
a. Statins 53 4 (8%) 49 (92%) 
i. Side-effects - worried about or experiencing SE  22 1 (5%) 21 (95%) 
ii. Questioning Need or Benefit 3 0 (0%) 3 (100%) 
iii. Length of therapy - are they forever? 4 0 (0%) 4 (100%) 
iv. Media - instilled doubt / created worry 7 1 (14%) 6 (86%) 
v. Made changes – with/without doctor’s knowledge 17 2 (12%) 15 (88%) 
b. Aspirin 18 3 (17%) 15 (83%) 
i. Side-effects - worried about or experiencing SE 7 1 (14%) 6 (86%) 
ii. Length of therapy - are they forever? 3 1 (33%) 2 (67%) 
iii. Media - instilled doubt / created worry 4 0 (0%) 4 (100%) 
iv. Made changes - with/without doctor’s knowledge 4 1 (25%) 3 (75%) 
c. Clopidogrel 3 1 (33%) 2 67% 
i. Side-effects – experienced/ing SE 3 1 (33%) 2 67% 
d. ACEI 7 3 (43%) 4 57% 
i. Side-effects - worried about or experiencing SE 4 2 (50%) 2 50% 
ii. Made changes – with/without doctor’s knowledge 3 1 (33%) 1 33% 
e. Beta Blocker 14 2 (14%) 12 86% 
i. Side-effects - worried about or experiencing SE 8 0 (0%) 8 100% 
ii. Length of therapy - are they forever? 1 1 (100%) 0 0% 
iii. Made changes – with/without doctor’s knowledge 5 1 (20%) 4 80% 
f. GTN 2 0 (0%) 2 100% 
i. Side-effects – experienced/ing SE 2 0 (0%) 2 100% 
 
 
 
The theme of “General concern about healthcare professionals” (Table 4.59) was 
mainly focused on the information and the attitude doctors have about medicines, 
doctors’ medicines review and pharmacists not being helpful in putting tablets into 
bottles. All patients who commented under this theme were non-adherent. The 
“General concern about sexual health” theme (Table 4.60) was mainly about erectile 
dysfunction and which medicines contribute to this. 
 
 
Results Chapter                                                                                                   The Heart Medicines Survey 
 
156 
Table  4.58 – Breakdown of comments under the theme of “General concerns about 
medicines” grouped in categories and sub-categories as identified by adherent and non-
adherent patients.  (Total number of comments =108) 
 
Theme, categories and sub-categories 
No. of 
comments 
Adherent Non-adherent 
2) General concerns about medicines 108 30 (28%) 78 (72%) 
a. Adverse effects  43 13 (30%) 30 (70%) 
i. Experienced / experiencing Side-effects  32 12 (38%) 20 (63%) 
ii. Worried about SE  9 1 (11%) 8 (89%) 
b. Review of Medicines 10 6 (60%) 4 (40%) 
i. Frequency  8 6 (75%) 2 (25%) 
ii. Quality and content 2 0 (0%) 2 (100%) 
c. Information about Medicines 6 0 (0%) 6 (100%) 
i. Quality and type of information  
   (SE, mode of action, purpose of multiple therapies) 
6 0 (0%) 6 (100%) 
d. Pharmaceutical Issues 14 2 (14%) 12 (86%) 
i. Repeat Prescriptions  
   (Freq, synchronising no. & type of meds issued)  
4 1 (25%) 3 (75%) 
ii. Packaging and presentation of medicines  10 1 (10%) 9 (90%) 
iii. Polypharmacy  3 1 (33%) 2 (67%) 
e. Forgetting Medicines 9 3 (33%) 6 (67%) 
i. What increases the likelihood of forgetting 5 1 (20%) 4 (80%) 
ii. What decreases the likelihood of forgetting  2 1 (50%) 1 (50%) 
iii. Intentional forgetting  2 1 (50%) 1 (50%) 
f. Therapeutic Issues 23 4 (17%) 19 (83%) 
i. Uncertain about benefit  4 0 (0%) 4 (100%) 
ii. Length of time of therapy  18 4 (22%) 14 (78%) 
iii. Individualising therapy 1 0 (0%) 1 (100%) 
g. Cost  2 1 (50%) 1 (50%) 
i. Medicines should be free esp. post MI and 
Medicines for ED 
2 1 (50%) 1 (50%) 
 
 
 
Table  4.59 – Breakdown of comments under the theme of “General concern about healthcare 
professionals” grouped in categories and sub-categories as identified by adherent and non-
adherent patients.  (Total number of comments =11) 
 
Theme, categories and sub-categories 
No. of 
comments 
  Adherent Non-adherent 
3) General concern about healthcare professionals 11 0 (0%) 11 (100%) 
a. Doctors  10 0 (0%) 10 (100%) 
i. Information provided  2 0 (0%) 2 (100%) 
ii. Attitude and approach of Side-effects  3 0 (0%) 3 (100%) 
iii. Advice & review of medicines (quality & who) 5 0 (0%) 5 (100%) 
b. Pharmacists 1 0 (0%) 1 (100%) 
i. Help with putting tablets in bottles 1 0 (0%) 1 (100%) 
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Table  4.60 – Breakdown of comments under the theme of “General concern about sexual 
health” grouped in categories and sub-categories as identified by adherent and non-adherent 
patients.  (Total number of comments =9) 
 
Theme, categories and sub-categories 
No. of 
comments 
  Adherent Non-adherent 
4) General concern about sexual health 9 2 (22%) 7 (78%) 
a. Erectile Dysfunction  9 2 (22%) 7 (78%) 
i. Medicines that cause ED  8 2 (25%) 6 (75%) 
ii. Medicines that protect against ED  1 0 (0%) 1 (100%) 
 
 
In Table 4.61, patients’ comments under the “Satisfaction and happiness related to 
medicines and services” theme mainly highlighted what makes patients feel satisfied 
with their medicines (48%), healthcare professionals and the healthcare service (48%). 
Patients also highlighted the role of family members in managing their medicines.  
   
Table  4.61– Breakdown of comments under the theme of “Satisfaction and happiness related 
to medicines and services” grouped in categories and sub-categories as identified by adherent 
and non-adherent patients.  (Total number of comments =50) 
 
Theme, categories and sub-categories 
No. of 
comments 
  Adherent Non-adherent 
5) Satisfaction and happiness related to 
medicines and services 
50 35 (70%) 15 (30%) 
a. Medicines  24 23 (96%) 1 (4%) 
i. Can feel benefit  21 20 (95%) 1 (5%) 
ii. Did not get Side-effects  3 3 (100%) 0 (0%) 
b. Healthcare Services / Professionals 24 12 (50%) 12 (50%) 
i. Doctors - (trust, prescribe when needed, accessible, 
reviews meds, checks for SE)  
17 10 (59%) 7 (41%) 
ii. Pharmacists – (review meds, help with tablets in 
bottles)   
2 0 (0%) 2 (100%) 
iii. Service in general was excellent 5 2 (40%) 3 (60%) 
c. Family members  2 0 (0%) 2 (100%) 
i. Help with medicines 2 0 (0%) 2 (100%) 
 
 
Comments under the theme of “Favouring alternative therapies” mainly focused on 
patients’ interest in alternative therapies (75%) and that healthcare professionals 
usually ignore the benefits of alternative therapies (25%) (see Table 4.62).   
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Table  4.62 – Breakdown of comments under the theme of “Favouring alternative therapies” 
grouped in categories and sub-categories as identified by adherent and non-adherent patients.  
(Total number of comments = 4) 
 
Theme, categories and sub-categories 
No. of 
comments 
  Adherent Non-adherent 
6) Alternative therapies (AT) 4 1 (25%) 3 (75%) 
a. Healthcare professionals & AT   1 0 (0%) 1 (100%) 
i. Healthcare professionals ignore benefits of AT 1 0 (0%) 1 (100%) 
b. Patients favour AT 3 1 (33%) 2 (67%) 
i. Take AT for cardiovascular disease  1 0 (0%) 1 (100%) 
ii. Asking for AT for angina   2 1 (50%) 1 (50%) 
 
 
 
In Table 4.63, the suggestions made by patients under the “Suggestions related to 
medicines and medicines related services” mainly focused on the information that 
should be provided about medicines with some details on how and when (65%), and 
the need for the review and monitoring of medicines (32%).  
 
 
Table  4.63 – Breakdown of comments under the theme of “Suggestions related to medicines 
and medicines related services” grouped in categories and sub-categories as identified by 
adherent and non-adherent patients.  (Total number of comments = 31) 
 
Theme, categories and sub-categories 
No. of 
comments 
  Adherent Non-adherent 
7) Suggestions related to medicines and medicines 
related services. 
31 4 (13%) 27 (87%) 
a. Review and monitoring of medicines   10 2 (20%) 8 (80%) 
i. Identified specific purpose (need to continue, SE, 
efficacy, minimal effective dose)  
4 1 (25%) 3 (75%) 
ii. Frequency  3 0 (0%) 3 (100%) 
iii. Who should do it?  3 1 (33%) 2 (67%) 
b. Ways to improve adherence  1 0 (0%) 1 (100%) 
i. Interventions - (reminder chart, reason for 
prescribing, leaflets)  
1 0 (0%) 1 (100%) 
c. Information about medicines 20 2 (10%) 18 (90%) 
i. How often and when to provide info  4 0 (0%) 4 (100%) 
ii. Methods to communicate information  4 0 (0%) 4 (100%) 
iii. What type of info needed - (SE & what to do, how 
do we know they work, purpose &mode of action, 
how long to take, min effective dose)  
10 2 (20%) 8 (80%) 
iv. Who should provide it 2 0 (0%) 2 (100%) 
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5 Discussion 
The main aim of this study was to investigate the prevalence and possible factors 
contributing to self-reported non-adherence to secondary prevention medicines in 
patients who have a well-established diagnosis of CAD. This chapter discusses the 
findings of this research, its implications for practice, policy, further research and 
evaluation.  The following is a summary of how the different sections of this chapter 
relate to the aims and objectives of the study: 
 
• The primary aim was to investigate the prevalence and possible factors 
contributing to self-reported non-adherence to secondary prevention medicines in 
patients living within West Yorkshire and nearby areas who have a well-established 
diagnosis of CAD. 
o This was covered in Sections 5.1, 5.2 and 5.4. 
 
• Objective 1: assess self-reported non-adherence to collective and individual 
secondary prevention medicines. Aspirin, clopidogrel, statins, beta-blockers, ACEI, 
ARBs. 
o This was covered in Sections 5.1.3.1 and 5.2.   
 
• Objective 2: compare the findings, practicality, sensitivity and reliability of three 
different instruments (questionnaires) which assess self-reported non-adherence; 
MMAS-8, Adherence Estimator™, and the Single Question approach. 
o This was covered in Section 5.3. 
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• Objective 3: identify barriers contributing to non-adherence to inform and change 
practice. 
o This was covered in Section 5.4. 
 
• Objective 4: Survey the prevailing individual beliefs and attitudes to use of 
medication among patients with established CAD. 
o This was covered in Section 5.4.2.6. 
 
• Secondary objective 1: Identify the level of secondary prevention medicines 
prescribing and use in patients with stable CAD. 
o This was covered in Section 5.1.3.1. 
 
• Secondary objective 2: Develop a practical approach to address non-adherence 
among this population. 
o This was mainly covered in Sections 5.6 and 5.7 and also in other various 
sections in this chapter.  
 
5.1 The participants 
This section discusses how representative the sample was, if the findings can be 
generalised, and the possible reasons for the high response rate and its implication for 
practice. Aspects related to the prescribed medicines and relevant to later discussions 
will be highlighted.  
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5.1.1 Representativeness of the sample  
 
The sample contained a good regional representation of CHD patients who accessed 
the LTHT cardiology services. Approximately 90% of the participants were from West 
Yorkshire and 10% from nearby regions. The median (Q1, Q3) age (years) of 
participants was 70 (63, 75) with 99.8% of the sample aged 40 years or older. This is 
consistent with the prevalence of cardiovascular disease which increases significantly 
after the age of 40 years (BHF, 2010; SEPHO: South East Public Health Observatory, 
2011). The age spread of the participants was similar to that seen nationally. In 2006, 
the prevalence of CHD in England was 6.5% in men and 4% in women (total of 10.5%) 
(BHF, 2010). Approximately 30% of those were 65 – 74 years old and 48% were 75 
years and older (BHF, 2010). In our study 80% of the participants were males. The 
prevalence of CHD is higher among men in England and is estimated to account for 60 
– 65% of patients with CHD (BHF, 2010). The low representation of females in our 
study could be explained by the fact that CHD is underdiagnosed, undertreated and 
under-researched among females. In recent years there has been more interest in 
addressing this gap (Mikhail, 2005). 
 
White people represented approximately 92% of the sample. There was an 
underrepresentation of Black and other ethnic minorities, which was estimated to be 
around 13% in 2009 in West Yorkshire (ONS: Office of National Statistics, 2011). This 
reflected the patient population in the ENCOURAGE database which did not have high 
representation of non-whites. Concerns about the low representation of ethnic groups 
in clinical trials has been reported in the literature and mainly attributed to lack of 
interest, language barriers and lower socio-economic status (Jolly et al., 2005). This 
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should be taken into account when interpreting and applying the findings of this 
research. It also highlights the need for researching medicines-taking behaviour of 
ethnic minorities with CHD. CHD is more prevalent at a younger age among South 
Asian men who also have higher rates of myocardial infarction (SEPHO, 2011; BHF, 
2010a). Minority ethnic groups also have a lower participation in cardiac rehabilitation 
programmes compared to the white population which could possibly make them at 
higher risk of non-adherence (BHF, 2010a).          
 
Patients with diabetes are three times more likely to suffer an MI and an estimated 
15% of MIs in Western Europe are due to diagnosed diabetes (BHF, 2010). In our study, 
a similar percentage (12%) of participants was identified to have diabetes controlled 
with medicines.    
 
5.1.2 The response rate and its implications for practice 
The response rate for postal questionnaires is usually around 25% (Matthews & Ross, 
2010). The high response rate (72%) achieved in this study could be attributed to 
several factors. Various measures were taken to improve the low response rate 
limitation of postal questionnaires (see Section 3.1.1). These advance considerations 
were possibly a contributing factor. In addition, the patients in the sample were 
probably more motivated than the average population to participate in research as 
they had already expressed their willingness to take part in future research 
opportunities (see Section 3.3). Another possible factor is the topic of this research: 
medicines. This was evident from the number of comments made by patients (221 out 
503 patients made comments) where they had many medicines related issues that 
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they wanted to discuss. Several patients clearly indicated their dissatisfaction with the 
frequency and quality of medicines reviews. They could, therefore, have taken this 
opportunity to highlight their experiences and issues related to their secondary 
prevention medicines, medicines in general, healthcare professionals and the 
healthcare system. This suggests the need to provide more frequent opportunities for 
patients to talk about their medicines with their healthcare professionals. Pharmacists 
have a major role to play in this field. Clinical pharmacists can enhance their medicines 
reconciliation service during in-patient admissions to give opportunities to raise any 
issues about medicines. Community pharmacists are frequently visited by patients with 
chronic conditions and can seize these opportunities to offer patients the chance to 
discuss their medicines (e.g. Medicines Use Reviews, the New Medicine Service and 
Repeat Dispensing). However, criticism of the way medicines reviews were conducted 
has been reported in the literature (Latif et al., 2011). One of the main findings was 
that the format of the review (e.g. asking closed questions, very brief session) did not 
give patients enough chance to ask questions and express their concerns (Latif et al., 
2011). Therefore, there is a need to take on board the suggestions made by patients 
about medicines reviews in our study (see Section 5.4.2.7).  
 
5.1.3 Overall Prescribed medicines  
 
The median (Q1, Q3) number of the overall medicines prescribed for patients was 7 (5, 
9). The frequency of daily medicines administration was once a day for 50% of patients 
and 37% of the participants had at least one medicine with a twice a day frequency. 
Patients with chronic conditions and co-morbidities are likely to be on a large number 
of medicines as evidence based guidelines recommend several drugs in the treatment 
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of a single condition (see Section 1.3). This is often referred to as polypharmacy. The 
definition of polypharmacy is variable and it has been defined as the concurrent use of 
multiple drugs (usually more than 4) (Fulton & Allen, 2005). Polypharmacy can be 
further exacerbated by multiple daily dosing regimens as it can increase the daily 
burden of medicines-taking. This makes drug treatment particularly challenging and 
more likely to contribute to non-adherence (Avorn, 2004).  See Section 5.4.2.1 for the 
association of polypharmacy with non-adherence in this study.  
 
5.1.3.1 Secondary prevention medicines  
The level of individual secondary prevention medicines prescribing was highest for 
statins (95%). Aspirin or clopidogrel monotherapy were prescribed in 94% of cases. 
This is above the target of 80% set by the CHD National Service Framework (DoH, 2000, 
BHF, 2010). Beta blockers were below the 80% target and prescribed for only 71% of 
patients. The prescribing of ACEI (or ARBs) was 78%. All these results were below 
England’s national average in 2008/2009 (97% for statins, 98% for aspirin, and 93% for 
beta blockers) (BHF, 2010). Capewell et al. (2006) suggested that consistently hitting 
the 80% target when prescribing secondary prevention medicines might result in some 
20,000 fewer CHD deaths each year in England and Wales. This highlights the level of 
benefit that could be potentially gained from prescribing optimal levels of secondary 
prevention medicines that are adhered to.    
 
Only 52% of patients were prescribed at least four secondary prevention medicines as 
recommended by NICE (NICE, 2007; NICE, 2011) and 34% were only prescribed three. 
These results indicate that there is room for optimising secondary prevention 
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medicines therapy in the absence of specific clinical contraindications. Patients need to 
be reviewed individually to identify reasons for omission of indicated individual 
secondary prevention medicines. DeWilde et al. (2008) reported that under half of 
patients in the UK in 2005 were receiving all four secondary prevention medicines. The 
results of this research show that despite higher levels of statins and antiplatelets 
prescribing, there is still room for increasing the benefits of secondary prevention 
medicines through the wider use of combined treatments. This area should be 
explored further to identify reasons behind low levels of prescribing secondary 
prevention medicines.    
 
Knowledge about secondary prevention medicines was assessed by asking patients in 
Part 1 of the questionnaire to identify the indication for each one of their medicines. 
This was used as a proxy for the level of knowledge patients had about the medicine. 
Patients were classed as “knowledgeable” and “not knowledgeable” as described in 
the Section 3.6.1.5. This approach is not sufficient to assess patients’ overall 
knowledge about the medicine (e.g. side-effects). However, knowing why one was 
prescribed a certain medicine is a good starting point, which reflects minimum 
understanding.   
 
Patients’ knowledge, as defined in this study, about why medicines were prescribed 
was the highest for statins (67%) compared to other secondary prevention medicines. 
This was followed by aspirin (52%). Participants knew very little about why they were 
prescribed beta blockers (36%). One explanation for this difference in levels of 
knowledge could be that it is easier to explain the mode of action of statins and 
antiplatelets than that of beta blockers or ACEI. While patients may understand that 
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both beta blockers and/or ACEI are for their hearts, they do not necessarily understand 
the difference between them compared to antiplatelets and statins. In addition, both 
statins and aspirin were frequently mentioned in the media which may have made 
patients more aware of their use and mode of action (see Section 5.4.2.2). This is 
consistent with patients who mentioned the impact of the media on their perception 
about these medicines (see Figure 4.15 and Table 4.57). The lack of understanding of 
the difference between these classes of medicines was possibly reflected in patients 
asking for more information about the reasons behind prescribing multiple therapies 
post MI (See Figure 4.15 and Table 4.58).           
 
Overall the sample had a tendency towards not knowing the indications for the 
secondary prevention medicines they were prescribed (mean ± SD = 1.7 ± 0.65, median 
(Q1, Q3) = 1.6 (1, 2) – where 1 = full knowledge and 3 = no knowledge).    
 
5.1.3.2 GTN 
Patients with symptomatic CAD should be prescribed sublingual GTN spray or tablets 
unless contraindicated (NICE, 2011). Evaluating the frequency for needing to use GTN 
can reflect how well patients’ angina is controlled and if there is a need to modify 
therapy (NICE, 2011). Only 73% of participants reported that they were prescribed 
GTN, which could indicate that the rest had asymptomatic CAD. Of those who were 
prescribed GTN, 49% reported using it which could indicate that the rest of them had 
well controlled stable CAD. However, studies have shown that prescribers erroneously 
omitted GTN from 38% of CAD patients’ prescriptions (Zimmerman et al., 2009). This 
issue could be addressed during a medicines review session. When asked to indicate 
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the frequency of use, only 62% of those who reported using their GTN provided the 
information. The majority of these used their GTN monthly or weekly. The low number 
of patients who reported frequency of GTN use made the analysis limited to 112 
patients.    
 
While information about GTN use can in principle be used to screen for patients who 
are likely to be non-adherent, this study showed that such an approach is not generally 
reliable. There was no statistically significant association between GTN use or 
frequency of use and non-adherence to secondary prevention medicines and anti-
anginals. This could be due to the small number of patients who reported the 
frequency of GTN use. However, it is more likely to be explained by the complex 
relationship between symptomatic CAD and use of GTN to alleviate the pain. Not all 
patients who experience angina necessarily use their GTN to control it. The researcher 
conducted various interviews and surveys with patients prescribed GTN to assess their 
knowledge and use of GTN (Khatib & Keenan, 2011). Patients were reluctant to use 
GTN for their angina due to side-effects (headaches and hypotension) or due to their 
perception that it should only be used when symptoms are very serious (Khatib & 
Keenan, 2011). This makes the Angina – GTN – Non-adherence relationship more 
complicated as not all patients who are non-adherent and experience angina 
necessarily use their GTN more frequently.            
 
5.2 Levels of non-adherence 
Adherence to collective and individual secondary prevention medicines was assessed 
using the MMAS-8 and SQ scale.  The level of collective self-reported non-adherence 
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according to the MMAS-8 scale (before excluding Qn5) was 49%. Medium adherence 
was identified in 39% of the sample and 10% had low adherence. After excluding Qn5, 
the level of non-adherence was 42%, medium adherence 32% and low adherence 10%. 
Reviewing the scores of the MMAS-8 revealed that 57 patients had a score of 7.75. 
This indicates that their only reason for being classified as non-adherent was that they 
“almost never” had difficulty remembering to take all their medicines as opposed to 
“never”. While this is classed as non-adherence according to the MMAS-8, one can 
argue that “almost never” is acceptable. However, 38% of the patients would still be 
classed as non-adherent according to the scale. This is consistent with non-adherence 
levels of a third to a half reported in the literature for patients with long term 
conditions (WHO, 2003; NICE, 2009). Non-adherence related to Factor 1 
(unintentional/ forgetfulness) and 2 (intentional / hassle non-adherence) highlighted 
that 69% of patients were non-adherent due to forgetfulness only, 12% due to 
intentional/medicines related hassle only and 19% due to an element of both.    
 
The levels of non-adherence according to the SQ scale were lower and estimated to be 
13% when 90%
‡
 was used as a cut-off point and 5% when 75%
‡
 was used. As discussed 
in Section 3.6.2.3, the original authors use of 75% (“most of the time”) as a cut-off 
point was not validated or chosen with reference to a “gold standard” adherence 
assessment method. Therefore, patients who said that they took their medicines 
“nearly all of the time” (90% cut-off point) did still have an element of non-adherence.  
 
                                                 
‡
 It should be noted that the 90% and 75% cut-off points used in the SQ scale are arbitrary (see Section 
3.6.2.3)  and they should not be confused with the cut-off points used to define acceptable non-
adherence which does not impact on benefits derived from prescribed medicines as discussed in Section 
1.4.1.    
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The modified SQ scale identified that the levels of non-adherence to aspirin, statins, 
clopidogrel, beta blockers, ACEI and ARBs were 9%, 8%, 7%, 5%, 4% and 3% 
respectively. Their contribution to SQ scale non-adherence was 62%, 67%, 7%, 30%, 
22% and 5% respectively. Aspirin and statins were least adhered to and contributed to 
most of the non-adherence identified by the SQ scale. This is contrary to previously 
reported non-adherence to individual secondary prevention medicines, where aspirin 
had the highest adherence (Newby et al., 2006). This further emphasises that patient 
populations with similar chronic conditions may have different medicines-taking 
behaviour. An increase in the number of secondary prevention medicines included in 
the various combinations was not necessarily associated with an increase in non-
adherence. Patients chose to adhere to certain secondary prevention medicines and 
not adhere to others. This confirms that non-adherence behaviour is not “all or none” 
and a patient could be adherent to one medicine and not the other (McHorney, 2009). 
For example: 214 patients were concomitantly prescribed four secondary prevention 
medicines; 6% did not adhere to only one of the four medicines, 2% did not adhere to 
two and 5% did not adhere to all four prescribed secondary prevention medicines.  
 
The AE estimated that 30% of the participants had low to medium probability of 
adherence and were likely to be intentionally non-adherent.    
 
The combined findings of the MMAS-8 (excluding Qn5) and SQ scale showed a level of 
non-adherence of 44%. Only 39% of these were predicted by the AE to have an 
element of intentional non-adherence.    
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5.3 Performance of the self-report adherence 
assessment tools 
 
Three self-reported adherence assessment tools were used in the study. There was no 
“gold standard” adherence measure to compare them against. Therefore, the 
performance of each individual tool on its own and as compared to other tools within 
the study will be discussed. 
 
5.3.1 The MMAS-8     
 
The MMAS-8 was simple and easy to administer. The calculation of the scores was also 
relatively straightforward. Qn5 in the MMAS-8 was reversed, possibly to reduce bias. 
However, the analysis of the MMAS-8 results revealed a problem with this question as 
it was the only reversed question and sometimes caused confusion and certain 
patients may have answered it incorrectly. Reliability analysis using Cronbach’s α 
confirmed this problem. Despite reversing the scores of Qn5 it had a negative 
correlation with the overall scale and its removal brought a significant increase in the 
value of Cronbach’s α. This indicated that the removal of this question increased the 
reliability of the scale. The factor analysis revealed that Qn5 did not load onto either 
factor and had a very low common associated variance of 8.9%. The researcher 
contacted the original inventor of the scale who stated that he had never encountered 
this problem before (Morisky, 2001, pers. comm.). 
 
This error could be explained by the concept of “acquiescence”. It is estimated that 
around 10% of a questionnaire’s participants may experience acquiescence, where 
they would agree or disagree with statements without considering the contents of the 
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statements or questions (McBurney & White, 2007). This could have been seen with 
the MMAS-8 Qn5 problem. One suggestion to address this problem would be to have 
an equal number of positively and negatively scored items in a questionnaire (Barker 
et. al., 1994).      
 
MMAS-8 (excluding Qn5) had a marginal Cronbach’s α of 0.602 indicating low 
consistency and possibly the presence of more than one construct in the scale. Indeed 
factorial analysis revealed two constructs or factors within the scale. These findings are 
contrary to the original validation of this scale which showed a very good Cronbach’s α 
of 0.83 and a single-factor scale using factor analysis to assess its dimensionality 
(Morisky et al., 2008). Sakthong et al. (2009) reported a Cronbach’s of 0.61 and factor 
analysis revealed three factors within the scale when tested in patients with diabetes. 
The two factors identified in this research included: Factor 1 (Questions 1, 2, 4 and 8), 
which is mainly about forgetfulness, with a Cronbach’s α of 0.681; and Factor 2 
(Questions 3, 6 and 7), which is mainly about intentional non-adherence and 
complexity of regimen, with a Cronbach’s α of 0.324. Though, Qn2 could have an 
element of intentional non-adherence as well, it seems that the majority of those who 
answered it were mainly considering forgetfulness. The low Cronbach’s α value for 
Factor 2 can be explained by the low number of patients who answered yes to Qn6 
and the possibility of the non-intentional element found in Qn7, which mainly asks 
about the complexity of the regimen. Patients on complex regimens may be hassled 
about sticking to their treatment; but this can be intentional or non-intentional.  
 
The MMAS-8 scale should be used with caution and tests of internal validity and 
dimensionality should always be conducted to inform the analysis of data. A modified 
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version of the scale which uses an equal number of positively and negatively scored 
items might perform better. Despite these limitations, the MMAS-8 was able to detect 
non-adherent behaviour which was confirmed by the SQ scale, AE or comments made 
by patients.  
 
5.3.2 The Adherence Estimator  
The AE was also a simple tool to administer and was very useful in exploring the 
underlying drivers of some of the non-adherence behaviour. It mainly looked at 
propensity to intentional non-adherence. Despite concerns about the applicability of 
question 3 about cost of medicines to the NHS in England, it proved very useful and 
relevant and will be elaborated on in Section 5.4.2.4. Of the 147 patients who were 
identified by the AE to have low or medium probability to be adherent, 86 were 
classed by MMAS-8 (excluding Qn5) or SQ scale to be non-adherent. There are three 
potential explanations for this: 
 
1) The non-adherence behaviour of those who had propensity was not yet apparent. 
2) The MMAS-8 (excluding Qn5) and the SQ failed to detect the non-adherence 
behaviour. 
3) The AE was incorrect in its classification of those patients. 
 
Whatever the reason, the information provided by the AE is clinically relevant and 
should be acted upon by healthcare professionals. If a patient is adherent and having 
concerns or worries about his or her medicines, then these concerns should be 
addressed regardless of the adherence status. It is also possible that if concerns are 
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genuine (e.g. suspecting a medicine to be causing a harmful side effect) then 
adherence might be inappropriate.  
 
The sensitivity of the AE was 40%. This is almost 50% lower than the reported 88% by 
the author of this tool (McHorney, 2009). The specificity was 78% and higher than the 
59% reported by McHorney (2009). This could be explained by the fact that the “gold 
standard” used in this study was MMAS-8 (excluding Qn5) or SQ scale. Those scales 
detect both intentional and unintentional non-adherence, whereas, the values 
reported by McHorney (2009) were for patients who were already identified to be 
intentionally non-adherent. In addition, the sociodemographic characteristics of the 
patients in the McHorney (2009) study were different to our study. For example: the 
median age was 58 and females constituted approximately 65% of the sample.   
 
This argument is substantiated by comparison between the AE and Factor 1 and 2 (see 
Table 4.33). Only 37% of patients identified by Factor 1 to be non-adherent had been 
predicted by the AE. However, almost twice this percentage (63%) of patients were 
found by Factor 2, which represents more the intentional element of non-adherence. 
In the Kappa statistic analysis, the AE had more agreement with Factor 2 than Factor 1 
or MMAS-8 (excluding Qn5). These findings highlight two further issues: 
 
First, the presence of two dimensions (intentional vs. un-intentional) in the 
MMAS-8 (excluding Qn5) scale as found by the factor analysis, is more likely to 
be true. 
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Second, forgetfulness is affected to some extent by underlying beliefs about 
medicines and it is not purely unintentional. This is evident from the fact that 
37% of non-adherent patients according to Factor 1 were predicted by the AE. 
The multivariate analysis for Factor 1 also showed a strong association between 
specific concern about secondary prevention medicines score and non-
adherence according to Factor 1. Every one unit increase in the score of specific 
concern was associated with 8% increase in the risk of non-adherence due to 
forgetfulness.  This increase in risk was 16% for Factor 2 non-adherence. 
Therefore, specific concern about medicines increases the risk of non-
adherence due to both elements, though it is a stronger driver of intentional 
non-adherence.  
 
Unni and Farris (2011) investigated this relationship between beliefs about medicines 
and forgetfulness to take medicines. They found that concerns about medicines were a 
significant predictor of forgetfulness in taking medicines (Unni & Farris, 2011). This 
could partially explain why interventions to address non-adherence due to 
forgetfulness were not always successful. The underlying beliefs should also be 
addressed.   
 
5.3.3 The SQ scale 
The SQ scale was the easiest to administer. Before modification the scale provided no 
information or detail about the reasons or the type of non-adherence behaviour. 
Therefore, it is best used as a screening tool to identify patients who may need further 
investigation into their medicines-taking behaviour. However, the SQ scale had very 
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low sensitivity (25%) compared to the MMAS-8 which means it is unable to identify 
many non-adherent patients. However, its very high specificity (97%) shows that 
patients identified by this scale almost certainly have issues that need exploring 
around their medicine-taking behaviour. In the Heart and Soul Study by Gehi et al. 
(2007) the SQ scale identified 8.3% of patients to be non-adherent using the 75% cut-
off point. They did not report the level of non-adherence for the 90% cut-off point 
(Gehi et al., 2007). 
 
The modification of the tool by the researcher provided useful information about the 
medicines-taking behaviour relating to individual secondary prevention medicines. 
Patients were able to comment on individual medicines, which proved to be invaluable 
during the analysis and interpretation of the findings. Based on participants’ 
responses, the modification does not seem to have made answering the tool 
burdensome. 
 
The introduction and exploration of the 90% (medium adherence) and 75% (low 
adherence) cut-off points in the tool provided additional information that can be used 
by healthcare professionals who use this tool. Patients classed as medium adherers 
(90%) correlated better with Factor 1 non-adherers. Whereas those who were 
classified as low adherers (≤75%) had a better agreement with the findings of Factor 2 
and the AE. The Kappa statistic showed better agreement between SQ75 and Factor 2 
than Factor 1 or MAAS-8.  Users of this scale may find that patients who score 75% or 
less (low adherence) are more likely to have a greater element of intentional non-
adherence compared to those who score 90% (medium adherence). The latter are 
more likely to have a greater tendency of forgetfulness non-adherence.   
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5.4 Barriers to adherence and factors associated with 
non-adherence    
 
There is a plethora of literature on the barriers and factors that are likely to be 
associated with non-adherence (WHO, 2003; Horne et al., 2005; NICE, 2009). The 
causes of medicines non-adherence are complex, multifactorial and cannot be 
explained by single fixed factors such as the type or severity of the disease and 
sociodemographics of patients (Horne et al., 2005) (see Section 1.4.2). Non-adherence 
is not necessarily related to sociodemographic factors such as age, gender, level of 
education or race (Horne, 2005; Brown & Bussell, 2011). Many of these factors are 
non-modifiable (e.g. gender, age) and should be mainly used for screening and for 
targeting resources. However, these can vary from one population to another. The 
modifiable factors should be targeted by interventions. It is important to emphasise 
that not all of these factors have been consistently associated with patient non-
adherence (Brown & Bussell, 2011). Both modifiable and non-modifiable factors had a 
different direction and level of association with medicines adherence depending on 
the studied population. The findings of this research concur with this (see Sections 
5.4.1 and 5.4.2).  
 
5.4.1 Non-modifiable Associations 
5.4.1.1 Age 
Comparing the adherent and non-adherent groups (according to all scales) identified 
that non-adherers were younger. The median (Q1, Q3; Min, Max) age of non-adherers 
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was 67 (62, 73; 38, 92) and for the adherers 71 (65, 71; 45, 92). The multivariate 
analysis showed that every one year increase in age was associated with a 4% 
reduction in the risk of being non-adherent regardless of the type of non-adherence 
(intentional or unintentional). Age is known to influence health related behaviour 
including the perception of risk (Deeks et al., 2009). Older patients are more likely to 
participate in health checks, read health promotion materials and have plans in place 
for future health and wellbeing compared to younger patients (Deeks et al., 2009). This 
may also translate into an effect on their medicines-taking behaviour.  
 
Several adherent elderly patients made comments like “I am still alive” when they 
wanted to explain their satisfaction with their medicines and others highlighted how 
much they trusted their prescribers “If you trust your doctor you trust what they 
prescribe” (see Figure 4.15). These findings are consistent with an exploratory study 
which investigated older patients' perceptions of medication importance and worth 
(Lau et al., 2008). The study identified that medication importance was influenced by 
three factors: drug-related (indications, side-effects, and alternatives); patient-related 
(knowledge, attitudes, and health); and external (the media, healthcare and family 
carers) (Lau et al., 2008). In the absence of detailed adequate knowledge about their 
medicines, patients relied on their personal experience of medicines or complete trust 
in their healthcare providers’ advice, to assign importance ratings (Lau et al., 2008). 
 
It can be argued that our findings are specific to this study, as in the literature older 
age has been associated with higher non-adherence, lower non-adherence and also a 
neutral impact (Gehi et al., 2007; Granger et al., 2009; Doggrell, 2010; Rolnick et al., 
2011). The evidence about these factors could be contradictory due to the complexity 
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of the interactions of the factors that can contribute to non-adherence (see Section 
1.4.2). Therefore, the findings may only be applicable to the population being studied.  
  
5.4.1.2 Gender 
 
Females were more likely to be adherent than males according to the multivariate 
logistic regression analysis of overall non-adherence. The analysis of non-adherence 
according to Factor 1 and Factor 2 showed that gender was only important in Factor 1 
(unintentional / forgetfulness). An interaction analysis showed that this was not 
dependent on age. 
 
Various studies have shown that gender is associated with health related behaviour 
(Davidson & Freudenburg, 1996; Deeks et al., 2009). Females were more likely than 
males to indicate preparedness to have an annual health check, have a greater 
willingness to seek advice from a healthcare professional and attend educational 
sessions (Deeks et al., 2009). The literature also suggests that females are more likely 
than males to report poor self-rated health, which could explain their higher 
adherence to medicines (Lim et al., 2007). However, these findings were not consistent 
in all studies and gender health behaviour was also influenced by cultural, ethnic and 
social factors (Lim et al., 2007). This could explain why, contrary to our research’s 
findings, Gehi et al. (2007) and Granger et al. (2009) found that females were more 
likely to be non-adherent than males in their studies. This is another example of why 
non-modifiable factors associated with non-adherence need to be considered in the 
population that is being studied and not over-generalised.  This underlines one of the 
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main conclusions of this thesis that individual patient profiling is essential for the 
success of any planned intervention. 
    
5.4.1.3 Cardiac history and co-morbidities  
Patients who had angioplasty were more likely to be non-adherent than those who did 
not have angioplasty according to the overall non-adherence findings and the AE. 
Those who had CABG were more likely to be adherent according to overall non-
adherence, AE and Factor 1 non-adherence than those who did not have CABG. A prior 
CABG was associated with a reduction in the risk of being non-adherent due to 
forgetfulness by 40%. This difference in medicines-taking behaviour might be due to 
the perception patients have about these procedures. The expected treatment 
benefits perceived by patients undergoing angioplasty is usually exaggerated (Ozkan et 
al., 2008; Chandrasekharan & Taggart, 2011). Post angioplasty patients took their heart 
disease less seriously, had the expectation that they would not get chest pain or MI, 
and had less fear of death (Ozkan et al., 2008). A review of patient perceptions about 
CABG and angioplasty found that 71% of those who had angioplasty erroneously 
believed that angioplasty would prevent future MIs (Chandrasekharan & Taggart, 
2011). CABG patients were better informed and their expectations were more realistic 
compared to angioplasty patients (Chandrasekharan & Taggart, 2011). Patients should 
be better educated about the outcomes of angioplasty to make their expectations 
more realistic. This could reduce their erroneous expectations and cause them to take 
their heart disease more seriously, which would be expected to possibly improve 
adherence and outcomes.  
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Patients with diabetes were less likely than those without diabetes (not on anti-
diabetic medicines) to be non-adherent according to Factor 1. Having diabetes was 
associated with a reduction in the risk of being non-adherent due to forgetfulness by 
56%. This is perhaps not surprising as patients with diabetes tend to ensure a good 
routine for taking their medicines as the consequences of missing their medicines are 
usually felt. 
      
5.4.2 Modifiable Associations 
5.4.2.1 Polypharmacy and forgetfulness 
In this study, polypharmacy was not associated with overall non-adherence in the 
bivariate or multivariate analyses (See Table 4.44 and Table 4.53). The frequency of 
daily medicines administration and number of individual daily doses were not 
associated with higher levels of overall non-adherence either. This is contrary to other 
studies which found that the complexity of the regimen (as the number of daily 
administrations of individual drugs) was negatively associated with adherence 
(Corsonello et al., 2009; Claxton et al., 2001). However, the systematic review 
identified no significant differences in levels of adherence between once daily and 
twice-daily regimens or between twice daily and 3 times daily regimens (Claxton et al., 
2001). The majority of our participants were on once or twice a day regimens, which 
could explain this difference. Exploring the association of polypharmacy with 
adherence according to Factor 1 and Factor 2 provides additional explanation.   
    
Adherent patients according to Factor 1 (unintentional / forgetfulness) were more 
likely to have polypharmacy than non-adherers. Patients on multiple therapies are 
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more likely to need to be organised with their medicines and fit them into their daily 
routine. Once this is established it should reduce the likelihood of forgetfulness. In 
Figure 4.15 (see also Table 4.58) both adherent and non-adherent patients said that a 
change of routine was the main cause of forgetting to take medicines. Midday doses 
and travelling were other causes. Though it was not assessed in this study, patients 
with polypharmacy are often offered multidose compliance aids which can help them 
better plan their medicines-taking.  Shalansky and Levy (2002) studied the levels of 
non-adherence among patients with CVD and identified that taking more medicines 
was associated with higher adherence. They also reported that the adherent group 
used more compliance aids and in the multivariate analyses using a compliance aid 
was associated with adherence (Shalansky & Levy; 2002).  
 
In Figure 4.15 (see also Table 4.61), patients cited the help of their family members as 
invaluable in reminding them to take their medicines. This could have been an 
important factor in improving adherence and reducing forgetfulness.  
 
In addition, polypharmacy can be a proxy for more advanced disease and co-
morbidities that can become more symptomatic. In Figure 4.15 (see also Table 4.58) 
patients reported that their “angina reminds them to take their medicines”. Some trials 
suggest that patients with greater illness severity may be more motivated to take their 
medicines (Balkrishnan, 1998; Billups et al., 2000). This can be further supplemented 
by the results of the BMQ which identified that adherent patients had a stronger belief 
(higher score) in the necessity of their medicines to maintain their health (see Table 
4.52). Every one unit increase in the score for specific necessity was associated with a 
10% reduction in the risk of being intentionally non-adherent (see Table 4.55). This 
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means that polypharmacy per se is not necessarily sufficient to lead to non-adherence, 
other factors which make the patient favour adherence might be more important (e.g. 
how well the treatment fits in with the individual patient’s routine, expectations and 
preferences). 
 
Non-adherent patients according to Factor 2 (intentional / hassle) were more likely to 
be on more medicines in both bivariate and multivariate analyses (see Table 4.41 and 
Table 4.55). Being on multiple therapies causes patients more “hassle” and concern 
about adverse drug reactions which can make them become non-adherent. In Figure 
4.15 (see also Table 4.58) patients raised concerns about polypharmacy and non-
adherent patients asked for more information on “why so many medicines are 
prescribed”. They also expressed a clear concern that taking so many medicines at the 
same time could lead to side-effects and interactions. While the most frequent 
interventions used to address polypharmacy involve compliance aids, the findings of 
this research indicate that a different approach should be adopted. After establishing 
the need for the medicines that a patient is prescribed, healthcare professionals 
should first evaluate and clarify why these multiple therapies are needed and address 
any specific concerns that patients have about their regimen.   
 
When analysing the association between different variables and non-adherence, it is 
recommended to distinguish between intentional and non-intentional non-adherence 
as they may differ. This in turn would have different implications for the interventions 
that should be employed to address non-adherence.  
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5.4.2.2 Secondary Prevention Medicines 
There was no correlation between the number of secondary prevention medicines 
prescribed, the number of daily doses or number of administrations per day and 
adherence in both bivariate and multivariate analysis (see Tables 4.40, 4.41, 4.44, 4.53, 
4.54 and 4.55). This could possibly indicate that non-adherence to secondary 
prevention medicines is not associated specifically with secondary prevention 
medicines’ polypharmacy. However, individual secondary prevention medicines were 
associated with an increase or a decrease in the level of non-adherence.  
 
Aspirin was positively associated with overall non-adherence, Factor 1 and Factor 2 
non-adherence in both bivariate and multivariate analyses (see Tables 4.40, 4.41, 4.44, 
4.53, 4.54 and 4.55). This was consistent with the findings of the SQ scale where 
aspirin was the secondary prevention medicine most non-adherence (see Table 4.28). 
This is contrary to previous studies, which showed that patient adherence to aspirin 
was usually the highest (Newby et al., 2006; Ho et al., 2008). In Figure 4.15 and Table 
4.57, patients cited high levels of concern about the side-effects of aspirin. This could 
have been a major contributing factor to aspirin non-adherence. Patients indicated 
that “media” added more concern about taking aspirin. Searching the BBC (British 
Broadcasting Corporation) website (www.bbc.co.uk) revealed 4 articles about aspirin 
in heart disease between 1/1/2009 and 1/1/2011. The reports were mainly around the 
increased risk of gastrointestinal bleeding and lack of evidence that aspirin was useful 
in primary prevention of MIs. The headlines were very confusing such as “Warning for 
healthy aspirin users ” and possibly few patients would distinguish between primary 
and secondary prevention use of aspirin. These findings may reflect the impact the 
media could have on adherence to secondary prevention medicines. “Media” was also 
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mentioned by patients in relation to statins indicating that it increased their worry 
about side-effects. A similar search of the BBC website revealed two articles about the 
side-effects of statins. One of the major articles started by claiming: “GPs should think 
more carefully about prescribing cholesterol-busting drugs say researchers who 
highlighted a range of ‘unintended’ side-effects”.  In this study statins were the second 
most non-adhered to secondary prevention medicine. The bivariate and multivariate 
analyses failed to identify any association between being prescribed a statin and non-
adherence possibly due to the lack of variation in statin prescribing (95% of 
participants were on statins).  
 
Similar searches were conducted for ACEI, beta blockers, clopidogrel and ARBs. No 
main headlines were identified about any of these classes of medicines in CAD.     
     
Beta blockers were associated with higher Factor 2 adherence (see Table 4.41 and 
4.55). This means that patients were less likely to intentionally not adhere to 
secondary prevention medicines if they were on a beta blocker. Though some patients 
reported modifying the dose of beta blockers (see Figure 4.15 and Table 4.57) due to 
side-effects, fewer patients were non-adherent to beta blockers compared to aspirin, 
statins and clopidogrel (see Table 4.28). This could possibly be explained by the advice 
that is repeatedly given to patients prescribed beta blockers and included in patient 
information leaflets and on the medicines label: “Warning: Do not stop taking this 
medicine unless your doctor tells you to stop”. During cardiac rehabilitation sessions 
this advice is emphasised and explained in detail. This, together with the lack of 
knowledge (hence lack of confidence) about this class of medicines could have made 
patients less likely to intentionally stop this medicine.      
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5.4.2.3 Knowledge about the indication of secondary prevention medicines 
Knowledge about the indications for the secondary prevention medicines that each 
patient was prescribed was variable and not associated with adherence. Despite the 
participants overall high level of knowledge about statins and aspirin, they still 
reported the highest non-adherence to these two classes of medicines. 
 
The overall knowledge of prescribed secondary prevention medicines among overall 
non-adherers was higher than adherers and was statistically significant (mean ± SD = 
1.6 (±0.62) vs. 1.8 (±0.66) respectively, median (Q1, Q3) = 1.5 (1, 2) vs. 1.7 (1.3, 2) 
respectively). This means that knowing the indication of secondary prevention 
medicines is not necessarily sufficient to increase adherence. Patients who know more 
about a medicine may read more about it and become concerned about its side-
effects. This concern may lead patients to non-adherence. This is supported by the 
findings of Karaeren et al. (2009) who investigated the effect of patients’ knowledge 
about their antihypertensives on adherence. They found that knowing the side-effects 
of medicines had a negative effect on adherence to antihypertensive therapy 
(Karaeren et al., 2009).  This is possibly due to the way the information about side-
effects was presented and the absence of healthcare professionals’ contribution to 
address patients concerns about side-effects. While information about side effects is a 
priority to many patients, a lot of them express dissatisfaction and lack of 
understanding with the way information about risk of harm and side-effects are 
presented in written information leaflets (Raynor et al., 2007). Healthcare 
professionals should also accept the possibility that patients may decide not to take a 
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medicine after receiving satisfactory information and weighing the benefits against the 
risks of taking that medicine (Raynor et al., 2007; NICE, 2009).   
 
In Figure 4.15 (see Tables 4.57, 4.58, 4.63) patients frequently mentioned that the 
information available through various sources (media, information leaflets and 
healthcare professionals) added to their concern about the medicines’ side-effects or 
did not answer their questions and worries about side-effects. Patients who had more 
knowledge about a medicine might also have felt more confident to change it. If 
patients suspected that healthcare professionals were likely to disagree or not listen to 
them, then they could act without consulting them. Some patients commented about 
healthcare professionals: “It is not easy to persuade them about the side-effects of 
medicines, they do not believe you”. A similar trend was seen in Factor 2 adherence. 
However, the difference was not statistically significant.  
     
In the bivariate analysis, patients who had less knowledge about beta blockers were 
more likely to be adherent (see Table 4.44, Table 4.40). This means that knowing why 
beta blockers were prescribed does not necessarily increase adherence. However, this 
was not statistically significant in the Factor 2 adherence assessment.      
 
While providing patients with information is recommended, it does not necessarily 
improve adherence. This conclusion is consistent with other studies (Horne et al., 
2005). Patients are clearly interested in more information about their medicines as can 
be seen in Figure 4.15 and Table 4.63. However, they were not satisfied with the 
information provided and made suggestions about the type they need. There is a 
significant demand for clearer information about side-effects as expressed in Tables 
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4.58, 4.59 and 4.63. This research recommends that healthcare professionals provide 
tailored patient information, which answers patients’ specific concerns and questions 
about their medicines. Such information may have a different impact on adherence as 
patients are more likely to find it satisfactory (Raynor et al., 2007). Further research is 
needed on the impact of tailored patient information on adherence.  
 
5.4.2.4 Prescription costs  
 
The AE identified that 21 patients had a propensity to be non-adherent because of the 
cost of prescriptions. Two of those patients were over 60 years of age and would be 
exempt from paying for their prescriptions. However, they commented that “erectile 
dysfunction medication should be free for a non-earning pensioner”. This indicates that 
they were referring to medicines that needed a private prescription (see Section 
5.4.2.6 for more about erectile dysfunction in CAD patients). Of the 19 patients under 
the age of 60, two identified cost as an issue. They could also have been referring to 
private prescriptions. There were 58 patients in the whole study who were possibly 
exempt from prescription charges and 37 of them were non-adherent. Of the 37 non-
adherers, 11 identified prescription charges as a reason.  
 
In Figure 4.15 and Table 4.58 cost was mentioned as a concern for both adherent and 
non-adherent patients. “All MI medicines should be free after suffering an MI” one of 
the patients commented. Prescription charges are per item and post MI patients are 
likely to be on at least 4 – 5 items (£29.6 - £37 per month or per three months 
depending on the quantity prescribed for each item in 2011). A 12 months prescription 
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prepayment certificate can save patients money, but it still costs £104 a year (DoH, 
2012).     
 
Though the majority of patients are exempt from paying NHS prescription charges, a 
substantial minority still have to pay for their prescriptions. It is estimated that 
patients in England paid prescription charges for 11.4% of items dispensed in 2007 
(4.1% through pre-payment certificates) (Information Centre, 2011). Furthermore, 
some medicines are prescribed on private prescriptions and can be expensive. For 
example the cost of 8 tablets of 100mg of sildenafil is £46.99 excluding additional 
dispensing costs (Joint Formulary Committee, 2011). While cost of medicines is 
considered to be a barrier to adherence, the majority of the evidence around this 
comes from the US and is not necessarily relevant to NHS settings (Horne et al., 2005; 
NICE, 2009). A few studies have been done in the UK to explore this issue (Schafheutle, 
2009; NICE, 2009). However, it is known that cost is an important external factor which 
influences patients’ adherence (Lexchin & Grootendorst, 2004). Though this might be 
true, its impact on patients is not the same and possibly dependent on the patient’s 
socioeconomic background. Schafheutle et al. (2004) showed that prescription charges 
may act as a stronger barrier to the use of prescribed among non-exempt patients on 
lower incomes. A recent American randomised study which eliminated all costs for 
medicines for post MI patients improved adherence by only 4 to 6 percentage points 
indicating that other factors contributing to non-adherence were still present 
(Choudhry et al., 2011). Nevertheless, even this small increase in the percentage of 
adherence is evidence for its impact.  
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The findings of our research add to the scarce evidence around this topic and suggest 
that prescription charges can be a barrier to adherence here in England. 18% of those 
who pay for prescription charges were found to be non-adherent due to cost.  
 
5.4.2.5 Practical barriers 
 
Opening medicine bottles or blister packs was a problem for 18% of patients and 22% 
needed a solution or an alternative (see Section 4.8). Patients complained about blister 
packs and that they were hard to open and others mentioned that tablets break when 
opening the blister pack (see Figure 4.15 and Table 4.58). Though this was not 
associated with overall non-adherence, patients with Factor 2 non-adherence 
(intentional / hassle) were more likely to have issues with opening medicines’ bottles 
and blister packs (see Table 4.50). This could be explained by the “hassle” element in 
Factor 2. Patients also wanted solutions or alternatives to reading labels on medicines 
bottles, swallowing medicines, and getting repeat prescriptions (8%, 9%, and 10%, 
respectively). Barber et al. (2004) described that 7% of patients with chronic diseases 
reported difficulties with the practical aspects of taking medicines. However, they did 
not provide enough detail about these practical issues. Problem swallowing tablets 
was listed as one of these difficulties (Barber et al., 2004).  
 
Getting repeat prescriptions had a strong association with non-adherence and patients 
who had issues with repeat prescriptions and needed a solution or alternative were 
nearly 2.5 times more likely to be overall non-adherent and 4 times non-adherent 
according to Factor 2. As seen in Figure 4.15 and Table 4.58 patients complained about 
the lack of synchrony between the number of medicines ordered and the short periods 
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of supply. When certain medicines are supplied for 28 days and others for 56 days the 
patient would need to remember to order repeat prescriptions every month for 
different medicines. Patients seem to favour three monthly supply as it causes them 
less hassle as well. The lack of smoothness in repeat prescription ordering can lead to 
forgetting medicines and hassle patients as it would require them to spend more time 
and effort sorting out their medicines.  
 
Though some of these barriers were not associated with non-adherence, they should 
still be addressed as they could be causing patients inconvenience and can cause 
patients to become non-adherent at a later stage. The pharmaceutical industry has a 
major role to play in ensuring that medicines packaging is suitable for patients and 
tablets/capsules are easy to swallow. Currently, there are no regulatory requirements 
or guidelines in Europe to test medicines during their manufacturing process for ease 
of opening of blister packs or swallowing medicines (MHRA : The Medicines and 
Healthcare products Regulatory Agency, 2012; MHRA, 2012, pers. comm). The MHRA, 
European Medicines Agency (EMA) and the pharmaceutical industry should address 
this issue. Furthermore, pharmacists and GPs have a major role to play in assessing and 
overcoming these barriers.         
   
5.4.2.6 Beliefs about medicines 
In the bivariate analysis non-adherent patients scored less for specific necessity and 
higher for specific concern and general overuse. The biggest difference in score was for 
specific concern, which indicates that it possibly had the biggest influence. This is 
confirmed by the multivariate logistic regression analysis, which showed that every 
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one unit increase in specific concern about secondary prevention medicines score was 
associated with a 12% increase in the risk of non-adherence. This association was 
found in both Factor 1 and Factor 2 elements. However, it had a stronger association 
with Factor 2 non-adherence indicating that it is a stronger driver of intentional non-
adherence than forgetfulness non-adherence. Specific necessity was only associated 
with intentional non-adherence but it had a weaker association than specific concern 
and general overuse of medicines. These findings highlight the areas that should be 
addressed and targeted with interventions.   
 
Though various studies have shown association between one or more of the BMQ 
subscales and adherence to medicines, the associations were different depending on 
the population studied (Horne & Weinman, 1999; Ross et al., 2004; Khanderia et al., 
2008). While hypertensive patients who believed in the necessity of medication were 
more likely to be adherent (Ross et al., 2004), this was not the case in patients with 
diabetes whose concerns regarding the use of treatments outweighed the benefits of 
regularly taking medicines (Horne et al., 1999). In another study CABG non-adherent 
patients were in stronger agreement on the general overuse and general harm scales 
(Khanderia et al., 2008).  
 
This re-emphasises the need to tailor interventions to the needs and characteristics of 
the targeted patient population. Our research also shows the benefit of the Factor 1 
and Factor 2 analysis, which revealed additional associations between beliefs and 
different types of non-adherence.  
 
Discussion Chapter                                                                                              The Heart Medicines Survey 
 
192 
The analysis of patients’ comments revealed that patients were concerned about the 
following issues in relation to their secondary prevention medicines: 
1) Side-effects 
2) Lack of understanding of need and benefit 
3) Length of therapy   
 
Some of these elements were also raised as a general concern about all medicines. 
Those who were satisfied with their medicines reported fewer side-effects and 
“feeling” the benefits. Examples of the statements used were: “I do not get any side-
effects”, “I am pain free, means they are working”, “I feel much better”, “I am still 
alive”.  It is also clear that the concern about side-effects was either “experienced” or 
“expected”. Some patients were concerned about side-effects that they were actually 
experiencing or had experienced and associated them with a specific medicine(s). 
Others, were not experiencing side-effects but were concerned that they might 
experience them either because of what they had read, heard in the media or simply 
because they had been on these medicines for long time. Patients are generally less 
likely to adhere to therapies that have / or are expected to have significant side-effects 
and these issues need to be addressed (Elwyn et al., 2003). However, the complexity of 
these scenarios reflects the need for suitable interventions. Patients who are 
experiencing side-effects will need different information and advice to those who are 
just worrying about side-effects happening. Those who are associating the increased 
likelihood of side effect and reduced benefit with the length of time they have been on 
a specific medicine would also need a different approach. Karaeren et al. (2009) 
reported that patients who knew about the duration of use of antihypertensive 
medicines were more likely to be adherent than those who did not know. 
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One of the main themes of concern identified by patients was “concern about sexual 
health”. Erectile dysfunction is very common in heart disease patients (38 - 78% after a 
MI) and is caused by organic causes (e.g. atherosclerosis), psychological issues and 
commonly prescribed secondary prevention medicines such as beta-blockers and 
statins (Sainz et al., 2004). Almost all non-adherent patients in that category identified 
all heart medicines to cause erectile dysfunction. This is an important concern that 
should be addressed as it can also lead to non-adherence (if it has not already). It 
needs addressing regardless of adherence as it could have an impact on patients’ 
quality of life. Patients should be offered opportunities to discuss any concerns they 
have about erectile dysfunction and they should be provided with the appropriate 
advice.  
     
5.4.2.7 Healthcare Professionals and Healthcare Services 
The Heart Medicines Survey did not have specific questions about healthcare 
professionals and healthcare services except for some questions mentioned in the 
BMQ. However, patients made many comments about healthcare professionals and 
services which became apparent from patients’ comments. Adherent patients 
generally expressed satisfaction with healthcare professionals and healthcare services 
(see Figure 4.15 and Table 4.61). Non-adherent patients spoke of concerns about 
various aspects of the healthcare service and healthcare professionals. However, non-
adherent patients made almost all the suggestions on how to improve healthcare 
services related to medicines and adherence. This suggests that if non-adherent 
patients are given opportunities to raise their concerns about their medicines (e.g. in a 
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medicines review), healthcare professionals would be more likely to know their needs 
and address non-adherence with targeted interventions.     
 
Satisfied patients identified the following reasons for their satisfaction: 
1) Trusted and accessible prescriber who prescribes only when necessary. 
2) Review of medicines and checking for side-effects. 
3) Help with access to medicines (puts medicines in bottles instead of blister packs). 
 
Unsatisfied patients cited the following reasons for their dissatisfaction: 
1) Lack of information at the point of prescribing medicines. 
2) Generally lack of information on side-effects, rationale behind multiple therapies, 
and length of time they should be taken for. 
3) Prescribers lack of acknowledgment of the side-effects patients experience (“not 
easy to persuade them about the side-effects of medicines – they do not believe 
you”). 
4) No help in accessing medicines (e.g. bottles instead of blister packs). 
5) Lack of medicines reviews (e.g. not had a medicines review for a long time). 
6) Medicines reviews lacked review of side-effects. 
7) Prescribers sometimes give conflicting advice. 
 
Most of the suggestions made by non-adherent patients were around the need for 
more frequent medicines reviews which assess efficacy, side-effects and patients’ 
experience and satisfaction. They also asked for better quality information which 
answers their questions and refreshes their memory during medicines reviews.  There 
also was a clear request for healthcare professionals to initiate questions about side-
effects, show more sympathy towards patients who experience them and offer 
solutions. In a study which assessed how physicians responded when patients 
presented with possible adverse drug reactions, it was found that in at least 86% of 
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cases physicians did not ask about any side-effects and they were more likely to deny 
than affirm the possibility of a connection between a side effect and a medicine 
despite high likelihoods (Golomb et al., 2007).  
   
These findings also clearly indicate the need for more frequent and structured 
medicines reviews which involve the patients. Despite the publication of a guide to 
medication review in 2008 (Clyne et al., 2008), there seems to be a need to implement 
these recommendations in both primary and secondary care settings so that patients 
can start to feel the benefits of such service. Pharmacists have a major role to play in 
the delivery of medicines review. Clinical pharmacists can conduct reviews on the ward 
and run medicines review clinics. Community pharmacists can revisit, restructure and 
better utilise their Medicines Use Reviews (MURs). The recent New Medicine Services 
in primary care is another opportunity that should not be missed (PSNC: 
Pharmaceutical Services Negotiating Committee, 2011). Pharmacists need to be 
trained and equipped with the right tools and time to conduct these reviews in the 
most clinically effective manner.  There is also a clear need to revisit the current 
structure and format of the GP medicines review under the Quality and Outcomes 
Framework (QoF) of the General Medical Services (GMS) contract (BMA, 2011). They 
should be redefined to include patients in the review and conducted in a structured 
format that meets patients’ needs.   
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5.5 Limitations of the study 
The limitations of using the questionnaire based method in cross-sectional studies 
were discussed in Chapter 3. The findings were undoubtedly limited by the cross-
sectional approach as adherence to medicines is dynamic and a longitudinal study 
would have revealed more findings about patients’ medicines taking behaviour. 
However, such a study would have needed more resources and time to conduct. 
Currently, the Medicines Heart Survey is being used in the longitudinal EMMACE-3 
study (Evaluation of the Methods and Management of Acute Coronary Events - 3: 
Investigating variation in hospital acute coronary syndrome outcomes) which aims to 
recruit 5000 patients and follow them for at least 1 year (UKCRN: United Kingdom 
Clinical Research Network, 2012).   
 
The use of self-reporting to measure adherence has its own limitations as was 
discussed in Chapter 2. Such tools usually under-estimate non-adherence and patients 
may feel inhibited from disclosing their real medicines- taking behaviour to healthcare 
professionals. Significant effort was made to draft the study documentation in a non-
judgmental way that made the patients feel comfortable with volunteering such 
information. 
 
“Questionnaire fatigue” is another factor which could have contributed to lower 
quality in the answers provided and missing data. Due to the length of the survey, 
respondents could have developed questionnaire fatigue towards the end of the 
questionnaire. Respondents usually would be more likely to make faster, more 
uniform answers and miss questions towards the end of the survey (Galesic & Bosnjak, 
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2009). This could have been overcome by rotating some of the sections/parts in the 
questionnaire. However, this approach could also raise problems.        
 
Despite the small amount of missing data, it can be considered a limitation. As 
discussed in Section 3.6.3, missing data arose mainly from patients not answering 
certain questions in the questionnaire. Patients may have been unsure about these 
questions, or chose not to share that information with the researcher. In very few 
cases, whole parts of the questionnaire were missed, possibly because the page was 
missed. Providing clear signposts in the questionnaire indicating the next question 
could have reduced such occurrences (Marston, 2010). The approach used by the 
researcher of scoring missing data by assuming the best case scenario (in favour of 
adherence) could have further reduced the true levels of non-adherence in the target 
population.  
 
One of the other limitations of the study was the potential bias in the sample. The 
sampling frame (ENCOURAGE database) could have contributed to that. The patients 
in this sample were people who had already participated in other cardiac related 
studies (which had their own inclusion and exclusion criteria) and had more exposure 
and input from healthcare professionals than the “real” targeted population. This 
created limitations and selectiveness in the type of patients included in the database. 
The patients’ ethnic distribution was also not fully representative of the ethnic 
diversity of the targeted population which can limit the generalizability of the study’s 
findings.    However, the diversity of the chosen patients in terms of their geographical 
location and the different clinical trials they participated in previously could have 
reduced some of this bias. The trial backgrounds of patients were diverse, which 
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meant that patients came from different trials rather than one trial. This may have 
improved the diversity and the representation of the population in the sample. 
The participants from the database were also more likely to have been better 
informed and more interested in their heart medicines. However, understanding the 
medicines related needs of this part of the population would undoubtedly still have 
been of great value and can inform practice. Furthermore, if levels of non-adherence 
were high among this sample, then this would probably indicate that the reality of the 
levels of non-adherence in the target population would be even lower. The findings are 
still valuable in informing a better approach to addressing non-adherence to secondary 
prevention medicines. 
 
Comparing respondents to non-respondents can be used to show if the characteristics 
of the respondents were very different to the non-respondents. However, this was not 
possible due to the lack of information or lack of up-to-date information about the 
non-respondents. Most of the information about medicines was derived from self-
report and not the database. However, as mentioned in Section 4.1 there was no 
difference in the distribution in gender between respondents and non-respondents. 
Higher participation might have revealed more non-adherence behaviour as non-
respondents were younger and this study showed that younger patients were more 
likely to be non-adherent.     
 
The study lacked a “gold standard” to compare all three adherence scales to objective 
reports such as MEMS® or repeat prescription data. This was not feasible and would 
have needed more resources and time to conduct. In addition, this was not the main 
aim of the study.  
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5.6 General summary and conclusions 
The Heart Medicines Survey was successful in fulfilling its aims and objectives. The self-
reported level of non-adherence to secondary prevention medicines by patients with 
established CHD in West Yorkshire and nearby areas was found to be 44% according to 
the MMAS-8 (excluding Qn5) or SQ scale. Of those 39% had an element of intentional 
non-adherence that was predicted by the AE. Only 52% of patients were prescribed at 
least four secondary prevention medicines. The levels of non-adherence to individual 
secondary prevention medicines were as follows (starting with the most non-adhered 
to): aspirin, statins, clopidogrel, beta blockers, ACEI and ARBs. The contribution of each 
one of those medicines to overall non-adherence as identified by the SQ scale was 
62%, 67%, 7%, 30%, 22% and 5% respectively.  
 
The amalgamated use of all the tools proved very useful in identifying barriers to 
adherence. Single use of any of the tools would not have been sufficient to identify all 
the barriers uncovered by the Heart Medicines Survey. The MMAS-8 identified more 
non-adherence behaviour than the other two scales. However, Qn5 was problematic 
and the scale had low internal consistency which revealed a lack of unidimensionality. 
Exploration of the tool with factor analysis identified Factor 1 (unintentional / 
forgetfulness non-adherence) and Factor 2 (intentional/hassle related non-adherence) 
which enriched the data analysis and enabled better understanding of the findings. 
The MMAS-8 will need modification before use in the future to prevent the Qn5 
problem. The use of any of the self-reported tools should be with caution and by 
testing their performance in the population in question. Interpretation of results 
should always consider that the association between different variables and non-
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adherence behaviour seems to depend on the type of non-adherence. This should 
better inform the types of interventions deployed to address factors contributing to 
non-adherence. 
 
The AE estimator had a low sensitivity (40%) and high specificity (78%). However, its 
findings were relevant to clinical practice even when the predicted non-adherence 
behaviour was not apparent. The modified SQ scale was good for screening and 
providing details about individual secondary prevention medicines. It had very low 
sensitivity (25%) and excellent specificity (97%). The additional questions introduced 
by the researcher about practical barriers and the open question at the end of the 
survey were very useful in informing about patients’ needs and population specific 
interventions. 
 
Younger age, male gender and angioplasty had some positive association with non-
adherence. Patients who had CABG or diabetes were less likely to be non-adherent. 
These non-modifiable associations were mainly useful for screening and resource 
targeting purposes. However, healthcare professionals need to better inform patients 
about angioplasty to ensure that their expectations are realistic.  
 
Interventions to address non-adherence by CAD patients in West Yorkshire and nearby 
areas need to consider the following modifiable barriers that were found to be 
associated with non-adherence:  
 
• Polypharmacy was associated with intentional/hassle non-adherence and 
therefore the interventions need to address patients’ concerns about 
polypharmacy after establishing that the prescribed medicines are appropriate. 
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• The interventions should also address any perception of general overuse of 
medicines because belief in general overuse of medicines was positively associated 
with intentional non-adherence.    
• Non-adherence to secondary prevention medicines seems to have been largely 
driven by concerns about their side-effects. Interventions need to alleviate these 
specific concerns (for statins and aspirin in particular). 
• Problems and difficulties surrounding repeat prescriptions had a strong positive 
association with non-adherence and should be addressed.  
• Specific concerns about medicines had a strong positive association with both 
unintentional and intentional non-adherence. However, it had a stronger 
association with intentional non-adherence. 
• Belief in the specific necessity of medicines was negatively associated with 
intentional non-adherence only. However, it had an association weaker than that 
of specific concern about medicines. 
 
In addition to the above, the interventions should take into consideration that better 
knowledge about the indication of secondary prevention medicines was not associated 
with better adherence. Tailoring the information provided to the needs of patients 
may have a different impact. Patients wanted more information about side-effects, the 
rationale for multiple therapies, and the length of time they should continue taking 
their medicines. In addition, 30% of patients who paid prescription charges cited it as 
at least one of the reasons for their non-adherence. Therefore, this barrier should be 
explored and alternative options offered where it is identified as a problem. Though 
opening medicine bottles / blister packs, reading labels and difficulty swallowing were 
not associated with non-adherence (except for some cases in bivariate analysis) they 
should be addressed because they cause patients inconvenience and may lead to non-
adherence in the future.  
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Healthcare professionals need to ask patients about how they are managing their 
medicines and specifically ask about side-effects during their consultations. They 
should show sensitivity and co-operation with patients while discussing possible side-
effects experienced by patients. Every effort should be made to address practical 
barriers to medicines-taking. Interprofessional communication is essential to reduce 
contradictions that can confuse patients, improve access and collectively address 
problems and difficulties that patients are experiencing.  
 
There is a clear demand from patients for better structured medicines reviews which 
involve them and are carried out at least once a year. This setting should give the 
opportunity for patients to share their medicines-taking experience, share their 
concerns about their medicines and ask any questions they want.   
This study clearly identified that rather than depending on extrapolations from the 
literature when developing interventions to address non-adherence, healthcare 
professionals need to frequently examine specific modifiable barriers to adherence in 
their patients in order to individualise interventions. This is thought to be more likely 
to improve adherence as discussed in Section 1.4.3.  
 
5.7 Recommendations and future work  
Based on the findings of this research the following recommendations can be made for 
practice, policy makers and future research: 
 
• Interventions to address adherence should always be preceded by exploring the 
medicines-taking behaviour of the population in question. The investigation should 
Discussion Chapter                                                                                              The Heart Medicines Survey 
 
203 
inform the interventions. Extrapolations from literature and assumptions should 
not be the main driver of the interventions. 
 
• Since adherence is a behaviour that changes depending on circumstances, it should 
be frequently assessed using appropriate tools. The aim of the screening should 
not only be to identify non-adherent behaviour. It should explore the patients’ 
medicine-taking experience and address actual and potential barriers to 
adherence. Though some of these barriers were not associated with non-
adherence, they should still be addressed as they could be causing patients 
inconvenience and could cause patients to become non-adherent in the future. 
 
• Self-report assessment tools should be used for the purpose of assessing non-
adherence more than other tools because they are more likely to reveal actual and 
potential modifiable barriers to adherence. Amalgamation of tools exploring 
different aspects of medicines-taking behaviour, similar to the Heart Medicines 
Survey, is more effective than a single tool. At least one open question should be 
included to enable the respondents to answer in their own way and add any other 
issues that they wish to share about their medicines-taking experience.   
 
• The performance of any tools used should be examined in the targeted population 
and modified according to their performance in the population in question rather 
than in relation to other populations from the literature. 
 
• More opportunities should be made for patients to talk about their medicines with 
their healthcare professionals. Such opportunities should be preceded by 
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completing a medicines-taking experience questionnaire, similar to the Heart 
Medicines Survey, which is more likely to make the consultation tailored to the 
patient’s needs. This area should be researched further to examine its impact on 
adherence. 
 
• Pharmacists have a major role to play in this field. Clinical pharmacists can enhance 
their medicines reconciliation service during in-patient admission to give 
opportunities to raise any issues about medicines. They can also conduct medicines 
review clinics. Patients attending outpatient clinics can also be assessed and if 
necessary referred for a full medicines review. Community pharmacists are 
frequently visited by patients with chronic conditions and can seize these 
opportunities to offer patients the chance to discuss their medicines. The 
Medicines Use Reviews (MURs) and the recent New Medicine Services by 
community pharmacists should take on board the findings of this study of how to 
approach the assessment of adherence and the formulation of interventions. 
Further research is also needed to assess the impact of these proposed changes in 
clinical practice on patients’ experience and adherence.   
 
• There is a clear demand from patients for better structured medicines reviews 
which involve them and are carried out at least once a year. There is a need to 
revisit the current structure and format of the GP medicines review under the 
Quality and Outcomes Framework (QoF) of the General Medical Services (GMS) 
contract. Patients should be consulted during these medicines reviews and a new 
approach, as suggested in this research, should be considered. If GPs cannot, due 
to time constraints, conduct such more comprehensive reviews, then other 
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healthcare professionals (e.g. community pharmacists) should be offered the 
chance to contribute to this service at least once a year.  The impact of the current 
and a modified version of the service need to be researched further.       
  
• Healthcare professionals should provide patients with tailored information, which 
answers their concerns and questions about their medicines. This is more likely to 
be beneficial than a “one-size fits all” information provision.  
 
• It is evident from the findings of this research that the cost of prescriptions is an 
added actual or potential barrier to adherence. The Department of Health should 
consider exempting patients who are prescribed secondary prevention medicines 
from prescription charges. The impact of prescription charges and any suggested 
exemptions, on adherence of CHD patients should be researched further.   
 
• The pharmaceutical industry has a major role to play in ensuring that medicines 
packaging is suitable for patients and tablets/capsules and other formulations 
available are easy to swallow. The MHRA, EMA and the pharmaceutical industry 
should incorporate into their manufacturing process “ease of opening packaging” 
and “ease of swallowing” tests as these seem to be actual or potential barriers to 
adherence that patients encounter frequently.  
 
• Pharmacists and GPs need to work together to simplify, synchronise and rationalise 
the repeat prescription ordering and supply system. This has major benefits for 
patients and is likely to improve adherence. Further research to explore this should 
be undertaken.          
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• Concerns about medicines side-effects seem to be a major driver of non-
adherence. Information about medicines’ side-effects need to be simplified and 
made clearer for patients. The MHRA, pharmaceutical companies and healthcare 
professionals need to work together to address this issue. Healthcare professionals 
need to be trained to ask, acknowledge and address patients’ concerns about the 
adverse effects of medicines. Research into how to do that is needed.  
 
• The assessment of sexual health should be part of the services provided to patients 
with CAD, not only during cardiac rehabilitation but at once a year reviews.  The 
impact of sexual health on non-adherence needs further exploring. 
 
• The media needs to be made aware of the impact it has on patients’ adherence to 
medicines. It needs to be more responsible and accurate when presenting 
information about medicines and take into account any confusion that it can cause 
patients. Specialist healthcare professionals should be consulted on presenting the 
information before breaking the news to the public.   
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